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Abstract 
 
Venous thromboembolism (VTE) has a background incidence of between 0.7 
and 2.69 per 1000 per year (L. N. Roberts et al., 2013). Risk factors are either 
permanent or transient. Permanent risk factors include thrombophilia (80 x 
increase risk if homozygous for factor V Leiden), cancer (58 x increase risk if 
metastatic cancer or diagnosis within last 3 months), increasing age (risk 
doubles for each decade over age 40 years), family or personal history of 
deep vein thrombosis (2-3 x increase risk) and increasing body mass index (2 
x increase for BMI > 35 kg/m2 in comparison with BMI <20 kgm2) (Y.-H. Kim & 
Kim, 2007) (Blom, Doggen, Osanto, & Rosendaal, 2005) (Anderson & 
Spencer, 2003) (Decramer, Lowyck, & Demuynck, 2008) (Holst, Jensen, & 
Prescott, 2010).  
Transient risk factors include surgery (165 x risk in first 6 weeks after total hip 
or knee replacement, equating to 2% symptomatic VTE rate) (Sweetland et 
al., 2009). Foot and ankle procedures including ankle fracture fixation, 
hindfoot fusion and 1st metatarsal osteotomy are associated with 18x, 8x and 
2x increase VTE risk respectively (Jameson et al., 2011). Other transient risk 
factors include postpartum state (21-84 x increase in first 6 weeks), use of 
oral contraceptive pill or hormone replacement therapy (at least 2 x risk) and 
lower limb cast immobilization (Jackson, Curtis, & Gaffield, 2011) (Grodstein 
et al., 1996). Within 90 days of lower limb cast treatment, asymptomatic DVT 
affects between 4 and 40% of patients, symptomatic DVT affects 1 in 250, 
symptomatic pulmonary embolism affects 1 in 500, with fatal pulmonary 
embolism affecting 1 in 15,000 (Jameson et al., 2014). It is apparent that 
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patients will therefore have a differing risks depending on their permanent and 
transient risks. 
The types of VTE include asymptomatic events, for which the relevance is not 
fully understood (often used in studies as a surrogate for symptomatic 
events). Symptomatic below knee DVT (approximately 20% propagate to 
become above knee) (Philbrick & Becker, 1988). Symptomatic above knee 
DVT (affecting popliteal vein or more proximal), which are 4 times more likely 
to occur (Baglin et al., 2010). Pulmonary embolism can also occur. The 
clinical relevance of DVT is that 6% of patients will have severe post 
thrombotic syndrome (venous ulceration, swelling, itching) at 10 years after 
the event, with 66% of patients displaying some signs (Schulman et al., 2006). 
Uncomplicated DVT does not appear to impact on quality of life, however if 
DVT is complicated by post thrombotic syndrome, patients will have 
significantly reduced quality of life, mental and physical health. Simple non 
fatal PE reduces physical health and if it is complicated by pulmonary 
hypertension (affecting approximately 2%) it results in significantly reduced 
quality of life, mental and physical health (Ghanima, Wik, Tavoly, Enden, & 
Jelsness-Jørgensen, 2017) (Lubberts, Paulino Pereira, Kabrhel, Kuter, & 
DiGiovanni, 2016).  
In view that VTE has significant effects on patients quality of life, it is 
important to try and prevent it. In order to develop strategies for preventing 
DVT in patients with lower limb injury treated with leg cast, it is important to 
investigate the relative contributions of injury, stasis and immobility to 
thrombogenesis. I start by performing systematic review of the literature to 
determine whether thromboprophylaxis reduces symptomatic venous 
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thromboembolism in patients with below knee cast treatment for foot and 
ankle trauma. 
A systematic review of randomised controlled trials of thromboprophylaxis in 
patients with foot and ankle injuries treated with cast immobilization was 
performed, searching MEDLINE and EMBASE from inception to June 2015 
(B. A. Hickey, Watson, et al., 2016b). Outcomes of interest were VTE 
(asymptomatic and symptomatic DVT and PE) and bleeding. 3 reviewers 
used a data extraction form and assessed the literature according to the 
Cochrane risk of bias tool. Statistical analysis was performed using RevMan. 
7 studies of chemical thromboprophylaxis were included, all except one used 
venography to assess for DVT, with one study using venous ultrasound. 2 
studies reported on mechanical thromboprophylaxis, neither reported 
symptomatic DVT events. Neither study of mechanical thromboprophylaxis 
found a reduction in asymptomatic DVT in the intervention group.  
Funnel plot of studies of chemical thromboprophylaxis suggested no 
publication bias. Pooled symptomatic DVT occurred in 1.58% of patients in 
the control group, with 0.43% sustaining symptomatic PE. At meta analysis, 
symptomatic DVT was reduced in the low molecular weight heparin chemical 
thromboprophylaxis group (OR 0.29, CI 0.09-0.95). Chemical 
thromboprophylaxis did not influence PE. There was one non-fatal 
retroperitoneal haemorrhage (major bleed), which equated to 0.11% (1 in 
886). Based on these findings, 11 symptomatic VTE events would be 
prevented for every 1 major bleed. These findings are comparable with the 
recent Cochrane review, which included 2 additional studies and a total of 
2924 participants. Meta analysis found reported a reduction of VTE in the 
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LMWH chemical thromboprophylaxis group (OR 0.40, 95% CI 0.21-0.76) 
(Zee, van Lieshout, van der Heide, Janssen, & Janzing, 2017).  
In order to develop strategies for prediction and prevention of VTE in patients 
with foot and ankle injury treated with cast immobilization, it is necessary to 
consider why venous thrombosis occurs in these patients. As previously 
discussed, patients may have permanent risk factors, which may influence 
hypercoagulability. The transient risk factors of injury and cast treatment may 
also influence risk by causing endothelial dysfunction and venous stasis 
(Virchow, 1856). Several important mechanisms for prevention of venous 
stasis have previously been found. Weight bearing is important; with Gardner 
et al (1990) reporting that 30ml of venous contrast was pumped out of the foot 
during weight bearing (Gardner & Fox, 1983). This is not always possible for a 
patient with foot and ankle injury treated with a cast, because they may be 
non-weight bearing. For patients who are non-weight bearing, it is still 
possible to influence venous flow. For example, Elsner et al (2007) previously 
found that movement of the 1st metatarsophalangeal joint increased popliteal 
vein flow from 13 to 39 cm/s (Elsner, Schiffer, Jubel, Koebke, & Andermahr, 
2007). In patients without leg casts, intermittent pneumatic compression of the 
leg or thigh to prevent venous stasis was found to be effective in reducing 
DVT and PE in a meta analysis of over 16, 000 patients (RR 0.43, 95% CI 
0.36-0.52) (Ho & Tan, 2013). It therefore seems that this is a viable 
mechanism. Furthermore, Whitelaw et al (2001) found that none of the IPC 
devices studied resulted in significantly better calf pump function when 
compared with simple passive or active ankle movements (Whitelaw et al., 
2001). To assess the influence of toe and ankle movement on venous stasis, I 
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examine the effect of these movements on venous velocities measured at the 
popliteal vein with ultrasound. To determine whether this is a viable strategy 
for prevention of DVT, I then assess the impact of application of below knee 
cast on venous velocities. 
In this proof of principle study, 20 healthy volunteers were recruited (B. A. 
Hickey, Morgan, Pugh, & Perera, 2014). All had measurement of calf pump 
function in the un-casted leg whilst seated, using ultrasound at the popliteal 
vein. Baseline and peak velocities were measured during active toe 
movement (dorsiflexion and plantarflexion) and during ankle movement 
(dorsiflexion and plantarflexion). A below knee cast was then applied and 
measurements were repeated. Mean resting baseline venous velocity was 10 
cm/s, which remained unchanged when the below knee cast was applied. 
There was approximately 5-fold increase in venous velocities with active toe 
movement (mean 54 cm/s for toe dorsiflexion, mean 50 cm/s for toe 
plantarflexion), and 10 fold increase from baseline with ankle movements 
(mean 115 cm/s ankle dorsiflexion, mean 87 cm/s ankle plantarflexion). All 
were statistically significant. When the below knee cast was applied, there 
was no statistically significant decrease in the peak velocities achieved during 
movement excepting for ankle dorsiflexion (isometric), however this was still 
increased approximately 8 times compared with baseline (88 cm/s). It was 
therefore apparent that venous stasis did not occur when a below knee cast 
was applied to healthy volunteers and that active toe movement may have a 
role in preventing stasis in patients with injury, with subsequent reduction in 
DVT. To determine whether this is true I assess the effect of active toe 
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movement on calf pump function and asymptomatic deep vein thrombosis in 
patients with foot and ankle injury treated with leg cast. 
In this prospective randomized controlled trial, patients between the ages of 
18 and 60 years with acute foot and ankle injury treated with non-weight 
bearing cast were recruited (B. A. Hickey, Cleves, et al., 2016a). Patients 
were within 3 days of their injury and considered low risk for VTE after risk 
assessment. Those with additional risk factors were provided with LMWH and 
not recruited. Patients who consented, were randomized to either active toe 
movement (AToM) intervention group (advised to perform active toe 
dorsiflexion and plantar flexion 60 times every 6 hours minimum, but more 
often if possible). Patients were managed through the trauma clinic according 
to their injury then had assessment of calf pump function on removal of cast 
and assessment for lower limb DVT of both lower limbs using venous 
ultrasound.  
Interim analysis was performed after the first 100 patients were recruited. 78 
patients completed the study, mean age was 37 years, 65% were male. 59% 
had leg cast for ankle fracture. Analysis of calf pump function revealed no 
significant difference between the intervention and control groups for any of 
the parameters, with mean baseline popliteal velocity of 7 cm/s in both 
groups, popliteal venous velocity during active toe dorsiflexion 44 cm/s 
(AToM) v 34 cm/s (control), p=0.36 and popliteal venous velocity during active 
toe plantar flexion 39 cm/s (AToM) v 32 cm/s (control) p=0.35). 27% of 
patients were found to have asymptomatic DVT, with no significant difference 
between groups. The important finding was that all asymptomatic DVTs 
occurred in the lower limb that had been injured and treated with cast. This 
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basic finding had not been previously reported in the literature. It was 
important to determine whether this finding could be attributable to venous 
stasis alone, or whether general immobility or the injury itself had any 
significant role. To answer this, I assess the association between patient 
mobility and development of asymptomatic DVT. 
As part of the AToM study, a triaxial accelerometer (MOVBand) was attached 
to the leg cast at time of recruitment to the study. This was removed in the 
trauma clinic at the first appointment and the first 5 days of accelerometer 
data was extracted. Unpaired t test was used to determine statistical 
significance between group means for patients who did and did not develop 
asymptomatic DVT. 78 patients completed the AToM study, 10 patients were 
excluded from accelerometer data analysis (4 trackers lost, 6 failed to record 
any data). There was no significant difference in accelerometer data between 
patients who did and did not sustain asymptomatic DVT. Average moves were 
1057/day (no DVT group) vs 1005/day (DVT group), p=0.85. Average steps 
were 877/day (no DVT group) vs 825/day (DVT group), p=0.82. In view of 
this, it appeared that mobility of patients during the first week of cast treatment 
for injury did not predict subsequent finding of asymptomatic DVT. In view that 
all DVT’s occurred in the lower limb that had been injured and treated in cast, 
it was apparent that local factors such as venous stasis or tissue injury were 
more important than general patient mobility, otherwise it would be anticipated 
that some DVT’s would have occurred in the uninjured, un-casted limb. To 
investigate the role of the injury I examine the association between 
biomarkers of coagulation and tissue injury with the outcome of asymptomatic 
DVT. 
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As part of the AToM study, 3.5ml venous blood was taken at time of 
recruitment. Centrifuged plasma was stored at -70 degrees centigrade. After 
the last patient exited the study, plasma was analysed for levels of tissue 
factor, interleukin 6, vascular cell adhesion molecule 1 (VCAM-1) and D-dimer 
(B. A. Hickey et al., 2017). 77 patients were included, 1 patient did not provide 
blood sample. Analysis of results found no difference between levels of tissue 
factor, IL-6, VCAM-1 and D-dimer in groups who did and did not sustain 
asymptomatic DVT. Mean Tissue factor 23.9 pg/mL (no DVT group) vs 20.3 
(DVT group), p=0.422. Median IL-6 3.9 pg/mL (no DVT group) vs 4.6 (DVT 
group), p=0.76. Median VCAM-1 553 ng/mL (no DVT group) v 496.8 ng/mL 
(DVT group), p=0.11. Median D-dimer 203.5 (no DVT group) v 236.0 (DVT 
group), p=0.49. I therefore appeared that severity of injury, measured using 
plasma levels of FT, IL-6, VCAM-1 and D-dimer could not predict which 
patients would develop asymptomatic DVT. This suggested that local factors 
of venous stasis might play a greater role in thrombogenesis than tissue 
injury. 
In summary, it appears that chemical thromboprophylaxis reduces the risk of 
symptomatic DVT in patients with foot and ankle injury treated with leg casts. 
Active toe movements can prevent venous stasis in healthy volunteers, 
however this does not appear to influence calf pump function or occurrence of 
DVT in patients with injury and leg cast. The important finding from this work 
is that asymptomatic DVT only occurs in the lower limb that has been injured 
and treated with leg cast. Biomarkers of coagulation do no appear to predict 
DVT in this patient group. Similarly, general patient mobility measured 
objectively with accelerometer during the first week of cast treatment does not 
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appear to be associated with development of DVT in patient with foot and 
ankle injury treated with leg casts. 
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1 Introduction 
 
Patients with trauma to the lower limb and cast treatment can develop venous 
thrombosis in the form of deep vein thrombosis or pulmonary embolism. It is 
important to prevent these from occurring if possible, because both have 
negative impact on patient health.  
 
Symptomatic Venous thromboembolism (VTE), presenting as either Deep 
Vein Thrombosis (DVT) or Pulmonary Embolism (PE) occurs in between 0.7 
and 2.69 per 1000 people per year in the United Kingdom (L. N. Roberts et 
al., 2013) (Holst et al., 2010) (Oger, 2000) (Isma, Svensson, Gottsäter, & 
Lindblad, 2009) (Eekhoff, Rosendaal, & Vandenbroucke, 2000) (Silverstein et 
al., 1998). DVT occurs approximately three times more often than PE (Oger, 
2000). In the context of Trauma and Orthopaedic surgery, VTE is usually 
considered to be a problem associated with major joint replacement, however 
it also occurs in young patients with non-operatively treated injuries such as 
ankle fracture. Acute PE is a dangerous clinical event, which can be fatal (L. 
Chen & Soares, 2006). It is often the first clinical indication of thrombotic 
disease (Slaybaugh, Beasley, & Massa, 2003). For those who survive the 
acute pulmonary embolic event, approximately 1.7% will die from PE within 3 
months (Goldhaber & Bounameaux, 2012). For those who survive, 2 to 4% 
will develop chronic pulmonary hypertension, marking the start of a chronic 
disease associated with disabling dyspnea (Exter, Van der Hulle, Lankeit, 
Huisman, & Klok, 2013; Goldhaber & Bounameaux, 2012).  
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Recently, it was reported that the incidence of fatal pulmonary embolism 
following non-operatively treated ankle fracture affects approximately 1 in 
15000 patients within 90 days of injury (Jameson et al., 2014). A significant 
limitation of this study was the lack of out of hospital death data, it is therefore 
likely that the true incidence of fatal pulmonary embolism is underestimated. It 
also is important to recognize that fatal pulmonary embolism is only one 
presentation of VTE, with DVT being more common and also having 
significant implications on the health of patients. 
 
Although Virchow suggested that endothelial dysfunction, hypercoagulability 
and venous stasis play a role in venous thrombosis over 150 years ago, it is 
still unclear which patients will develop venous thrombosis (Virchow, 1856). 
All people are at risk of VTE, the main determinants being either intrinsic e.g. 
genetic abnormalities in haemostasis or extrinsic e.g. vessel wall injury due to 
trauma and subsequent treatments including surgery and cast immobilization. 
The multifactorial aetiology of VTE makes it difficult to accurately predict who 
is most likely to sustain VTE. Risk factors combine to increase VTE risk until a 
threshold is reached i.e. no risk factor is identified to be a single cause great 
enough to cause VTE alone but in addition to other risk factors, VTE will 
occur. One theory as to why some patients with apparently the same transient 
risk factors will develop PE, whereas other will not, is that everyone’s 
threshold is different (Lippi & Franchini, 2008). Several risk factors have been 
identified as having an association with the development of venous 
thrombosis. 
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Permanent risk factors 
 
Age 
Age has been shown to be an independent risk factor for the development of 
VTE, with an odds ratio of 1.03 in hospitalized patients with acute medical 
illness who are aged 75 years of older (Alikhan et al., 2004). After the age of 
40 years, VTE risk approximately doubles for each subsequent decade 
(Anderson & Spencer, 2003). A large population based study of 2218 patients 
in America found that the incidence of first time VTE increased with age, 
independent of gender, with <5/100,000 per year in children, increasing to 
500/100,000 over the age of 80 years (Silverstein et al., 1998). In view of this, 
a cut off age which dichotomises patients into high and low risk based on age 
is not helpful (Anderson & Spencer, 2003). 
 
Previous VTE 
As part of the IMPROVE study (International Medical Prevention Registry on 
Venous Thromboembolism), using Cox multiple regression analysis of data 
from 15,156 medical patients, previous VTE was found to be an independent 
risk factor for subsequent symptomatic VTE (Spyropoulos et al., 2011). In 
hospitalised patients with acute medical illness, the risk of VTE is highest in 
those with previous history of VTE (OR 2.06), acute infectious disease (OR 
1.74), cancer (OR 1.62) and age >75 years (OR 1.03) (Alikhan et al., 2004). 
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Thrombophilia and family history of VTE 
Approximately 20% of patients who sustain VTE have a family history of VTE, 
with 11.4% and 6.4% of patients subsequently being found to have factor V 
Leiden mutation or G20210A prothrombin gene variant (Noboa et al., 2008). 
These are the most commonly inherited thrombophilias and are present in 
between 3 and 5% of the population (Nizankowska-Mogilnicka et al., 2003) 
(Y.-H. Kim & Kim, 2007). The factor V Leiden mutation increases VTE risk 7 
times in heterozygotes and 80 times in homozygotes (Y.-H. Kim & Kim, 2007). 
In patients with the factor V Leiden mutation and an associated injury, there is 
a 50 fold increase in risk (van Stralen, Rosendaal, & Doggen, 2008). The 
prothrombin promotor G20210A mutation is less potent, with homozygotes 
having a 20 times increased VTE risk (Y.-H. Kim & Kim, 2007). Even in the 
absence of these inherited thrombophilias, it was shown in a case control 
study of 698 patients that those with first time episode of VTE and a first 
degree relative history of VTE had a 2.7 times increased risk of VTE 
compared to those without (Noboa et al., 2008). Sonnevi et al (2013) reported 
similar findings in a large case-control study of 1288 women between the 
ages of 18 and 64 years with first time VTE. Those with a positive family 
history of VTE had at least doubled risk of VTE compared to controls if they 
used HRT/CHC or had surgery and/or cast, regardless of presence of one of 
the two most common thrombophilias (Sonnevi, Bergendal, Adami, Lärfars, & 
Kieler, 2013). 
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Cancer 
A diagnosis of cancer is an independent risk factor for objectively confirmed 
VTE (Alikhan et al., 2004). In a population based case control study, with 
3220 patients with cancer and 2131 patients without cancer, the diagnosis of 
cancer was associated with a 7 fold increase in VTE risk (Blom et al., 2005). It 
is important to recognize that the risk was much greater in those who were 
diagnosed within the preceding 3 months (53 fold increase in VTE compared 
with those without cancer). These patients are not routinely advised to receive 
chemical thromboprophylaxis by NICE (National Clinical Guideline Centre – 
Acute and Chronic Conditions (UK), 2010). The extent of cancer is also 
relevant, with the highest VTE risk being present in patients with metastatic 
disease (58 times increased risk) (Blom et al., 2005). 
 
Obesity 
Obesity is perceived by many to be a risk factor for VTE. To support this, the 
MEGA study found that BMI >30kgm2 increases the venous thrombosis risk 
2.4 fold (Pomp, le Cessie, Rosendaal, & Doggen, 2007). Holst et al (2010) 
confirmed this in the Copenhagen City Heart study of 18, 954 patients, at a 
median follow up of 19.5 years. BMI >35kgm2 was associated with an 
increased risk of VTE when compared to a BMI of <20kgm2 (HR 2.1), even 
after adjustment for age and cardiovascular risk factors (Holst et al., 2010). 
The addition of oral contraceptive pill increases the VTE risk in patients with 
BMI >30kgm2 from 2.4 to 24 fold in comparison to non obese women who do 
not use the OCP (Pomp et al., 2007). It is important to consider this when 
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treating patients with lower limb injuries treated with cast, who may appear 
unlikely to develop VTE. An example is a 24 year old lady who developed a 
calf DVT 8 days after a non-operatively treated ankle fracture, with 
subsequent non fatal PE 2 weeks later (Harvey & Runner, 2011). Apart from 
her injury and cast treatment, her additional risk factors were current use of 
the oral contraceptive pill and that her body mass index was 34 kgm2. This 
patient required intensive care treatment for 2 days, with a total in patient stay 
of 6 days. She also required warfarin treatment for 6 months. This may have 
been prevented with chemical thromboprophylaxis (Harvey & Runner, 2011).  
 
Transient risk factors 
 
Pregnancy and post-partum related thrombosis 
VTE is responsible for 14.9% of maternal deaths in developed countries 
(Friedman, Ananth, Lu, D’Alton, & Wright, 2013). In a 30 year population 
based study of VTE during pregnancy or postpartum including 50 080 births, 
the annual incidence of VTE during pregnancy was 95.8 per 100 000 (Heit et 
al., 2005). The annual incidence of VTE in the postpartum period was 5 times 
higher (511.2 per 100 000). When pregnant women are admitted to hospital 
for one or more days other than for delivery or VTE, their annual risk of VTE 
was found to be 1752 per 100 000 in a study of 206 785 pregnant women in 
the United Kingdom. The annual incidence remained increased at 28 days 
after discharge (676/100 000) (Abdul Sultan et al., 2013). To put this into 
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context, a systematic review of comparative studies of VTE in first 6 weeks 
postpartum with non-pregnant, non-postpartum women of reproductive age 
found rates were 21.5 - 84 times higher in the postpartum women in first 6 
weeks postpartum (Jackson et al., 2011). In view of this increased risk of VTE 
in the postpartum period, which is higher than found in patients with lower 
limb trauma and cast treatment it is surprising that RCOG only recommends 6 
weeks of postpartum thromboprophylaxis for patients with thrombophilia and 
other VTE risk factors. In comparison, NICE guidelines recommend all 
patients with lower limb casts should be risk assessed for increased risk of 
VTE and provided with thromboprophylaxis where increased risk is identified 
(National Clinical Guideline Centre – Acute and Chronic Conditions (UK), 
2010). 
 
Oral Contraceptive Pill  
In an early study of 155 women who sustained VTE, with no risk factors for VTE 
apart from OCP use in the month prior to VTE, their relative risk of VTE was found to 
be increased (RR 3.8, 95% CI 2.4 - 6.0), when compared to 169 age matched 
healthy controls who did not use the OCP (Vandenbroucke et al., 1994). It seems 
apparent that the influence of OCP on VTE depends not only on the dose of 
estrogen, but also on the type of progestogen (Van Hylckama Vlieg & Rosendaal, 
2014). A systematic review and meta analysis in 2013 confirmed early findings by 
Vandenbrouke et al (1994), concluding that all combined oral contraceptives 
increased the risk of venous thrombosis (RR 3.5, 95% CI 2.9 to 4.3) (Stegeman et 
al., 2013). The safest combination reported as being 30 micrograms of 
ethinylestradiol with levonorgestrel by the recent Cochrane review (de Bastos et al., 
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2014). Progestin only contraceptives and implants to not appear to increase risk of 
venous thrombosis when used for contraceptive purposes (Mantha et al., 2012) 
(Tepper, Whiteman, Marchbanks, James, & Curtis, 2016).  
 
Hormone Replacement Therapy 
In a large case control study including 1082 women over age 50 years who sustained 
first time VTE and 1468 controls, oral contraceptive pill used to treat symptoms of the 
menopause was associated with an 6.3 fold increased risk of VTE (4.6 - 9.8). Other 
types of oral hormone replacement therapy increased the risk of VTE 4 fold (range 
1.8 - 8.2) (Roach et al., 2013). A recent Cochrane review of HRT in postmenopausal 
women confirmed this increased risk with both oestrogen only and combined therapy 
(Marjoribanks, Farquhar, Roberts, Lethaby, & Lee, 2017). Surprisingly, retrospective 
and prospective cohort studies suggest that transdermal HRT does not appear to 
increase VTE risk, although there are no randomized controlled studies to confirm 
this (Roach et al., 2013) (Eisenberger & Westhoff, 2014). 
 
Achilles tendon rupture 
Fatal pulmonary embolism can occur in young patients with no risk factors for 
VTE as early as within the first week following Achilles tendon rupture 
(Nesheiwat & Sergi, 1996; Venkatachalam & Wright, 2012). In a series of 205 
patients with partial or complete Achilles rupture, 6.3% sustained symptomatic 
VTE within 90 days of injury in the absence of thromboprophylaxis (Healy, 
Beasley, & Weatherall, 2010). Even after excluding patients who sustained 
below knee DVT, the combined incidence of symptomatic DVT or PE was 
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2.9% (n=7), all of whom were under the age of 60 years of age, with 3 
patients having no additional VTE risk factors (Healy et al., 2010). A study by 
Wallace at al (2011) found a lower incidence of symptomatic VTE, with 1.1% 
and 0.2% of 945 patients with Achilles tendon rupture sustaining DVT and PE 
respectively within 14 weeks of non-operative functional management 
(Wallace, Heyes, & Michael, 2011). Considering asymptomatic DVT events, it 
was recently shown that 62% (n=15) of 24 patients with open Achilles repair 
had evidence of thrombosis on Doppler ultrasound within 6 weeks of surgery 
in the absence of chemical thromboprophylaxis (Domeij-Arverud, Latifi, 
Labruto, Nilsson, & Ackermann, 2013). It appears that patients with Achilles 
tendon rupture are at particularly high risk of DVT, with many of these 
asymptomatic DVT’s resolving without causing symptoms. Considering that 
VTE events can occur early following injury it is critical that any form of VTE 
prophylaxis is provided as soon as possible following injury.  
 
Surgery 
The background risk of VTE for a middle aged female is approximately 
0.017% within a 90 day period (Sweetland et al., 2009). Comparing this to 
patients who undergo day surgery, including varicose vein surgery, the risk 
ranges from 0.15% to 1.2% depending on associated risk factors, such as 
active cancer (Pannucci et al., 2012). For patients who undergo in patient 
surgery, the risk of VTE is 100 times increased compared to non-operative 
controls in the first 6 weeks following surgery (Sweetland et al., 2009). The 
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risk of symptomatic VTE or death from PE is also highest in first 6 
postoperative weeks (Sweetland et al., 2009).  
 
In the context of Orthopaedic surgery, foot and ankle operations are 
considered by most health care professionals to be low-risk for the 
development of VTE (Wukich & Waters, 2008) (Jameson et al., 2011). 
However, in a study of symptomatic VTE rates within 90 days of 88,241 foot 
and ankle procedures over a 42 month period across the English NHS it was 
found that VTE rates following ankle fracture fixation, hindfoot fusion or first 
metatarsal osteotomy, were 0.28%, 0.142% and 0.027% respectively 
(Jameson et al., 2011). Comparing this with the data from the million women 
study by Sweetland et al (2009), these rates are 17, 8 and 1.6 times the 
background VTE rate respectively (Sweetland et al., 2009). This paper 
concluded that thromboprophylaxis was not necessary in these patients 
(Jameson et al., 2011). It is important to recognize however that the 
aforementioned studies may not be directly comparable. The background 
incidence of VTE found in the million women study may differ from the 
background risk in the study by Jameson et al (2011) due to differences in the 
patient population (gender, age, co-morbidities). When compared to surgery 
in general, which increases risk 100 times in the first 6 post-operative weeks, 
and compared to VTE risk following hip or knee replacement (165 times 
increased risk) these rates may appear low, however they are still increased 
compared to patients who do not undergo surgery (Sweetland et al., 2009). It 
is also important to acknowledge that the study by Jameson et al (2011) has 
several limitations, including that it was not even stated whether patients 
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received thromboprophylaxis (Jameson et al., 2011). It also appears that VTE 
rates in this study underestimate true VTE rates. One example is that only 
0.061% of 1633 patients who underwent total ankle replacement (TAR) 
sustained symptomatic VTE. This is considerably lower than the incidence in 
the study by Barg et al (2011), in which 3.9% of 665 patients sustained 
symptomatic DVT within a mean of 15.2 days following TAR, despite the use 
of chemical thromboprophylaxis (Barg, Henninger, & Hintermann, 2011). Even 
if the below knee DVT’s are excluded from the study by Barg et al (2011), the 
symptomatic DVT incidence is still 0.45%, which is more than 7 times greater 
rate than reported by Jameson et al (2011) (Jameson et al., 2011).  
 
In contrast, elective hip or knee arthroplasty is universally considered high risk 
for VTE irrespective of other factors (Mont et al., 2011). Symptomatic VTE or 
fatal PE is even more common in patients undergoing hip or knee arthroplasty 
than those who undergo cancer surgery in first 6 postoperative weeks 
(Sweetland et al., 2009). Within 90 days of surgery, between 1.69 and 1.84% 
of over 100,000 patients who underwent hip or knee replacement sustained 
symptomatic VTE (Jameson, Bottle, Malviya, Muller, & Reed, 2010). The 
increased risk in comparison with foot and ankle surgery is multifactorial but is 
likely to be related to the greater surgical insult to bone and soft tissue. 
Although patients who undergo TKR may have complete venous stasis in the 
lower limb secondary to tourniquet, a study by Hanslow et al (2006) did not 
find an association between tourniquet use and objectively confirmed 
symptomatic VTE in 602 patients who underwent foot and ankle surgical 
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procedures, despite use in 90% of cases for a mean duration of 62 minutes 
(Hanslow, Grujic, Slater, & Chen, 2006). 
 
Lower limb trauma and cast treatment 
Lower limb trauma and fracture is considered to be a major transient risk 
factor for VTE (White, 2012) (Bĕlohlávek, Dytrych, & Linhart, 2013). For 
example, in a large case-control study of 1470 women with first time VTE and 
1590 controls, the highest risk for VTE was a combination of lower limb cast 
and surgery, which resulted in a 50 times increased risk of VTE in both pre 
and post-menopausal women (Bergendal et al., 2012). However, it is difficult 
to isolate the trauma from other factors that influence VTE, including 
treatment with cast, surgery and associated immobility. In a large population 
based, case-control study of 2471 patients and 3534 controls with minor lower 
limb injuries, not requiring surgery or plaster cast were associated with 3 fold 
increase in VTE. The excess risk disappeared at 10 weeks post injury (van 
Stralen et al., 2008). In reality, almost 80% of patients with a lower limb cast 
or splint have an additional risk factor, including age over 40 years, personal 
or family history of VTE, thrombophilia, immobilization (>4 days bed rest), 
pregnancy or post partum (within 6 weeks), cancer, heart failure, respiratory 
failure or inflammatory disease, hormonal therapy or obesity (BMI >30 kgm2) 
(Decramer et al., 2008). 
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Many studies suggest that lower limb cast and trauma account for a relatively 
small number of cases of deep vein thrombosis. For example, of 882 patients 
who sustained symptomatic DVT, only 3.9% of patients reported use of a 
lower limb cast in the preceding month (Isma et al., 2009). Similarly, in a 
series of 577 patients who underwent duplex USS for suspected DVT, 
Geersing et al (2010) reported that only 4% had leg trauma in the preceding 4 
weeks (Geersing et al., 2010). Galanaud et al (2009) reported a greater 
association in a series of 933 patients with symptomatic distal DVT, in which 
9% reported a history of recent plaster cast of the leg (Galanaud et al., 2009). 
Similarly, Aldington et al (2008) found in a cross sectional study of 61 patients 
under the age of 65 years of age who sustained VTE that 12% reported an 
injury in the preceding 4 weeks (Aldington et al., 2008). However, there was 
no control group for comparison.  
 
Many assumptions have been made regarding the pathogenesis of deep vein 
thrombosis in patients treated with lower limb cast, however many basic 
questions remain unanswered. For example, it is unknown whether DVT 
occurs solely in the limb that has been injured and casted. Furthermore, the 
cast has been assumed to cause stasis, but this also has never been proven. 
The cast has also been assumed to cause immobility of the wearer, but again, 
this has never been studied. Perhaps it is the tissue injury that predisposes to 
venous thrombosis?  
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2 Narrative Review 
 
2.1 Thromboprophylaxis in patients with below knee cast 
immobilization for trauma 
 
DVT has a consistent relationship with PE (National Clinical Guideline Centre 
– Acute and Chronic Conditions (UK), 2010), with 20% of calf DVT’s 
propagating to the thigh before they embolise (Philbrick & Becker, 1988). One 
of the challenges is that symptoms and signs for DVT are unreliable, with 
approximately 50% of patients with suspected DVT having normal venous 
phlebography (Cranley, Canos, & Sull, 1976). Distal DVT is more often 
associated with transient risk factors whereas proximal is associated more 
with permanent risk factors such as cancer (Galanaud et al., 2009). However, 
after excluding deaths by cancer, the 3 month mortality rate following proximal 
and distal DVT is equivalent (Galanaud et al., 2009). Patients with first time 
symptomatic DVT have a recurrence rate of 23.2% at 5 years follow up. 
However, the risk of recurrence in patient with symptomatic DVT confined to 
the calf is 4 times lower compared with patients with symptomatic proximal 
DVT or PE (Baglin et al., 2010). Nevertheless, despite chemical treatment for 
a VTE event provoked by a non-surgical factor such as lower limb trauma with 
cast immobilisation, 5.8% will develop a recurrence within the following year 
(Iorio et al., 2010). Even if this risk of morbidity and mortality associated with 
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acute venous embolism was acceptable to the patient, one of the greatest 
burdens to society is post-thrombotic syndrome and the cost of treating long 
term complications of VTE. In England alone, this is estimated to cost in 
excess of £640 million per year (L. N. Roberts & Arya, 2011).  
 
Another significant outcome of DVT is the development of post-thrombotic 
syndrome. This is a chronic condition characterized by lower limb skin 
changes and ulceration, which results from damage to the deep veins of the 
lower limbs following deep vein thrombosis. During the process of 
recanalization, venous valves are destroyed which causes venous 
hypertension secondary to reflux (O'Donovan, O'Keeffe, Grace, & Lyons, 
2005). Incomplete thrombus resolution results in residual venous obstruction 
which further impairs venous return (Kahn, 2006). Following first time DVT, 
20% of all segments develop reflux on duplex scanning at 3 months, despite 
anticoagulation and compression stockings (M. C. Janssen, Wollersheim, 
Haenen, van Asten, & Thien, 1998). However, Janssen et al (1998) also 
found a statistically significant reduction in thrombus mass in all of 60 patients 
on duplex ultrasound at 3 months following symptomatic first time DVT, who 
had been treated with coumarin derivatives and compression stockings, with 
total clot resolution in 40% (M. C. Janssen et al., 1998). Clinical symptoms 
and signs of post-thrombotic syndrome occur in between 20 to 50% of 
patients who sustain symptomatic DVT (Kahn & Ginsberg, 2004). Even with 
elastic compression stocking treatment, 25% of 1668 patients with first time 
DVT were found to develop post-thrombotic syndrome within the following 
year (Tick, Kramer, Rosendaal, Faber, & Doggen, 2008). In a prospective 
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study of 111 patients by Tick et al (2010), post-thrombotic syndrome was 
clinically evident in 46% of patients at 3 months on CEAP scoring, with no 
further increase at 2 years (Tick et al., 2010). In a series of 254 patients with 
objectively proven DVT, Kahn et al (2008) reported similar findings, with 43% 
of patients showing signs of post-thrombotic syndrome at 2 years after VTE 
event, 3% of which were severe (Kahn et al., 2008). However, at follow up of 
10 years following symptomatic DVT, only 27% of 82 patients had no signs of 
post-thrombotic syndrome (Haenen et al., 1999) suggesting that with 
increased time following the index DVT event, chronic venous hypertension 
will eventually result in post-thrombotic changes. Milne et al (1993) found all 
of 107 patients at median follow up of 8 years after venographically proven 
DVT had signs of post-thrombotic syndrome, of which 35% of these cases 
were severe with lipodermatosclerosis or skin ulceration (Milne, Stonebridge, 
Bradbury, & Ruckley, 1994). In view of the costs to society and the fact that 
there are few effective treatments for post-thrombotic syndrome, it is critical 
that VTE is respected and prevented (Prandoni & Kahn, 2009) (Kahn & 
Ginsberg, 2004). 
 
Venous thromboembolism affects approximately 1 in 1000 people per year 
(Silverstein et al., 1998). Lower limb trauma and cast immobilization increases 
this risk, with incidences of VTE ranging from 4.3 to 40% in patients who have 
been treated with cast immobilization for at least 1 week (Testroote, Stigter, 
de Visser, & Janzing, 2011b). Chemical thromboprophylaxis can reduce the 
risk of developing VTE in this patient group (Testroote, Stigter, Janssen, & 
Janzing, 2014). In view of this, it is recommended that all patients with lower 
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limb trauma treated with cast immobilization should be individually assessed 
for risk of venous thromboembolism risk and provided with 
thromboprophylaxis where increased risk is identified (National Clinical 
Guideline Centre – Acute and Chronic Conditions (UK), 2010). The 
assumption is that patients without additional risk factors for VTE do not 
require thromboprophylaxis because their risk is lower. However, according to 
some VTE risk assessment tools, it is suggested that any patient with an 
immobilizing cast is at moderate risk of developing DVT (10-20%) and 
thromboprophylaxis is indicated (Caprini, 2005). Some authors recommend 
thromboprophylaxis for all patients with immobilisation of the lower extremity, 
irrespective of age and other risk factors (Testroote, Morrenhof, & Janzing, 
2011a). The benefit of this practice is that all patients who would otherwise 
develop VTE would be provided with prophylaxis, however many patients who 
would not otherwise develop this complication would un-necessarily receive 
LMWH with associated risks and costs. 
 
Patients with lower limb trauma and immobilization are at risk of venous 
thromboembolism (VTE). The most serious complication of this is death from 
Pulmonary Embolism (PE), which occurs in approximately 1 in 15000 patients 
(Jameson et al., 2014). Although fatal pulmonary embolism is the most 
serious thromboembolic complication, it is not the only significant outcome. 
Approximately 1 in 500 patients will develop a symptomatic PE within 90 days 
of injury (Jameson et al., 2014). Many of these patients will be functionally 
impaired at long term follow up (Chow et al., 2014). The other significant 
complication is symptomatic deep venous thrombosis, which occurs in 
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approximately 1 in 250 patients with non-operatively treated lower limb trauma 
(Selby et al., 2014). 20 to 50% of these patients will develop post-thrombotic 
syndrome (Kahn & Ginsberg, 2004). This condition is difficult to treat and 
therefore it is important to avoid. Considering that lower limb casts and splints 
are commonly used for a variety of soft tissue and bony traumatic conditions, 
the population of patients at risk of developing VTE is significant.  
Many consider immobilisation of the lower limb to be an independent risk 
factor for deep vein thrombosis and pulmonary embolism and therefore 
provide chemical prophylaxis to all patients with leg casts (Menakaya et al., 
2013) (Hanslow et al., 2006). Other authors have suggested prevention of 
VTE should be provided to patients with additional risk factors, which include 
age over 50 years of age, non-weight bearing and severe injury (Horner, 
2011). National guidance recommends that patients with trauma and lower 
limb immobilization should be risk assessed for VTE. Where elevated risk is 
identified they should be provided with chemical thromboprophylaxis (National 
Clinical Guideline Centre – Acute and Chronic Conditions (UK), 2010).  
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2.2 Effect of below knee cast application on calf pump 
function in healthy volunteers 
 
Plaster of Paris has been used to immobilise fractures for over 150 years (R. 
T. Austin, 1983). An assumption has been made that lower limb cast 
immobilization results in venous stasis, which predisposes these patients to 
VTE (Craik, Clark, Hendry, Sott, & Hamilton, 2015). However, there is little 
published literature to support this. Although Craik et al (2015) found that full 
weight bearing in 10 healthy volunteers with below knee casts applied 
resulted in significantly greater time averaged peak and mean venous 
velocities measured in the popliteal vein as compared to partial or non-weight 
bearing, they failed to compare popliteal velocities before and after cast 
application (Craik et al., 2015). Therefore, although weight bearing with as 
cast applied is important, this study did not show that application of a below 
knee cast causes venous stasis. In a small study of 8 healthy volunteers who 
had below knee casts applied, Sugwara et al (2004) found that arterial blood 
flow and femoral artery lumen diameter was reduced after just 7 days, 
however these changes were completely reversed without any specific 
rehabilitation within 14 days of removal of cast (Sugwara et al., 2004). In the 
absence of cast application, lower limb trauma has been shown to result in 
impaired venous outflow. Wilson et al (2002) found in their study of 126 
patients with hip fracture, that venous outflow measured using strain gauge 
plethysmography was significantly reduced in the injured limb at 6 weeks 
postoperative as compared to pre operative measurements and the un injured 
lower limb (D. Wilson et al., 2002). This reduction in venous outflow was 
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found to be associated with the development of venous thromboembolism. 
Considering that none of these patients were treated with lower limb casts, it 
appears that venous stasis and subsequent thromboembolism occurs 
following lower limb trauma even in the absence of below knee cast (D. 
Wilson et al., 2002). The starkest example of stasis causing thrombogenesis 
is in patients who sustain cardiac arrest. In a study of 88 adult patients with 
out of hospital cardiac arrest, all patients had blood drawn at time of CPR for 
arrest and measured for thrombin-antithrombin (TAT) complexes. Mean time 
prior to initiating CPR was 12.1 minutes, during which time complete 
circulatory stasis can be assumed. Mean TAT was 159.2 micrograms per litre 
(range 0.79 to 1343.9). Only one of these patients had a TAT in the normal 
range, indicating that increased thrombogenesis is universally present among 
patients with non-traumatic out of hospital cardiac arrest. It is not stated what 
proportion of these patients went on to develop venous thromboembolism 
(Hostler, Callaway, Newman, & D'Cruz, 2007). Considering that complete 
circulatory stasis results in increased thrombin-antithrombin complexes, which 
indicate a hypercoagulable state, it would be reasonable to consider that 
tourniquet use may have similar effects. However, although a lower limb 
tourniquet was applied in 97% of 1000 consecutive patients who underwent 
foot and ankle surgery, only 4 patients sustained symptomatic DVT. In one of 
these cases, an intra-operative tourniquet was not used. The other 3 who did 
have tourniquet had it applied for 21, 60 and 90 minutes respectively. None of 
the other patients developed symptomatic DVT despite their tourniquet use. In 
view of this, it appears that even complete venous stasis below knee is 
unlikely to result in symptomatic DVT and is likely to be a weak factor in the 
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pathogenesis of venous thromboembolism (Wukich & Waters, 2008). It 
therefore appears unlikely that application of a below knee cast will result in 
significant stasis. Rather, other factors common to patients with casts, 
including the injury, resulting in subsequent endothelial dysfunction may be 
more important. This requires further study. 
Muscle bulk and joint range of motion has consistently been shown to 
decrease in a lower limb which has been treated with cast immobilization 
(Halanski & Noonan, 2008).  In a study of 18 patients with stable ankle 
fractures, MRI cross sectional imaging of calf muscles revealed a statistically 
significant reduction in calf muscle anatomical cross-sectional area within just 
8 days of below knee cast treatment (Psatha et al., 2011). After cast treatment 
for 6 weeks, the gasctrocnemius and soleus muscle atrophied by 17-24% 
(Psatha et al., 2011). The longest recorded duration of below knee cast 
treatment was in a 45 year old lady who wore a below knee polymer cast for 
28 months due to psychological dependence. Her calf circumference was 
reduced by 5.5cm compared to her uncasted limb. Surprisingly she did not 
develop deep vein thrombosis. In healthy volunteers, above knee cast 
application has similar effects on muscle bulk. Thom et al reported that after 
just 10 days of non-weight bearing above knee cylinder cast application to the 
lower limb in 8 healthy females, quadriceps muscle cross sectional area 
decreased significantly by almost 12 percent (Thom et al., 2001). Snijders et 
al (2013) reported similar findings in 12 men of mean age 24 years after 2 
weeks of above knee cast application. Quadriceps cross sectional area 
reduced by 8%, with 7% and 13% reduction in type 1 and type 2 muscle fibre 
sizes respectively (Snijders et al., 2013). In the same study, lower limb muscle 
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strength was also found to decrease, with a reduction in single leg extension 
one rep max by 23% (+/-3). Following 6 weeks of natural rehabilitation, 
strength returned to baseline values (Snijders et al., 2013). In a larger study of 
48 healthy volunteers by Hortobágyi et al (2000), above knee cylinder cast for 
3 weeks resulted in a 47% reduction in eccentric, concentric and isometric 
quadriceps muscle strength. Interestingly, spontaneous recovery occurred 
over the 2 weeks following cast removal (Hortobágyi et al., 2000). Type 1 and 
2 muscle fibre cross sectional area from vastus lateralis muscle biopsy also 
reduced by between 13 and 10% respectively (Hortobágyi et al., 2000). 
Similar findings were reported by Hvid et al (2011) in vastus lateralis biopsies 
of 9 healthy young men who worse above knee casts for 2 weeks. Cross 
sectional area of myosin heavy chain 2a fibres significantly reduced by 4% 
(p=<0.05), however myosin heavy chain 1a remained unchanged (Hvid, 
Ortenblad, Aagaard, Kjaer, & Suetta, 2011). A marked reduction in single 
muscle fiber force of contraction, of between 21 and 30% was also evident. 
 
Even bone density is affected in patients lower limb trauma treated with casts. 
This occurs in both children and adults. In an age and sex matched study of 
adolescents between 10 and 16 years of age who were treated with cast for 
leg or ankle fracture, bone mineral density was reduced by between -5.8 and -
31.7% (Ceroni, Martin, Delhumeau, et al., 2012a). These changes were not 
present at 18 months follow up (Ceroni et al., 2013). In a series of 14 adult 
patients with non-operatively stable ankle fractures, bone mineral density was 
significantly reduced at 6 weeks following injury (12% reduction) compared to 
un injured ankle as control (Ingle, Hay, Bottjer, & Eastell, 1999). This returned 
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to normal within 1 year following injury. However, there was also a statistically 
significant reduction in bone mineral density in the greater trochanter (3% 
reduction), which did not return to normal within a year following injury (Ingle 
et al., 1999). 
Application of a lower limb cast has traditionally been considered to cause 
venous stasis in the casted limb (Thomas & Van Kampen, 2011). Stasis leads 
to hypoxia at the level of the deep venous valve cusps, which can trigger 
thrombogenesis (Agutter, Malone, & Silver, 2012). The two predominant 
factors influencing venous blood flow are ‘vis a tergo’, resulting from the 
continuous entry of blood into venules from capillary beds and secondly, the 
upward pressures of weight bearing on the foot with subsequent muscle 
contraction. In the absence of weight bearing or muscle contraction, the ‘vis a 
tergo’ results in continuous non-pulsatile flow in the deep veins, which 
subsequently results in vortices at the mouth of deep vein valve cusps with 
stagnation of blood and local hypoxia at the level of valve cusp endothelium. 
This thrombogenic environment results in local damage to valve cusp 
endothelium, with release of tissue factor, which attracts platelets and 
leukocytes with subsequent thrombus formation. During calf pump contraction 
or weight bearing, intermittent flow is restored, which empties stagnant valve 
pockets, bringing fresh blood with active platelets and leuokocytes, which 
subsequently attack the necrotic valve cusp endothelium. It is felt that these 
cycles of continuous and turbulent blood flow result in formation of layered 
thrombus (Agutter et al., 2012). With this in mind, application of a lower limb 
cast may interfere with the normal balance of continuous and pulsatile flow in 
the lower limb venous system, due to restriction of muscular contraction of the 
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calf pump. This may be the result of both immobilization of joints, but also by 
functional inactivation of the calf pump resulting from restricted weight bearing 
in these patients. 
 
The first demonstration of this theory in practice was by Gardner and Fox in 
1983. In their study, intravenous contrast was injected into the dorsal vein of 
the foot of 5 participants, who subsequently had imaging of lower limb venous 
system with video phlebography during weight bearing. During weight 
bearing, it was shown that 20 to 30ml of blood was forcefully pushed into the 
deep veins of the legs. The majority of this blood came from the venae 
comitantes of the lateral plantar artery of the foot (Gardner et al., 1990). 
Surprisingly, it appeared that active toe or ankle movement in the non-weight 
bearing limb did not influence the pooling of contrast in the plantar veins. The 
interpretation of this study was that weight bearing is the more important than 
muscular activity in influencing venous return from the leg. However, it is 
important to recognize that although active muscular contraction of the calf 
pump did not empty the veins of the foot, it is also clearly stated that active 
ankle dorsiflexion and plantar flexion both also empty the deep veins of the 
calf (Gardner et al., 1990). 
 
Elsner et al subsequently examined the venous anatomy of the foot and found 
networks of veins closely related to the plantar aspect of flexor hallucis longus 
tendon at the levels of the inter phalangeal and metatarsophalangeal joints 
(Elsner et al., 2007). These veins had valves and were surrounded by a thick 
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connective tissue capsule, which was put under tension during passive 
dorsiflexion of the great toe. Passive movement of the 1st 
metatarsophalangeal joint in 10 cadaveric feet revealed that this venous 
system acted like a pump, to expel blood proximally into the foot (Elsner et al., 
2007). In the clinical setting this was also found to be the case in 40 healthy 
volunteers who performed passive toe mobilization. In this study, Doppler 
ultrasound was used to measure baseline and peak venous velocities at the 
popliteal vein at rest and during passive and active toe movement. Baseline 
velocity significantly increased from 13.7 cm/s to 33.3 cm/s during passive 
and 38.9 cm/s with active toe movement respectively. The conclusion of this 
study was that toe movements could provide a means for mechanical 
thromboprophylaxis (Elsner et al., 2007). It is interesting to note that in a 
similar study by Craik et al, baseline popliteal velocity in a non-weight bearing 
casted leg was 8cm/s, which significantly increased to 24.3cm/s during 
simulated weight bearing in cast (Craik et al). However, comparing these 
findings with those by Elsner et al, it appears that passive and active toe 
movement result in greater increases in popliteal velocity as compared to 
weight bearing alone. 
 
In a dynamic study of foot pump function during gait, the foot pumping 
mechanism was examined in 20 healthy volunteers during treadmill walking at 
differing speeds. This examined the combined effect of weight bearing and 
active toe movement. It is impractical to measure popliteal vein velocity during 
gait, therefore venous pressures in the dorsal vein of the foot were directly 
measured by a transducer system. In the upright resting position, foot 
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pressures were approximately 90mmHg. During walking, blood was pumped 
out of the lower limb and pressures decreased to 60-70mmHg. The relevance 
of this study to patients with lower limb cast immobilization was that restricting 
the range of motion at the knee or ankle resulted in reduced foot pump 
efficiency, with less reduction in venous pressures during walking. This study 
suggests that a patient with cast immobilization of the ankle, will have less 
efficient foot pump function. In contrast to the study by Elsner et al, the effect 
of great toe movements were not examined (Kügler, Strunk, & Rudofsky, 
2001).  
 
The clinical implication of isolated ankle immobilization appears to have an 
insignificant effect on venous thromboembolism. For example in patients with 
hind foot fusion, the symptomatic rates of deep vein thrombosis or non-fatal 
pulmonary embolism were found to be only 0.028% and 0.114% respectively 
in a series of 7033 patients in the English NHS (Jameson et al., 2011). This 
suggests that the foot pump mechanism may be able to compensate for 
reduced ankle motion, providing toe movement and/or weight bearing 
continue.  
 
Cast application to the lower limb appears to have significant detrimental 
effects on the lower limb muscle bulk and strength, with changes seen also in 
the bones of the lower limb. However, there is little evidence that cast 
application to the lower limb in isolation results in venous stasis. Further study 
is necessary to determine the relative importance of venous stasis, 
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endothelial dysfunction and hypercoagulability in patients with lower limb 
trauma treated with casts in order to improve understanding of the 
development of venous thromboembolism in these patients. 
 
2.3 The effect of active toe movement (AToM) on calf pump 
function and asymptomatic deep vein thrombosis in patients 
treated with acute foot and ankle injury treated with cast – A 
Prospective Randomised Controlled Trial 
 
Thromboprophylaxis is clinically and financially beneficial compared with 
treatment of thromboembolic events once they have occurred (Alikhan et al., 
2004). In patients with lower limb trauma treated with cast, 
thromboprophylaxis significantly reduces venous thromboembolism rate, with 
thirteen patients requiring prophylaxis with low molecular weight heparin to 
prevent one asymptomatic DVT (C. Roberts, 2012) (Testroote, Stigter, de 
Visser, & Janzing, 2011b) (Ettema, Kollen, Verheyen, & Buller, 2008). 
Considering that chemical thromboprophylaxis for patients with lower limb 
cast immobilisation represents 5.3% of the outpatient tariff for trauma, this is a 
significant expense (Menakaya et al., 2013). This also represents a potential 
risk, in view that chemical thromboprophylaxis can cause major bleeding 
(National Clinical Guideline Centre – Acute and Chronic Conditions (UK), 
2010). Patients with lower limb trauma treated with casts are also advised to 
participate in activities of early mobilisation and calf pumping exercises to 
reduce their risk of developing DVT (Le Sage, Marianne McGee BSc, & 
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Jessica D Emed RN, 2014). Although it has previously been found that active 
toe movement increases venous velocities in the popliteal vein in healthy 
volunteers, even with a below knee cast applied, the clinical importance of 
these findings requires further investigation (B. A. Hickey et al., 2014) 
(Parsons, Hiskens, Price, Achten, & Costa, 2011). Most studies rule out 
mechanical thromboprophylaxis in patients with below knee casts for various 
reasons (Parsonage, 2009) (Decramer et al., 2008). However, considering 
that venous stasis is thought to contribute to thrombogenesis, it is possible 
that regular active toe movement (AToM) in the form of regular active 
dorsiflexion and plantarflexion could reduce the development of deep vein 
thrombosis in patients with injury and cast treatment (Virchow, 1856).  
 
2.4 The association between mobility and subsequent 
development of Deep Vein Thrombosis in patients with lower 
limb trauma and cast treatment 
 
Immobility has long been recognized to be a contributory factor in the 
development of deep venous thromboembolism. Almost 60 years ago, Gibbs 
et al (1957) reported in a post mortem study of 253 patients, that patients who 
were confined to bed rest of 0 to 4 days prior to death had a deep vein 
thrombosis (DVT) incidence of 8% (n=6) at post mortem as opposed to 28% 
(n=10) in those who were confined to be for 4 to 7 days prior to death (Gibbs, 
1957). In view of this, patients are encouraged to mobilise early following 
surgery, as it is felt that early mobilization will stimulate the calf muscle pump 
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and limit venous stasis (E. Wilson, 2007). One of the challenges in the study 
of mobility and subsequent development of VTE is that the definition of 
immobility is variable between studies and mobility in many patient groups, 
such as those with lower limb casts, has not been studied (Emed, Mossison, 
Rosiers, & Kahn, 2010). For example, Spyropoulos et al defined immobility as 
confinement to a bed or chair for more than 24 hours (Spyropoulos et al., 
2011). In contrast, other studies have used definitions of immobility as 
expected bed rest of up to 10 or more days (Harenberg et al., 1990). A recent 
systematic review of immobility in hospitalized medical patients acknowledged 
this considerable inconsistency in the definition of immobility and it was 
concluded that further research is needed to define and standardise this 
concept (Emed et al., 2010). Although the most frequent definition of 
immobilization in epidemiological studies of venous thromboembolism is 
confinement to bed or bed rest lasting more than 3 days (Pottier et al., 2009), 
this issue is further complicated by the recent finding that overall correlation 
between patient reported mobility and accelerometer-assessed physical 
activity can be low (Spearman’s r = 0.3) (Sabia et al., 2014).  
 
Although seated immobility at work for more than 8 hours in a 24 hr period, 
within the 4 weeks prior to VTE is common in patients who develop DVT/PE 
(34% of 61 patients), this is not conclusive evidence of a causal relationship 
because there was no control group (Aldington et al., 2008). It could be 
argued that this level of mobility reflects the sedentary jobs of modern society. 
The term eThrombosis was coined in 2003, when a 32 year old man 
developed a life threatening pulmonary embolism after prolonged immobility 
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sitting at a computer, regularly for periods of between 12-18h per day, with 
consecutive sitting of 1-6 hrs without standing. (R. Beasley, Raymond, Hill, 
Nowitz, & Hughes, 2003). A similar case was reported by Chang et al (2013) 
of a 31 year old man who developed a DVT after sitting playing computer 
games for 8 hours per days for four days whilst on holiday (Chang, Burbridge, 
& Wong, 2013). Death from fatal pulmonary embolism has also been 
attributed to several consecutive days of immobility following sleeping in a car 
following an earthquake and from physical restraint in a man with acute 
psychosis (Inoue, 2006) (Cecchi, Lazzaro, Catanese, Mandarelli, & Ferracuti, 
2012).  
Patients who are physically trapped prior to hospital admission, for example in 
a car and requiring extrication have been shown to have increased VTE rates. 
In a retrospective review of 15,159 trauma patients over a 10 year period, 
1176 patients were identified from a database which recorded pre-hospital 
entrapment. This was significantly associated with both increased risk of DVT 
(OR 5.22) and PE (OR 3.16). Even with multivariate analysis this proved to be 
a contributing factor for VTE (OR 1.54) (Rogers et al., 2011). It appears that 
there is an association between reduced mobility and development of VTE, 
however this is difficult to quantify. 
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2.5 Can we use biomarkers of coagulation to predict which 
patients with foot and ankle injury will develop deep vein 
thrombosis? 
 
Patients with foot and ankle trauma treated with leg casts are at risk of venous 
thrombosis (VTE). The majority of VTE risk assessment tools assess patient 
and treatment factors, including mobility, body mass index and surgery to risk 
stratify patients, but they have limited accuracy for predicting VTE in this 
patient group. None consider the endothelial dysfunction and 
hypercoagulability that occurs secondary to injury. It would be useful to be 
able to predict which patients will develop DVT after injury because this would 
enable thromboprophylaxis to be provided to those at greatest risk, which 
would provide greatest benefit.  
 
Tissue injury results in activation of the coagulation cascade through initiation 
of the extrinsic coagulation pathway. The primary cellular activator of this 
process is tissue factor (TF), which is released by tissues in response to injury 
(Manly, Boles, & Mackman, 2011) (Caprini, Arcelus, & Reyna, 2001). Tissue 
injury may be the result of trauma, such as an ankle fracture. More recently it 
has been suggested that other mechanisms including heavy smoking with 
oxidative stress, cancer and immobilization with focal vessel ischaemia may 
share a common pathway of cell death to trigger venous thromboembolism 
(Golomb, Chan, Denenberg, Koperski, & Criqui, 2014). Once TF is exposed to 
blood, it acts as a receptor for factors VII and VIIa. This complex subsequently 
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activates coagulation factors IX and X, which marks the beginning of the 
common coagulation pathway whereby prothrombin is converted to thrombin, 
which stimulates the formation of a fibrin clot (Manly et al., 2011).  
 
Under normal conditions, the endothelial surface is not thrombogenic, with 
substances including thrombomodulin, tissue factor pathway inhibitor and 
plasminogen activator acting to prevent thrombosis (Wakefield, Myers, & 
Henke, 2008). However, in the conditions of endothelial injury, the endothelial 
surface vasoconstricts to become pro-inflammatory, due to the action of 
endothelin 1, platelet activating factor and other procoagulant molecules 
(Wakefield et al., 2008) (Piazza, 2013). Activation of the endothelial surface 
also results in movement of the adhesion molecule, soluble p-selectin (sPsel) 
from the endothelial cell Wiebel-Palade body to the endothelial surface (Ley, 
2003). This regulates leukocyte migration from the circulation and supports 
initial tethering to the endothelial cells and platelets (Antonopoulos, Sfyroeras, 
Kakisis, Moulakakis, & Liapis, 2014). Combined with abnormal venous flow 
with relative stasis and low shear at the endothelial surface, these conditions 
are optimal for thrombogenesis (Virchow, 1856).  
 
Samuels and Webster (1952) first documented the effects of vascular 
endothelial injury on haemostasis in a dog model. In this experiment, 14 
femoral veins, 25 jugular veins and 7 inferior vena cavae were dissected and 
removed under anaesthetic and subjected these to mechanical and chemical 
injury to assess the response. The initial phase of thrombosis occurred with 
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minimal trauma as a sequence of platelet adherence to cement substance, 
with coalescence of platelets to form thrombi. Finally, fibrin was deposited on 
the platelet thrombi surface with subsequent fibrin masses spread along inter-
cellular lines and across the cell bodies (Samuels & Webster, 1952). If the 
injury was severe or prolonged, the process progressed to phase 2 in which 
the endothelial surface was disrupted, with pathologic anatomic changes to 
the endothelial cells. These changes were proportional to the time of 
application of crushing, indicating that more severe trauma results in more 
significant changes in the venous endothelium (Samuels & Webster, 1952).  
 
As discussed, tissue factor release from endothelium and p selectin represent 
the initiation of thrombogenesis. In the clinical context, these markers of 
haemostasis have been used to identify hypercoagulable states secondary to 
injury or identify cases in which venous thrombosis has occurred. For 
example, p selectin has been shown at meta analysis level of 2429 patients to 
be significantly elevated in patients with deep vein thrombosis, independently 
of other factors know to be associated with increased levels e.g. solid organ 
tumour, HIV (odds ratio for venous thromboembolism 2.89, 95% CI 2.32-3.61, 
P<0.001) (Antonopoulos et al., 2014). In the context of Orthopaedic surgery, 
encrypted mononuclear cell tissue factor procoagulant activity significantly 
increases on day 1 and 2 after knee replacement, decreasing to normal levels 
by day 6. In this study, it was raised in all 19 patients (G. J. Johnson, Leis, & 
Bach, 2009).  
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Recently, Inflammatory cytokines such as Interleukin 6 and adhesion 
molecules including Vascular cell adhesion molecule 1 (VCAM-1) have been 
found to be associated with development of venous thrombosis (Mosevoll, 
Lindås, Tvedt, Bruserud, & Reikvam, 2015) (Hou et al., 2012). However, it is 
unclear whether these can be used to predict which patients will develop 
venous thrombosis.  
 
During clot resolution, fibrin is degraded into d-dimer and fibrin degradation 
products (Rectenwald et al., 2005). Thrombin-antithrombin (TAT) complexes 
are also found in patients with thrombus formation (Hostler et al., 2007). In a 
study of d-dimer levels pre and post total hip replacement in 63 patients, 
mean d-dimer levels increased approximately 10 times baseline levels at day 
7 following surgery (preoperative level 0.88 +/- 0.71 micrograms per mil to 
9.26 +/- 4.87). D-dimer was still significantly raised compared to pre surgery 
levels at 21 days following surgery. Although none of these patients had lower 
limb venous imaging to screen for deep vein thrombosis, this study suggests 
that hip replacement surgery is a prothrombotic event (Fujisawa, Naito, 
Asayama, Kambe, & Koga, 2003). This has been well established in previous 
studies (Mont et al., 2011) (Abraham, Ternisien, Hubert, Pidhorz, & Saumet, 
1999).  
Considering the literature discussed, it may be possible to use biomarkers of 
tissue injury and coagulation to identify patients with prothrombotic states 
following lower limb trauma. This may enable risk stratification of those who 
would benefit most from thromboprophylaxis. 
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2.6 Aims and objectives of this work 
 
The aim of this work is to firstly to critically interrogate the literature for the 
effects of chemical and mechanical thromboprophylaxis in patients with foot 
and ankle trauma treated with leg cast immobilisation. The secondary aims 
are to determine the laterality of venous thrombosis in relation to the casted 
and injured leg, and determine the roles of venous stasis, immobility and 
tissue injury in the development of DVT in these patients.  
Only by understanding the relative contributions of each will it be possible to 
develop strategies to identify those at greatest risk of developing thrombosis 
and accurate methods of prevention. 
 
Objectives 
In order to identify best practice in the prevention of VTE in patients with acute 
foot and ankle injury treated with leg cast, it is pertinent to review the literature 
for or against use of chemical or mechanical thromboprophylaxis in these 
patients. In Chapter 3, the evidence is critically analysed by systematic 
review. Results are pooled and presented as a meta-analysis. 
 
To quantify the role of below knee cast immobilization on venous stasis, I will 
assess the effect of below knee cast immobilization on baseline popliteal 
venous velocity in healthy volunteers. Further, to develop potential 
thromboprophylactic strategy I will assess the effect of active toe and ankle 
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movements on popliteal venous velocity before and after application of a 
below knee polymer cast. 
 
To confirm that active toe movements are an effective strategy for prevention 
of venous stasis and venous thrombosis in patients with foot and ankle injury, 
I will assess the effects of AToM on calf pump function and asymptomatic 
deep vein thrombosis in patients with below knee cast immobilization of the 
leg. 
 
To determine the relative contribution of mobility in the development of 
venous thrombosis I will objectively measure mobility in patients with lower 
limb trauma treated with non-weight bearing below knee cast and determine 
the association between level of mobility and subsequent development of 
DVT. 
 
In order to develop potential strategies to predict which patients with foot and 
ankle injury treated with leg cast will subsequently develop venous 
thrombosis, I will measure tissue factor, interleukin 6, VCAM-1 and d-dimer at 
time of presentation to the Emergency department (within 3 days of injury) 
and examine the association with subsequent finding of asymptomatic venous 
thrombosis. 
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3 Systematic review and meta-analysis of 
thromboprophylaxis in patients with below 
knee cast immobilization for trauma 
 
The OVID interface was used to search MEDLINE and EMBASE databases 
up to 1st June 2015. The following search strategy, previously used by 
Roberts et al. (2012) was used: (exp venous thrombosis OR exp 
thromboembolism OR exp pulmonary embolism OR DVT.mp OR deep vein 
thrombosis.mp OR PE.mp OR pulmonary embolism.mp OR venous 
thromb$.mp) AND (exp casts surgical OR plaster cast$.mp OR exp 
immobilization OR immobilization.mp) (C. Roberts, 2012). The search was 
limited to randomized controlled trials, with no language exclusions. One 
author performed the study selection based on the following defined inclusion 
and exclusion criteria. Inclusion criteria: Studies including adult patients of any 
venous thromboembolism risk stratification (including operative and non-
operative treatment) with foot or ankle trauma treated with below knee cast or 
immobilizing splint. Study interventions were chemical or mechanical 
thromboprophylaxis started within 72 h of injury, with a control group, which 
had no thromboprophylaxis. The outcomes of efficacy were symptomatic 
venous thromboembolism (pulmonary embolism and deep vein thrombosis) 
objectively proven with imaging.  
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The outcomes of safety were:  
1. Major bleeding i.e. bleeding resulting in death, risk to life or blood 
transfusion.    
2. Clinically important non-major bleed i.e. bleeding that required withdrawal 
from the study.    
3. Minor bleed i.e. any other type of bleed which was not major or clinically 
important. 
 
Only full papers were reviewed. For trials that reported results in more than 1 
publication, data from the most complete publication was extracted and used 
the other publications to clarify the data. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting of 
systematic reviews and meta-analyses of randomized clinical trials was 
followed. Two reviewers performed data extraction independently using 
standardized data extraction sheets (Figure 3.1). Discrepancies between the 
reviewers were reviewed by a third reviewer. Odds ratio and absolute risk 
reduction for symptomatic DVT were used to calculate number needed to 
prevent with thromboprophylaxis. Mantel Haenszel method was used to 
assess dichotomous outcomes. Statistical heterogeneity was determined 
using I
2 statistics. Fixed effects model was used when heterogeneity was 
<30%, using Review Manager (RevMan 5.0).  
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Fig. 3.1 Data items extracted from the included papers 
 
Study Title: 
Reference: 
Study design/type of study: 
Source of funding: 
Included injuries with number of each: 
Included participants (risk factors for thromboembolism): 
Exclusion criteria: 
Treatment (cast only, splint only, surgery +/- splint or cast): 
Treatment group intervention: 
Time between injury and recruitment into study: 
Control group (e.g. placebo): 
Outcome measure (symptomatic or asymptomatic venous thromboembolism) 
Method of objective confirmation of thromboembolism: 
 
 
 
 
Study 
drug/intervention 
Control group HR/RR (95% 
CI) 
p-
value 
 n % n %   
Patients       
Symptomatic DVT – state 
location (vein involved, 
above or below knee) 
      
Asymptomatic DVT – 
state location (vein 
involved, above or below 
knee) 
      
Symptomatic PE       
Asymptomatic PE        
Major bleed       
Adverse events        
Death       
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The risk of bias for each article was determined by two authors, who 
independently reviewed the full articles. Data was extracted from articles and 
a judgment with supporting information was made according the Cochrane 
Risk of Bias tool (Figure 3.2). In cases where authors disagreed, the evidence 
for the judgment was discussed and a consensus opinion was reached. A 
score from 1 to 3 was given for each of the 7 parameters. Where an item was 
deemed low risk of bias, a score of 1 was given for the item. A score of 2 was 
given if the risk of bias was deemed unclear. A score of 3 was given if the 
item was deemed high risk. The lowest risk of bias score for the 7 items was 
7. The highest score was 21. Studies were ranked in decreasing order of risk 
of bias. Where assessors of outcome were not blinded to intervention group, 
the study was rated as high risk of bias.  
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Fig. 3.2 Risk of bias tool 
 
Bias domain 
 
Source of 
bias 
Support for judgment Review authors’ 
judgment (assess as 
low, unclear or high 
risk of bias) 
Selection 
bias 
 
 
Random 
sequence 
generation 
Describe the method used to 
generate the allocation sequence in 
sufficient detail to allow an 
assessment of whether it should 
produce comparable groups 
Selection bias 
(biased allocation to 
interventions) due to 
inadequate 
generation of a 
randomised 
sequence 
Selection 
bias 
 
 
Allocation 
concealment 
Describe the method used to 
conceal the allocation sequence in 
sufficient detail to determine 
whether intervention allocations 
could have been foreseen before or 
during enrolment 
Selection bias 
(biased allocation to 
interventions) due to 
inadequate 
concealment of 
allocations before 
assignment 
Performance 
bias 
 
Blinding of 
participants 
and 
personnel* 
Describe all measures used, if any, 
to blind trial participants and 
researchers from knowledge of 
which intervention a participant 
received. Provide any information 
relating to whether the intended 
blinding was effective 
Performance bias 
due to knowledge of 
the allocated 
interventions by 
participants and 
personnel during the 
study 
Detection 
bias 
Blinding of 
outcome 
assessment* 
Describe all measures used, if any, 
to blind outcome assessment from 
knowledge of which intervention a 
participant received. Provide any 
information relating to whether the 
intended blinding was effective 
Detection bias due 
to knowledge of the 
allocated 
interventions by 
outcome 
assessment 
Attrition bias 
 
 
 
Incomplete 
outcome 
data* 
Describe the completeness of 
outcome data for each main 
outcome, including attrition and 
exclusions from the analysis. State 
whether attrition and exclusions 
were reported, the numbers in each 
intervention group (compared with 
total randomised participants), 
reasons for attrition or exclusions 
where reported, and any re-
inclusions in analyses for the 
review 
Attrition bias due to 
amount, nature, or 
handling of 
incomplete outcome 
data 
Reporting 
bias 
 
Selective 
reporting 
State how selective outcome 
reporting was examined and what 
was found 
Reporting bias due 
to selective outcome 
reporting 
Other bias 
 
Anything 
else, ideally 
pre-specified 
State any important concerns about 
bias not covered in the other 
domains in the tool 
Bias due to 
problems not 
covered elsewhere 
 
*Assessments should be made for each main outcome or class of outcome 
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Patients and Interventions 
Nine prospective randomized controlled trials were included in this review 
(Table 3.1). Study details according to data extraction form are displayed in 
Table 3.2. A Funnel plot revealed no publication biases (Figure 3.3) (Egger, 
Davey Smith, Schneider, & Minder, 1997).  
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Table 3.1 Studies included 
 
Author Year Title Journal 
Selby R, Geerts WH, 
Kreder HJ, Crowther 
MA, Kaus L, Sealey F 
2015 A double-blind, randomized 
controlled trial of the prevention of 
clinically important venous 
thromboembolism after isolated 
lower leg fractures 
 
J Orthop Trauma. 
2015 
May;29(5):224-30 
Sultan, M. J., Zhing, T., 
Morris, J., Kurdy, N., & 
McCollum, C. N. 
2014 Compression stockings in the 
management of fractures of the 
ankle: a randomised controlled trial 
 
The Bone & Joint 
Journal, 96-B(8), 
1062–1069.  
Domeij-Arverud, E., 
Latifi, A., Labruto, F., 
Nilsson, G., & 
Ackermann, P. W. 
2013 Can foot compression under a 
plaster cast prevent deep-vein 
thrombosis during lower limb 
immobilisation? 
 
The Bone & Joint 
Journal, 95-B(9), 
1227–1231. 
Lapidus, L. J., Ponzer, 
S., Elvin, A., Levander, 
C., Lärfars, G., Rosfors, 
S., & De Bri, E. 
2007 Prolonged thromboprophylaxis with 
Dalteparin during immobilization 
after ankle fracture surgery: a 
randomized placebo-controlled, 
double-blind study 
 
Acta Orthopaedica, 
78(4), 528–535.  
 
Lapidus L.J., Rosfors 
S., Ponzer S., Levander 
C., Elvin A, Lärfars G, 
de Bri E. 
2007 Prolonged Thromboprophylaxis 
With Dalteparin After Surgical 
Treatment of Achilles Tendon 
Rupture: A Randomized, Placebo-
Controlled Study 
 
J Orthop Trauma. 
2007 Jan;21(1):52-
7. 
 
Jørgensen, P. S., 
Warming, T., Hansen, 
K., Paltved, C., Vibeke 
Berg, H., Jensen, R., et 
al. 
2002 Low molecular weight heparin 
(Innohep) as thromboprophylaxis in 
outpatients with a plaster cast: a 
venografic controlled study. 
Thrombosis 
Research, 105(6), 
477–480. 
Lassen, M. R., Borris, L. 
C., & Nakov, R. L. 
 
2002 Use of the low-molecular-weight 
heparin reviparin to prevent deep-
vein thrombosis after leg injury 
requiring immobilization 
 
The New England 
Journal of Medicine, 
347(10), 726–730.  
Kock, H. J., Schmit-
Neuerburg, K. P., 
Hanke, J., Rudofsky, 
G., & Hirche, H. 
1995 Thromboprophylaxis with low-
molecular-weight heparin in 
outpatients with plaster-cast 
immobilisation of the leg 
 
The Lancet, 
346(8973), 459–
461. 
Spannagel, U., & 
Kujath, P. 
 
1993 Low molecular weight heparin for 
the prevention of thromboembolism 
Seminars in 
Thrombosis and 
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in outpatients immobilized by 
plaster cast 
Hemostasis, 19 
Suppl 1, 131–141. 
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Table 3.2 Details of included studies 
Study 
 
 
Year Injuries 
included 
and total 
number of 
participants 
 
Participants included 
(VTE risk factors) 
Exclusion criteria Treatment Treatment group intervention Control Time between 
injury and 
recruitment 
Outcome measure Method of objective 
confirmation of VTE 
Selby, R. et 
al 
 
 
 
 
2015 Operated 
lower limb 
trauma 
(tibia, 
fibula, 
ankle +/- 
associated 
foot or 
patella 
fractures) 
Age 18-87 years 
Surgery 
BMI not stated 
OCP not stated 
Smoking status not 
stated 
Major trauma 
Other anticoagulant use 
Allergy to LMWH 
Pregnancy 
Active cancer 
Previous VTE 
Hypercoagulable state 
Active bleeding or bleeding disorder 
Intracranial bleed in previous 4 weeks 
Vascular injury needing repair 
All surgical and cast or splint Dalteparin 5000 and Xa for 14 
+/- 2 days 
Matching 
placebo 14 +/- 
2 days 
<72 hours Symptomatic VTE 
within 3 months or 
asymptomatic 
proximal DVT on 
lower limb venous 
ultrasound at 14 
days 
Lower limb venous 
ultrasound 
Sultan, M.J. 
et al 
 
 
 
2014 Operated 
and non 
operated 
ankle 
fractures 
(n=90) 
Age 16-90 years 
BMI up to 40 
Some patients had 
surgery 
Previous ankle fracture or ankle surgery 
Open fracture 
Pilon complex fracture 
Injury or condition that impaired mobility 
Peripheral arterial disease or abnormal Doppler 
waveform 
Malignancy 
Chronic debilitating illness 
Treating Orthopaedic surgeon choice 
Aircast boot +/- surgery 
Patients who had surgery, 
also had clexane 20mg 
Non-weight bearing for all 
Ankle Injury Stocking – 
25mmHg pressure at ankle, 
17mmHg mid calf and 
10mmHg upper calf –
equivalent to class 2 stockings 
Tubigrip under 
aircast 
Within 72hrs 
of injury 
A secondary 
outcome measure 
was asymptomatic 
DVT on duplex at 4 
weeks 
An experienced 
vascular technologist 
undertook duplex 
ultrasound imaging of 
the deep veins in the 
calf and thigh at four 
weeks. 
 
Domeji 
Averyd, E. 
et al 
 
 
2013 Acute 
unilateral 
Achilles 
rupture  
(n=24) 
 
Age 18-75 years 
BMI up to 39.1 
Operated within 72 hours 
 
Inability to give informed consent 
Ongoing anticoagulation treatment (including 
high dose Aspirin) 
Planned follow up at different hospital 
Inability to follow instructions 
Kidney failure 
Heart failure with pitting oedema 
Thrombophlebitis 
Previous VTE – during preceding 3 months 
Surgery in previous month 
Malignancy 
Haemophilia 
Pregnancy 
Unwillingness to participate 
Surgery and postoperative 
cast. Then at 2 weeks post 
surgery, all patients went into 
DonJoy walking boot for 4 
weeks. 
 
Foot intermittent pneumatic 
compression beneath the cast  
 
Nothing Within 72 
hours 
Symptomatic and 
Asymptomatic DVT 
 
All patients were 
screened for DVT in 
the operated leg using 
unilateral color duplex 
sonography (CDS) at 
two and six weeks 
post-operatively 
 
Lapidus, 
L.J., 
Ponzer, S. 
et al 
 
 
2007 Operatively 
treated 
ankle 
fractures 
(n=272) 
18-75 years 
All operated 
Inability or refusal to sign consent 
Inability to comply (dementia, alcoholism) 
Current anticoagulants 
Allergy to contrast 
Planned follow up at another hospital 
Renal disorders including transplant  
VTE within 3 months 
Surgery within 1 month 
Malignancy 
Current bleeding disorder 
Pregnancy 
Aspirin use >325mg or other platelet inhibitors 
Polytrauma 
Surgery and cast 
 
1,000ml Dextran 60 on 
admission for all patients, 
Dalteparin subcut 5,000 IU 
once daily for 1 week for all 
patients, then randomized to 
continue or placebo until 
plaster removed at 5 weeks 
post surgery 
 
Placebo in 
identical 
syringe to 
intervention 
Within 72 
hours of injury 
Asymptomatic at 
time of cast 
removal 
 
All patients had 
phlebography on 
operated limb only, on 
day of cast or splint 
removal. Colour 
duplex was done is 
phlebography failed.  
– All duplex done by 1 
of 4 vascular 
technologists. Also did 
venography if clinical 
VTE during study 
period. 
CTPA or V/Q if PE 
clinically suspected 
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Lapidus, 
L.J., 
Rosfors, S. 
et al 
 
2007 Achilles 
tendon 
ruptures 
(n=105) 
18-75 years 
Surgical treatment 
Refusal or inability to consent 
Ongoing anticoagulants 
Contrast allergy 
Intended follow up in alternative hospital 
Inability to comply with study 
Renal disorder 
Recent VTE within 3 months 
Surgery in preceding month 
Malignancy 
Bleeding disorder 
Pregnancy 
High dose aspirin or platelet inhibitors 
Other injuries 
Surgery with a postoperative 
cast or orthosis for 6 weeks 
 
Dalteparin 25,000 units anti 
Xa/ml, 5000 Unit dose once 
daily injection 
 
Placebo 
injection with 
0.9% saline in 
an identical 
syringe, 6 
weeks supply 
 
Within 72 
hours of injury 
Asymptomatic and 
symptomatic VTE 
Unilateral colour 
duplex USS followed 
by plethysmography 
for confirmation if 
duplex positive 
 
Jorgensen, 
P.S. et al 
 
 
2002 Fracture 
and tendon 
injuries 
(n=300) 
Planned lower limb cast 
for at least 3 weeks 
Oral contraceptive pill 
Previous DVT 
Smokers 
Varicose veins 
Surgery 
Pregnancy 
Allergy to heparin or contrast media 
Renal or liver impairment 
Uncontrolled hypertension 
Bleeding disorders 
Cerebral insults due to bleeding 
GI bleeding 
Inability to perform self-injection 
All patients had below knee 
casts. 86pts in Innohep group 
had surgery, 89 pts in control 
had surgery. Injury 
demographics and surgery 
was not significantly different 
between groups. 
 
3,500 IU anti Xa tinzaparin 
(Innohep) s/c once daily for 
total casting period – mean 
duration was 5.5 weeks 
 
Nothing 
 
Not stated Asymptomatic DVT Unilateral ascending 
venography 
 
Lassen, 
M.R. et al 
 
 
 
2002 Fractures 
(tibia, 
patella, 
malleoli, 
foot), 
Achilles 
tendon 
rupture 
(n+438) 
Age up to 56 years 
BMI up to 28 
Previous VTE 
Varicose veins 
OCP use 
HRT use 
Surgery 
Casts 
Smokers 
Body weight <35kg 
Current VTE 
Systolic BP >200mmHg or diastolic >110 
Cerebral aneurysm 
CVA within 3 weeks 
Active GI ulcer 
Haemorrhagic diathesis 
Bacterial endocarditis 
Platelets <100,000 per cubic mm 
Previous heparin use 
Immobilisation .4 days prior to enrolment 
Heparin or contrast allergy 
Contraindication to venography 
Surgery or cast immobilisation 1750 anti-Xa units of reviparin 
(Clivarine, Knoll) subcut to be 
injected once daily whilst 
immobilised 
The patients 
received 
identical 
prefilled 
syringes with 
placebo to 
take once 
daily for time 
of 
immobilization 
 
Within 4 days 
of injury 
Symptomatic or 
asymptomatic VTE 
ascending 
venography of the 
injured leg within one 
week after removal of 
the plaster cast or 
brace. Venography 
was performed earlier 
if there was a clinical 
suspicion of 
thrombosis 
Kock, H.J. 
et al 
 
 
 
1995 Fractures 
or sprains 
Age up to 65 years 
Obesity (Broca index 
>1.2) 
Varicose veins 
Smokers 
OCP 
Cast 
Surgical treatment 
Previous DVT 
Pregnancy 
Clotting disorders or anticoagulant medication 
Bleeding sources 
Chronic venous insufficiency 
Contra-indication to heparin 
Non-operative treatment with 
cast 
LMWH (Mono-Embolex) daily 
s/c injection 32mg for duration 
of cast 
 
Nothing Not stated – 
but all had 
imaging to 
exclude DVT 
prior to 
randomization 
Asymptomatic DVT Ultrasound and 
phlebography 
Spannagel, 
U. et al 
 
 
 
1993 Fractures, 
soft tissue 
injuries 
Age up to 76 years 
Cast 
Smoking 
Overweight (110% 
Broca) 
Previous thrombosis 
Varicose veins 
Malignant disease 
OCP 
Pregnancy 
Heart failure 
Hypersensitivity to heparin 
Thrombopathy 
Treatment with oral anticoagulation or platelet 
inhibitors 
Acute cerebral or GI bleeding 
Acute pancreatitis 
Inflammatory heart disease 
Arterial hypertension (diastolic more than 
120mmHg) 
Renal failure (serum creatinine 3mg/dL or 
greater) 
 
Non-operative soft tissue and 
bony injury with plaster cast 
for at least 7 days 
If patients went on to have 
operation they were scanned 
prior to this and exited the 
study 
LMWH 36mg injection once 
daily for period of cast 
 
Nothing Not stated All were scanned. 
Asymptomatic 
DVT. Some had 
symptoms at time 
of scanning (33.3% 
of those with 
positive scans, but 
criteria for 
‘symptomatic’ not 
defined) 
Compression 
ultrasound on cast 
removal 
Phlebography on 
cases of positive 
compression 
ultrasound 
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Fig. 3.3 Funnel plot of Total DVT (Symptomatic and Asymptomatic) 
 
 
Seven of these studies focused on chemical thromboprophylaxis and two 
studied mechanical thromboprophylaxis. Only two studies considered patients 
treated non-operatively (Kock, Schmit-Neuerburg, Hanke, Rudofsky, & Hirche, 
1995; Spannagel & Kujath, 1993), with all others including patients who 
underwent surgery. Two have focused on patients with ankle fractures 
(Lapidus et al., 2007; Sultan, Zhing, Morris, Kurdy, & McCollum, 2014), two 
have focused on Achilles tendon ruptures (Domeij-Arverud et al., 2013), 
(Lapidus et al., 2007), and the remaining 5 studies include patients with a 
variety of soft tissue and bony injuries (Kock et al., 1995; Lassen, Borris, & 
Nakov, 2002; Spannagel & Kujath, 1993; Wille-Jørgensen, Jorgensen, & 
Crawford, 2005) (Selby et al., 2015). Included studies did not provide details 
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of numbers of patients with individual risk factors for venous 
thromboembolism. 
 
In view of current knowledge of risk factors for venous thromboembolism 
(VTE in patients with lower limb immobilization, and in accordance with 
guidelines of the Emergency College of Medicine, the most important 
permanent risk factors appear to be: current hormone replacement 
therapy/oral contraceptive pill, personal or first degree relative history of VTE, 
active smoker, any recent hospital admission or major surgery, pregnancy or 
immediate postpartum, any serious co-morbidity including cardiac failure, 
chronic obstructive pulmonary disease, chronic renal failure or inflammatory 
bowel disease, extensive varicosities, active cancer, obesity (BMI >30), 
known thrombophilia, age >60 years. Considering these risk factors, all of the 
studies included at least some patients who would be considered ‘high risk’ 
for VTE, with current recommendation to provide low molecular weight 
heparin. The earlier four papers even included patients with malignancy, 
which would be ethically impossible by today’s standards. (Kock et al., 1995; 
Lassen et al., 2002; Spannagel & Kujath, 1993; Wille-Jørgensen et al., 2005). 
In 5 studies, patients were recruited within 72 hours of injury (Sultan et al., 
2014) (Domeij-Arverud et al., 2013) (Lapidus et al., 2007) (Selby et al., 2015). 
Lassen et al recruited patients within 4 days of injury (Lassen et al., 2002). In 
the study by Kock et al, the time to recruitment was not stated, however all 
patients underwent imaging to exclude DVT prior to entering the study (Kock 
et al., 1995). In two studies, the time between injury and recruitment is not 
stated (Wille-Jørgensen et al., 2005) (Spannagel & Kujath, 1993). It is 
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therefore possible that some patients in these studies may have developed 
asymptomatic DVT prior to entering the study. 
 
Mechanical thromboprophylaxis studies, included an Ankle Injury 
compression stocking in one study (25mmHg pressure at the ankle, 17mmHg 
mid calf and 10mmHg upper calf) (Sultan et al., 2014). The second 
mechanical thromboprophylaxis study examined the effect of a pneumatic foot 
compression device beneath the cast (Domeij-Arverud et al., 2013). It is 
clearly difficult to blind patients to the latter, in which the control group 
received no placebo. 
 
In the 7 studies of chemical thromboprophylaxis, all focused on low molecular 
weight heparin as the intervention: Subcutaneous Dalteparin 5000 
international units once daily (Lapidus et al., 2007) (Selby et al., 2015), 
Subcutaneous Tinzaparin (Innohep) 3500 international units once daily 
(Jørgensen et al., 2002), 1750 anti-Xa units of reviparin (Clivarine, Knoll) 
subcutaneous once daily (Lassen et al., 2002), LMWH (Mono-Embolex) daily 
s/c injection 32mg (Kock et al., 1995), LMWH 36mg injection once daily 
(Spannagel & Kujath, 1993). Some of these studies included overweight 
patients, and without dose adjustment for body weight it is possible that doses 
may have been sub prophylactic in some patients (Spannagel & Kujath, 
1993), (Kock et al., 1995). 
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All chemical thromboprophylaxis studies used venography to confirm 
asymptomatic DVT, except for the most recent study by Selby et al (2015) 
(Selby et al., 2015). It is important to recognize that technological advances 
and increased operator experience in the use of non-invasive duplex 
ultrasonography has made this commonplace. Venography has generally 
been replaced by utrasound which is more economical, less invasive and 
safer (Rectenwald et al., 2005) (L. N. Roberts & Arya, 2011) (Goldhaber & 
Bounameaux, 2012). In the hands of an experienced operator, 
ultrasonography has a sensitivity of 100%, specificity of 98% and accuracy of 
98% for patients with lower limb DVT when compared with venography 
(Garino, Lotke, Kitziger, & Steinberg, 1996). In the three recent studies, 
conducted in 2013 (Domeij-Arverud et al., 2013) and 2014 (Sultan et al., 
2014), duplex ultrasound was used to image the lower limb venous system 
(Selby et al., 2015).  
 
Asymptomatic Venous Thromboembolic Outcomes 
All studies presented data for asymptomatic DVT. A summary of events is 
displayed in Table 3.3. None of the included studies assessed for 
asymptomatic pulmonary emboli. Events that occurred are denoted 
numerically with percentages. The incidence of asymptomatic DVT in the 
control group ranged from 4.3% (Kock et al., 1995) and 42% (Domeij-Arverud 
et al., 2013). Two studies considered the effect of mechanical 
thromboprophylaxis on asymptomatic DVT rate (Domeij-Arverud et al., 2013; 
Sultan et al., 2014). In the latter paper this was a secondary outcome 
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measure and with 90 patients recruited it was underpowered to detect a 
statistically significant difference. The paper by Domeij-Averyd et al 
considered the effects of an intermittent pneumatic foot compression pump 
under cast in patients with Achilles tendon rupture. The asymptomatic DVT 
rate was very high in both the intervention group (67% n=8/12) and the control 
group (42% n=5/12), which did not reach statistical significance. In view of this 
high DVT rate the study was stopped early. There were no reported 
symptomatic DVT’s reported in these studies and no Pulmonary Emboli 
occurred (symptomatic or asymptomatic). In view of this, there is no present 
evidence that mechanical thromboprophylaxis is effective in patients with 
lower limb trauma and cast immobilization. Further adequately powered, 
prospective randomized controlled studies are necessary to answer this 
question. 
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Table 3.3 Summary of Asymptomatic venous thromboembolic events 
Note that no studies reported asymptomatic pulmonary embolism 
 
 
 
 
Study 
 
 
Year Intervention 
group 
Control group p-value 
Selby, R. et al 
 
2015 1/128 
(0.78%) 
all proximal 
1/130 (0.77%) all 
proximal 
0.99 
Sultan, M.J. 
et al 
2014 5/42   (12%) 10/44   (23% 0.26 
Domeji 
Averyd, E. et 
al 
2013 8/12  (67%) 
 
All distal 
5/12   (42%) 
All distal 
0.08 
Lapidus, L.J., 
Ponzer, S. et 
al 
2007 21/101   
(21%) 
27/96   (28%) 0.25 
*note that a secondary 
analysis of patients  with 
casts (excluding splints) did 
find a statistically significant 
reduction 
Lapidus, L.J., 
Rosfors, S. et 
al 
 
2007 16/47   
(34%) 
 
1 proximal 
DVT  
16/36   (36%) 
 
3 proximal DVT 
0.8 
Jorgensen, 
P.S. et al 
 
 
2002 10/99 (10%) 18/106   (17%) 
 
All below knee 
except one above 
knee in this group 
0.16 
Lassen, M.R. 
et al 
 
 
 
2002 3 
proximal/18
9   (2%) 
 
14 
distal/183   
(8%) 
10 proximal/191   
(5%) 
 
25 distal/188   (13%) 
0.09 
 
 
 
0.09 
Kock, H.J. et 
al 
 
 
 
1995 0/176   (0%) 7/163 (4.3%) 
 
3 proximal, 4 distal 
<0.006 
Spannagel, 
U. et al 
 
 
1993 6/126   (4.8) 21/127   (16.5) <0.01 
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The seven prospective randomized controlled trials studying the effects of 
chemical thromboprophylaxis in patients with trauma and lower limb 
immobilization were conducted between 1993 and 2015. The first of these 
was the study of 253 patients with lower limb fractures or soft tissue injuries 
treated with casts by Spannagel et al (1993), in which LMWH resulted in a 
statistically significant reduction in asymptomatic DVT (4.8% LMWH group v 
16.5% control p <0.01). However, there were no details of the location of the 
DVT’s therefore this study was not included in the meta-analysis. 
Furthermore, 33% of 27 patients found to have DVT on screening were 
reported to have some clinical symptoms, but it is not discussed whether 
these were in the control or intervention group. Only 3 DVT events were 
above knee (Spannagel & Kujath, 1993). Although Kock et al (1995) found 
pooled total of above and below knee asymptomatic DVT events were 
statistically significantly reduced in the intervention group (p=0.006) in their 
study of 339 patients with lower limb fractures or sprains (176 provided with 
LMWH), this was not the case when analyzing above and below knee DVT 
events individually (Kock et al., 1995). 3 studies (Table 3.4) provided details of 
asymptomatic below knee DVT outcomes. In all of these, the confidence 
interval of the odds ratio crossed 1, therefore there was no statistically 
significant reduction in DVT in patients who received LMWH. However, on 
pooling the results at meta analysis, the odds ratio was 0.54 (95% CI 0.32 – 
0.90), indicating that asymptomatic below knee DVT is reduced in these 
patients. Meta-analysis of asymptomatic above knee DVT events included 4 
studies (Table 3.5), none of these found statistically significant DVT 
reductions in individual studies or on pooling of results. Meta-analysis of 
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Asymptomatic total DVT (Table 3.6) found a reduction in total asymptomatic 
total DVT (OR 0.53, 95% CI 0.36 – 0.77). Based on this, 19 patients would 
require thromboprophylaxis with LMWH to prevent one asymptomatic DVT. 
Table 3.4 Asymptomatic distal DVT 
 
Table 3.5 Asymptomatic proximal DVT 
 
Table 3.6 Asymptomatic total DVT 
 
Number needed to prevent asymptomatic DVT = 1/((711-50/711) – (697-85)/697)) = 19 
 
Study or Subgroup
Jorgensen 2002
Kock 1995
Lapidus Ankle 2007
Selby 2015
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.09, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.87 (P = 0.39)
Events
0
0
4
1
5
Total
99
176
117
130
522
Events
1
3
3
1
8
Total
106
163
109
128
506
Weight
15.9%
40.0%
33.1%
11.0%
100.0%
M-H, Fixed, 95% CI
0.35 [0.01, 8.78]
0.13 [0.01, 2.53]
1.25 [0.27, 5.72]
0.98 [0.06, 15.91]
0.63 [0.22, 1.79]
LMWH Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours [experimental] Favours [control]
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Symptomatic Venous Thromboembolic Outcomes 
Five of the nine studies presented data on symptomatic DVT events 
(Jørgensen et al., 2002; Lapidus et al., 2007; Lassen et al., 2002; Spannagel 
& Kujath, 1993) (Selby et al., 2015). 2 of these studies reported no 
symptomatic events in control of intervention groups and were excluded from 
meta-analysis (Table 3.7) (Jørgensen et al., 2002) (Spannagel & Kujath, 
1993). Considering the 5 studies presenting symptomatic DVT data, the 
overall incidence was 11/697 (1.58%) in the control group (Table 3.8). 
Considering the 3 studies included in the meta-analysis (Table 3.7) none of 
these studies found a statistically significant symptomatic DVT reduction 
individually, however at meta-analysis of pooled results there was a 
statistically significant reduction in symptomatic DVT in the patients who 
received LMWH (OR 0.29, 95% CI 0.09 – 0.95) (Lapidus et al., 2007) (Lassen 
et al., 2002) (Selby et al., 2015).  
Table 3.7 Symptomatic DVT meta analysis 
 
 
 
 
Study or Subgroup
Lapidus Ankle 2007
Lassen 2002
Selby 2015
Total (95% CI)
Total events
Heterogeneity: Chi² = 1.17, df = 2 (P = 0.56); I² = 0%
Test for overall effect: Z = 2.04 (P = 0.04)
Events
2
0
1
3
Total
117
189
130
436
Events
6
4
1
11
Total
109
191
128
428
Weight
52.8%
38.6%
8.6%
100.0%
M-H, Fixed, 95% CI
0.30 [0.06, 1.51]
0.11 [0.01, 2.06]
0.98 [0.06, 15.91]
0.29 [0.09, 0.95]
LMWH Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LMWH Favours control
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Table 3.8 Symptomatic DVT 
Study 
Intervention 
(n) 
Symptomatic 
DVT (total) Control 
Symptomatic 
DVT (total) 
Kock 1995 176 0 163 0 
Lassen 2002 189 0 191 4 
Jorgensen 2002 99 0 106 0 
Lapidus Ankle 2007 117 2 109 6 
Selby 2015 130 1 128 1 
 Total 711 3 697 11 
 
Six studies presented data for symptomatic pulmonary embolism (Lapidus et 
al., 2007) Lapidus and Rosfors 2007, (Jørgensen et al., 2002; Lassen et al., 
2002; Spannagel & Kujath, 1993) (Selby et al., 2015) (Table 3.9). The highest 
symptomatic pulmonary embolism occurrence was 1%, found in the study by 
Lassen et al (Lassen et al., 2002). The overall symptomatic pulmonary 
embolism rate considering studies presenting this data was 3/692 (0.43%). 
None of these pulmonary emboli were fatal. Meta-analysis was not possible 
with only 3 events. LMWH did not result in statistically significant reductions in 
symptomatic pulmonary emboli in any of these studies. Symptomatic VTE 
events were not reported in either of the two studies which examined the 
effect of mechanical thromboprophylaxis (Domeij-Arverud et al., 2013; Sultan 
et al., 2014). 
Table 3.9 Symptomatic Pulmonary Embolism 
Study 
Intervention 
(n) 
Symptomatic 
PE Control Symptomatic PE 
Kock 1995 176 0 163 0 
Spannagel 1993 126 0 127 0 
Lassen 2002 217 0 221 2 
Jorgensen 2002 99 0 106 0 
Lapidus Ankle 2007 117 0 109 0 
Lapidus Achilles 2007 49 0 47 0 
Selby 2015 130 0 128 1 
 Total 914 0 901 3 
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Considering the overall number of symptomatic VTE events reported by 
included studies (Table 3.10), 82 patients would require thromboprophylaxis 
with LMWH to prevent on symptomatic VTE (including Pulmonary Embolism 
and Deep Vein Thrombosis). 
Table 3.10 Symptomatic Venous Thromboembolism (PE or DVT) 
Study 
Intervention 
(n) 
Symptomatic VTE Control Symptomatic VTE 
Kock 1995 176 0 163 0 
Spannagel 1993 126 0 127 0 
Lassen 2002 217 0 221 6 
Jorgensen 2002 99 0 106 0 
Lapidus Ankle 2007 117 2 109 6 
Lapidus Achilles 2007 49 0 47 0 
Selby 2015 130 1 128 2 
Total 914 3 901 14 
Number needed to prevent one symptomatic VTE = 1/((914-3)/914) – ((901-14)/901) = 81.6 
 
Bleeding events 
The 7 studies of chemical thromboprophylaxis reported major bleeding, with 
one non fatal retro-peritoneal hemorrhage event occurring in the study by 
Lassen et al (2002) (Lassen et al., 2002) (Table 3.11). Considering the total 
number of patients who received LMWH in these studies, the overall 
incidence of major bleeding was 1 in 886 (0.11%), number needed to harm = 
886. Considering that the number needed to prevent symptomatic VTE was 
found to be 82, 10 symptomatic VTE events would be prevented for every 
major bleed. Clinically relevant non-major and minor bleeds were more likely 
to occur in the LMWH groups (Table 3.12, Table 3.13) however at meta-
analysis the 95% confidence interval crossed 1 in both cases and therefore 
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the difference in bleeding event rates for these outcomes was not statistically 
significant. 
 
Table 3.11 Major bleeding events 
Study Intervention 
Major 
bleed Control Major bleed 
Kock 1995 176 0 163 0 
Spannagel 1993 126 0 127 0 
Lassen 2002 189 1 191 0 
Jorgensen 2002 99 0 106 0 
Lapidus Ankle 2007 117 0 109 0 
Lapidus Achilles 2007 49 0 47 0 
Selby 2015 130 0 128 0 
 
Table 3.12 Clinically relevant non-major bleed 
 
 
Table 3.13 Minor bleed 
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Risk of bias assessment  
The risk of bias for each article was determined by two authors, who 
independently reviewed the full articles (BH and UW). Data was extracted 
from articles and a judgment with supporting information was made according 
the Cochrane Risk of Bias tool (Table 3.14) (Higgins et al., 2011). In cases 
where authors disagreed, the evidence for the judgment was discussed and a 
consensus opinion was reached (RA). A score from 1 to 3 was given for each 
of the 7 parameters. Where an item was deemed low risk of bias, a score of 1 
was given for the item. A score of 2 was given if the risk of bias was deemed 
unclear. A score of 3 was given if the item was deemed high risk. The lowest 
risk of bias score for the 7 items was 7. The highest score was 21. Studies 
were ranked in decreasing order of risk of bias. Where assessors of outcome 
were not blinded to intervention group, the study was rated as high risk of 
bias. 
 
None of the studies were free of risk of bias. The study deemed to be at least 
risk of bias was by Lassen et al. This study was generally low risk of bias, 
however there were no details provided in the paper of the method of group 
allocation concealment (Lassen et al., 2002). A recent study of mechanical 
thrombopropylaxis using intermittent pneumatic compression under a cast 
was also deemed low risk of bias (Domeij-Arverud et al., 2013). This study 
was stopped early due a very high rate of asymptomatic deep vein thrombosis 
in the intervention group (8/12 in intervention group v 5/12 in control p=0.08). 
The study by Lapidus and Ponser (Lapidus et al., 2007) scored a 3 ‘high risk 
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of bias’ in the category of ‘Other’ because all patients (those in intervention 
and those in control) received LMWH for 1 week prior to being randomized. It 
is possible that this may have reduced the effect size of the LMWH provided 
to the intervention group after randomization. This may account for the failure 
of this study to find statistically significant reduction in asymptomatic DVT 
between intervention and control groups. However, despite this, there was a 
statistically significant reduction in asymptomatic DVT in the LMWH group for 
a secondary analysis of patients treated with cast immobilization (excluding 
those with splints). The studies by Kock and Spannagel (Kock et al., 1995; 
Spannagel & Kujath, 1993) were considered to be at highest risk of bias 
overall. Also, these studies did not state whether assessors of outcome of 
DVT were blinded to participant intervention group. The results of these 
studies should be viewed with caution. The study of ankle injury stockings in 
patients with ankle fracture by Sultan et al (Sultan et al., 2014) was generally 
low risk of bias however the study is inadequately powered to find a 
statistically significant reduction in DVT as an outcome (n=90), which was a 
secondary outcome measure. 
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Table 3.14 Risk of bias assessment 
Study 
 
 
Year Selection bias – 
Random sequence 
generation 
Selection bias – 
Allocation 
concealment 
Performance bias – 
Blinding of participants 
and personnel 
Detection bias – Blinding of 
outcome assessment 
Attrition bias – 
Incomplete outcome 
data 
Reporting bias – Selective reporting Other bias Total risk 
of bias 
score 
Selby, R. et 
al 
2015 Randomisation using 
a computer 
randomization code 
 
Low risk of bias (1) 
 
 
 
Medications were 
pre-packaged by 
study sponsor and 
distributed by them 
 
Low risk of bias (1) 
 
 
Patients and all research 
personnel were blinded 
to the study medication. 
However, does not state 
that study/placebo were 
identical 
 
Unclear risk (2) 
Bilateral Doppler ultrasound 
by certified vascular 
technologist with 
confirmation by staff 
radiologist, both blinded 
 
Low risk (1) 
Compliance assessed 
by syringe count. 
Clear about who was 
lost and why 
 
Low risk of bias (1) 
Made it clear that they only looked at 
clinically important venous 
thromboembolism events 
 
Low risk of bias (1) 
Nil. Low risk of bias (1) 8 
Domeji 
Averyd, E. et 
al 
2013 Computer-generated 
random numbers in 
permuted blocks of 
four to undergo either 
standard plaster cast 
treatment alone or 
plaster cast 
 
Low risk of bias (1) 
Computer 
generated 
 
Low risk of bias (1) 
Participants could not be 
blinded 
 
High risk of bias (3) 
Two experienced 
ultrasonographers (FL, AL), 
who were blinded to the 
treatment regimens, 
performed all the screening 
for DVTs  
 
Low risk of bias (1) 
26 were randomized, 
only 2 dropped out 
because they could 
not tolerate IPC 
 
Low risk of bias (1) 
All VTE outcomes were reported 
 
Low risk of bias (1) 
No power calculation but incidence was 
much higher than anticipated 
 
Low risk of bias (1) 
9 
Lassen, 
M.R. et al 
2012 Randomization was 
performed by 
computer in blocks 
of four 
 
Low risk of bias (1) 
 
 
 
No details of 
allocation 
concealment 
 
 
Unclear risk (2) 
 
 
 
 
 
 
Control group received 
identical placebo 
injection. All the data 
were collected by a 
Danish contract research 
organization and 
transferred to the 
statistical department of 
the 
sponsor 
 
Low risk of bias (1) 
Review of venography 
centrally by 3 radiologists 
blinded to group 
 
Low risk of bias (1) 
 
 
 
 
 
 
4 patients dropped out 
due to adverse events 
but not stated what 
these events were 
 
Unclear risk of bias (2) 
 
 
 
 
 
Reported that one patient had 
venogram more than 1 week after cast 
removal and excluded this because it 
did not meet inclusion, which was 
good. Reported on planned outcome 
measure. 
 
Low risk of bias (1) 
Malleolar fractures significantly less 
common and Achilles tendon rupture 
more common in LMWH group 
Unclear risk of bias (2) 
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Lapidus, 
L.J., Ponzer, 
S. et al 
 
 
2007 Randomisation 
method not stated 
 
Unclear risk (2) 
 
 
 
 
 
Allocation 
concealment not 
stated 
 
Unclear risk (2) 
 
 
 
 
Control group received 
identical placebo 
injection pen 
 
 
Low risk of bias (1) 
 
 
 
An independent radiologist 
who was blinded to the 
randomization 
Low risk of bias (1) 
 
 
All patients accounted 
for 
 
Low risk of bias. 
75/272 randomised 
were lost to follow up. 
Reasons were stated 
but this is high (28%). 
(1) 
 
All patients accounted for and 
intention to treat analysis done for 
primary outcome i.e. venographic DVT 
 
Low risk of bias (1) 
 
 
All patients received LMWH for a week 
before randomization, which could have 
equalized the results. This was felt to be 
necessary ethically 
 
High risk of bias in a sense that LMWH 
effect size could have been reduced 
between groups after randomization (3) 
11 
Lapidus, 
L.J., 
Rosfors, S. 
et al 
 
2007 Consecutive 
recruitment computer 
randomization (1) 
Not stated 
 
Unclear risk (2) 
 
 
 
All participants got an 
identical injection 
(control was placebo) 
 
Low risk of bias (1) 
Radiologist blinded to 
randomized group 
Low risk of bias (1) 
All accounted for 
 
Low risk of bias (1) 
 
 
 
Secondary analysis was done based 
on USS endpoint whereas it was 
planned that USS+phlebo 
 
Unclear risk of bias (2) 
This study is likely to be underpowered 
 
High risk (3) 
 
 
11 
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Jorgensen, 
P.S. et al 
 
 
2002 Random numbers in 
sealed envelopes – 
details of 
randomization 
sequence not given 
 
Low risk of bias – 
randomization 
appeared to work (1) 
 
 
 
 
 
Sealed envelopes. 
Not stated when 
patients were 
allocated 
 
Unclear risk of bias 
(2) 
 
 
 
 
Control group did not 
receive anything 
therefore may have 
known which group they 
were in. Patients were 
therefore unlikely to be 
blinded. 
 
Unclear risk. Even if 
patients knew which 
group they were in, I 
don’t think this would 
influence outcome (2) 
Two experienced 
radiologists, independent of 
treatment group assessed 
venograms. 
 
Assessor blinded. Low risk 
of bias (1) 
Although all 
randomized 
participants were 
accounted for, the 
loss to follow up was 
very high (32% i.e. 
95/300 lost). The 
study is therefore 
underpowered. 
High risk of bias due 
to inadequate 
participants 
completing study, 
making it 
underpowered to 
detect a significant 
difference (3) 
No flow diagram. Difficult to follow 
how and why patients were lost 
through study. 
 
 
Unclear risk (2) 
 
 
 
 
 
With such a high rate of patient 
withdrawal from study due to injections, 
how did they check compliance with 
injections? 
 
Unclear risk of bias (2) 
 
 
13 
Sultan, M.J. 
et al 
 
 
 
2014 Computer based 
randomization 
 
Low risk of bias (1) 
 
 
 
 
Not described 
 
Unclear risk of bias, 
however, 
randomization 
worked (2) 
Assessor blind 
 
Low risk of bias (1) 
 
 
 
The vascular technician 
undertaking duplex imaging 
was also blinded 
 
Low risk of bias (1) 
4 patients did not 
attend for Duplex. Not 
stated what happened 
to them. Could have 
died of fatal PE 
 
Unclear risk of bias (2) 
 
DVT reporting was not clear. Table of 
DVT rates between operated and non-
operated not displayed. Surgically 
treated patients also received clexane 
(in a subtherapeutic dose) 
 
Unclear risk of bias (2) 
Study underpowered to assess 
secondary outcome measure of VTE 
rates (n=90 only) 
 
 
High risk of bias for VTE outcome, study 
underpowered (3) 
14 
Spannagel, 
U. et al 
 
 
 
1993 Not stated 
 
Unclear risk of bias (2) 
 
 
 
 
 
 
 
 
 
 
 
Not stated 
 
Unclear risk of bias 
(2) 
 
 
 
 
 
Not stated if 
sonographers were 
blinded to group 
 
Control did not receive a 
placebo injection 
 
 
Unclear risk of bias (2) 
 
Not stated if sonographers 
were blinded to group 
 
Unclear risk of bias (3) 
306 randomised. 53 
excluded (14 in 
control got LMWH by 
someone else, 12 in 
LMWH group stopped 
it on own accord, 3 
casts removed before 
7 days, 6 underwent 
surgery before 7 days 
in cast, 18 casted 
patients did not return 
for any follow up!). 
Therefore 253 
included. 
 
Low risk of bias (all 
accounted for. 17% 
lost, therefore still high 
quality (1) 
USS was performed to detect DVT, 
then phlebography to confirm. 
Phlebographic rates slightly lower. 
Authors chose to present USS rates. 
 
 
Unclear risk (2) 
They have done stats on multiple 
outcome measures, Not stated if they 
used Bonferroni correction 
 
 
Unclear risk (2) 
14 
 
Not stated 
if 
assessors 
were 
blinded to 
treatment 
group 
Kock, H.J. et 
al 
 
 
 
1995 Randomised with lists 
stratified for varicose 
veins and obesity 
(>20% above ideal 
Broca weight) 
 
Unclear risk of bias (2) 
Not stated 
 
Unclear risk of bias 
(2) 
 
 
 
 
 
 
 
 
Control did not get a 
placebo injection 
because it was felt to be 
unethical. Therefore 
patients were unlikely 
blinded 
 
Unclear risk of bias (2) 
Not stated if assessors of 
DVT imaging were blinded 
 
Unclear risk of bias (3) 
Its unclear how many 
patients were 
randomized and 
subsequently were 
lost to follow up 
 
Unclear risk of bias (2) 
 
Primary outcome was reported 
 
 
Low risk of bias (1) 
Significantly more patients in control 
group on OCP and significantly longer 
duration of cast in control group also 
 
High risk of bias (3) 
15 
 
 
Not stated 
if 
assessors 
were 
blinded to 
treatment 
group 
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Orthopaedic surgical patients are generally regarded as high risk of venous 
thromboembolic complications. Patients undergoing surgery for hip fracture, 
total hip or knee replacement have deep vein thrombosis incidences of up to 
60% (National Clinical Guideline Centre – Acute and Chronic Conditions (UK), 
2010). Prevention of VTE is more desirable than treating VTE events from 
both a clinical and financial perspective (Alikhan et al., 2004), and there is no 
doubt that mechanical and chemical thromboprophylaxis are effective in 
patients undergoing major Orthopaedic surgery. For example, in the context 
of total knee replacement, the addition of mechanical to chemical 
thromboprophylaxis (pneumatic compression) significantly reduces the 
incidence of DVT from 18.7% to 3.7% with combined prophylaxis. The effects 
are similar for patients undergoing total hip replacement (reduction in DVT 
from 9.71% to 0.94%) (Kakkos, Warwick, Nicolaides, Stansby, & Tsolakis, 
2012). In patients who undergo hip fracture surgery, heparin or mechanical 
thromboprophylaxis with foot or calf pumping devices are also effective in 
reducing the incidence of DVT (Handoll et al., 2000). In view of this, it has 
become accepted that patients undergoing major Orthopaedic surgery should 
be provided with thromboprophylaxis unless contra-indicated. 
 
Another group of patients which account for a large workload for the 
Orthopaedic surgeon are patients with lower limb trauma. Many of these 
patients are treated as outpatients, non-surgically with casts or splints. Some 
studies indicate that these patients are also at increased risk of venous 
thromboembolism due to a combination of patient, injury and treatment factors 
(Spannagel & Kujath, 1993). In the United Kingdom, it is recommended that 
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all patients treated with cast or splint immobilization should be assessed for 
risk of venous thromboembolism and provided with thromboprophylaxis where 
increased risk is identified (NICE, Gemnet). Some authors recommend 
thromboprophylaxis for all patients with immobilisation of the lower extremity, 
irrespective of age and other risk factors (Testroote, Morrenhof, & Janzing, 
2011a) (Spannagel & Kujath, 1993). In some U.K. hospitals, all patients 
treated with lower limb immobilization are provided with chemical 
thromboprophylaxis. It has been reported that this practice is cost effective 
when considering the potential savings in litigation (Menakaya et al., 2013). 
This may be true, however it is vital to review the evidence of the effects of 
thromboprophylaxis in patients with lower limb cast or splint immobilization to 
enable clinicians to make informed decisions for or against its use. 
 
Considering studies which reported symptomatic venous thromboembolism, 
deep vein thrombosis occurred in 1.58% of patients randomized to no 
prophylaxis group (11/697) (Table1.3) (Kock et al., 1995) (Lassen et al., 2002) 
(Jørgensen et al., 2002) (Lapidus et al., 2007) (Selby et al., 2015) Table 3.7, 
Table 3.8). Symptomatic pulmonary embolism occurred in 0.33% of patients 
(3/901) (Kock et al., 1995) (Spannagel & Kujath, 1993) (Lassen et al., 2002) 
(Lapidus et al., 2007) (Selby et al., 2015) (Table 3.9).  
The most serious complication of this is death from Pulmonary Embolism 
(PE), which has recently been shown to occur in approximately 1 in 15000 
patients (Jameson et al., 2014). None of the included studies in this review 
are therefore adequately powered to assess a reduction in this outcome. It is 
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therefore not surprising that there is uncertainty amongst Orthopaedic 
surgeons on the effectiveness of chemical thromboprophylaxis to prevent fatal 
PE (Mirkazemi, Bereznicki, & Peterson, 2012). 
 
The majority of studies included in this review, focus on the effects of 
chemical thomboprophylaxis (n=7). Two have studied mechanical 
thromboprophylaxis. All chemical thromboprophylaxis studies focused on low 
molecular weight heparin. None considered alternatives such as aspirin or 
newer oral anticoagulant direct thrombin inhibitors.  
 
Effect of Chemical Thromboprophylaxis 
None of the included studies found a significant reduction in symptomatic DVT 
at individual study level, however at meta analysis (Table 3.7), there was a 
statistically significant reduction (OR 0.29, 95% CI 0.09 – 0.95) (Lapidus et al., 
2007) (Lassen et al., 2002) (Selby et al., 2015). The number needed to 
prevent symptomatic VTE was 82, considering all studies reporting this 
outcome for each group (Table 3.10). To put this into context, the numbers 
needed to prevent recurrent hip fracture in post menopausal women with hip 
fracture is 100 (Wells et al., 2008). For asymptomatic DVT, clinically important 
DVT has recently been restricted to events which are above knee, or 
symptomatic events within 90 days of injury (Selby et al., 2015). With focus on 
studies which reported outcomes of asymptomatic above knee DVT (Table 
3.3), none of these studies found significant reductions in asymptomatic 
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above knee DVT, pooled meta-analysis also failed to find an effect of LMWH 
(Table 3.5). It is important to discuss the earliest two studies into the effect of 
LMWH in patients with lower limb trauma and cast treatment, which both 
found statistically significant reductions in asymptomatic composite results of 
above and below knee DVT (Kock et al., 1995; Spannagel & Kujath, 1993). In 
the larger study by Kock et al (1995), 339 patients with lower limb fractures or 
sprains treated with non-operatively with below knee cast or above knee 
cylinder cast, LMWH (Mono-Embolex) daily s/c injection 32mg resulted in a 
statistically significant reduction in asymptomatic deep vein thrombosis, with 
no events occurring in the LMWH group and seven in the control (p=0.006). 
Out of the seven asymptomatic DVT’s which occurred in the control group, 
only 3 were above knee. It is also of note that this paper is 20 years old and 
current management of lower limb traumatic injuries has changed 
significantly. For example, the majority of patients in this study (74%) were 
treated with cast for soft tissue injuries and sprains. Considering the 7 patients 
in the control group who sustained asymptomatic deep vein thrombosis, 2 of 
these patients sustained fractures of the 5th metatarsal of hallux, both of which 
would nowadays be treated with a heel weight bearing shoe rather than a 
cast. 2 patients with knee contusions or meniscal injuries would likely to have 
been provided with a temporary brace rather than an above knee cylinder 
cast. The other three patients had casts for ankle sprains, contusion or 
distortion and it is likely that they would have also been provided with a 
walking boot or functional brace rather than cast immobilization in a modern 
fracture clinic. A final important limitation is that it is not stated in this paper 
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whether the assessors of outcome of venous thromboembolism were blinded 
to patient intervention group.  
 
The second paper, which found a statistically significant effect of LMWH on 
overall asymptomatic DVT outcomes, was by Spannagel et al (1993). This 
paper found the greatest reduction in asymptomatic deep vein thrombosis of 
all studies, from (4.8% LMWH group v 16.5% control p <0.01). It is unclear in 
this paper how many of these asymptomatic deep vein thrombosis were 
below or above knee. Patients were all treated with cast immobilization. 
Similarly to the study by Kock et al (1995), 70% of these patients had soft 
tissue injuries rather than fractures. There are no details provided of the 
reasons for cast immobilization. This study suffers from the same limitation as 
the former study by Kock et al, because it is not stated whether the 
assessment out outcome of deep vein thrombosis was blinded. These studies 
are at high risk of bias. This has been previously noted in other reviews of this 
literature (Ettema 2008). 
 
Even if a composite reduction in asymptomatic DVT has clinical relevance in 
regards to longer term outcomes such as post thrombotic syndrome, it is 
important that patients are provided with chemical thromboprophylaxis as 
soon as possible following their injury. If there is a delay in commencing 
thromboprophylalxis, which may be due to patients presenting several days 
after their injury, they may have already developed asymptomatic deep vein 
thrombosis.  There are no studies which quantify this effect, however the 
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majority of RCT’s included in this review recruited patients within 3 days of 
injury. In a study of thromboprophylaxis in patients with acute stroke, both leg 
doppler USS performed at 3 days following admission found that 8% had 
already developed an asymptomatic DVT (Bembenek, Karlinski, Kobayashi, & 
Czlonkowska, 2011).  
 
Another important consideration is that patients must comply with LMWH 
injections in order to achieve reductions in venous thromboembolism. Some 
studies suggest that 12% of patients stop taking LMWH due to discomfort 
(Jørgensen et al., 2002). In a prospective study of 214 patients of mean age 
34 years, using enoxaparin injections in France, 20.5% were deemed 
inappropriate for training or refused, with a further 12% failing to use LMWH 
after being trained to perform injections (Le Gall et al., 2006). This will 
significantly affect the efficacy of prophylaxis in clinical practice. 
 
Effect of Mechanical Thromboprophylaxis 
There is no evidence that mechanical thromboprophylaxis results in a 
statistically significant reduction in either asymptomatic or symptomatic 
venous thromboembolic events in patients with lower limb trauma treated with 
cast immobilization (Domeij-Arverud et al., 2013; Sultan et al., 2014). Both of 
these studies lacked statistical power to detect a statistically significant effect 
on deep asymptomatic deep vein thrombosis, which was a secondary 
outcome measure for the paper by Sultan et al. It was acknowledged by the 
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authors that a larger study is required to examine the effects of the ankle 
injury stocking on deep vein thrombosis incidence. 
 
In theory, intermittent pneumatic compression, as used in the study by Domeij 
Averud (2013) could have been effective in reducing venous 
thromboembolism. IPC foot pumps work by compression of the plantar 
venous plexus (Broderick et al., 2010). It may also increase fibrinolytic activity 
(Ho & Tan, 2013) (Salzman et al., 1987). In empirical studies, A-V foot pumps 
do result in statistically significant increases in calf pump function (measured 
as increases in popliteal venous velocities from baseline) (Killewich, 
Sandager, Nguyen, Lilly, & Flinn, 1995). This is also true for neuromuscular 
electrical stimulation (Kaplan, Czyrny, Fung, Unsworth, & Hirsh, 2002) 
(Corley, Birlea, Breen, & Olaighin, 2009) (Warwick et al GEKO), weight 
bearing (Craic et al 2014) and active or passive foot and ankle movements 
(Whitelaw et al., 2001) (Hickey et al 2014). The limitation of these studies of 
calf pump function is that the majority were performed under test conditions in 
healthy volunteers. Most of these studies conclude that further study is 
required to determine the effects of these interventions on venous 
thromboembolism, however very few persist to investigate this.  
 
Early weight bearing and range of motion has been studied in patients who 
underwent ankle fracture fixation. Although there was a non statistical 
reduction in DVT in the early range of motion group, this benefit was 
outweighed by wound complications, which were statistically more likely in 
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those treated with splint and early motion as compared to the group treated in 
cast. (Lehtonen et al., 2003). 
 
There is good clinical evidence that intermittent pneumatic compression is 
effective at reducing venous thromboembolism in hospitalized patients 
(Pascarella, 2014). At meta-analysis level of 16,164 surgical and non-surgical 
patients from 70 trials, IPC was significantly more effective than control in 
reducing DVT (7.3% v 16.7%, absolute risk reduction 9.4% p<0.01, relative 
risk 0.43), as well as pulmonary embolism (1.2% v 2.8%), RR 0.48). It was as 
effective as chemical thromboprophylaxis, and the addition of the two was 
most effective (RR 0.54) compared to IPC alone. 39% of these studies were 
on Orthopaedic surgical patients, however none were patients with lower limb 
trauma and cast immobilization (Ho & Tan, 2013).  It is of note that in clinical 
practice, pneumatic compression devices are frequently applied with errors 
(Elpern, Killeen, Patel, & Senecal, 2013). 
 
There are several potential reasons why Domeij Arverud et al (2013) failed to 
show a significant effect of IPC on DVT rates in patients with casts, including 
patient discomfort leading to withdrawal from the study in 2 out of 14 patients 
within 1 week, the mean duration of IPC being only 5.4 hours per day. 
Furthermore, 58% of patients in the intervention group reported IPC 
malfunction within 2 weeks of use (the majority due to low pressure readings). 
It is therefore un surprising that IPC failed to work effectively in this study 
(Domeij-Arverud et al., 2013). 
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The study by Sultan et al used an ankle injury stocking under an immobilizing 
boot in patients with ankle fractures. The main aim was to reduce ankle 
swelling and improve function, which was convincingly shown to be the case 
(Sultan et al., 2014). DVT was a secondary outcome, for which the study is 
underpowered. This requires further study. Using an ankle injury stocking in 
clinical practice may be difficult, as it was stated in this study that many 
patients in the ankle injury stocking study required entonox inhalation 
analgesia for application. Although there were no serious complications 
reported in this study, it is difficult to monitor for skin complications if this was 
used under a cast rather than a boot (Warwick et al., 2013).  
 
The main strength of this review is that only included level 1 evidence studies. 
The benefit of this is that randomization equalizes both known and unknown 
confounding variables between groups (Bederman, Chundamala, & Wright, 
2010). Symptomatic and above knee asymptomatic DVT were differentiated 
from below knee asymptomatic DVT, which may account for differences in 
conclusions as compared with previous reviews of LMWH in patients with 
lower limb immobilization (Ettema et al 2008, Testroote et al).  
 
 
 
0846014   89 
4 Methods 
 
4.1 Effect of below knee cast application on calf pump 
function in healthy volunteers 
 
Twenty healthy adult volunteers between the ages of 21 and 58 years of age 
(mean 31 years) were enrolled in this prospective study. Eleven were female. 
The Institutional review board and local research and ethics committee 
approved this proof of principle study (REC reference number 11/WA/0089). 
All participants signed a consent form prior to participation. Participants with 
previous medical history of peripheral vascular disease, diabetes, varicose 
veins, venous thromboembolism or previous foot and ankle surgery were 
excluded because these factors could have an adverse effect on calf pump 
function.  
 
All participants had baseline and peak popliteal velocity measurements 
measured at the Popliteal vein by one Medical Physicist using a Doppler 
ultrasound probe. This technique has been validated and used recently by 
Izumi et al (2010) and Griffin et al (2010) to determine the effects calf 
compression and electrical stimulation on calf pump function. Baseline and 
peak velocity measurement has been in many studies of calf pump function, 
particularly to examine the effects of intermittent pneumatic foot or calf 
compression devices (R. J. Morris & Woodcock, 2010). Measurements of 
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peak venous velocities at the Popliteal vein have previously been found to 
accurately reflect flow volumes in the Femoral vein (Delis, Slimani, Hafez, & 
Nicolaides, 2000) (Ricci, Fisk, Knight, & Case, 1997). Measurements were 
performed at the Popliteal vein due to ease of access.  
 
A standardized protocol was followed for each participant. Baseline popliteal 
vein velocity was measured in the right leg using Doppler ultrasound (cm/s) 
with the participant in the seated position, with hips, knees and ankles in the 
90 degrees position. The participant was then shown a toe or ankle 
movement and was asked to perform the movement to their best effort, during 
which peak systolic velocity was measured at the popliteal vein. It has 
previously been shown that it takes approximately 7.5 seconds for the leg 
veins to refill (Griffin, Nicolaides, Bond, Geroulakos, & Kalodiki, 2010). 
Therefore, after each exercise, the toe and ankle were returned to the neutral 
position for at least 1 minute to allow the baseline velocity to return to normal 
before performing the next movement. Peak velocities were measured for the 
following movements: active ankle dorsi flexion, active ankle plantar flexion, 
active great toe dorsi flexion, active great toe plantar flexion. Ankle 
movements have previously been shown to result in high levels of calf muscle 
activity, measured using electromyography (O'Donovan et al., 2005). Toe 
movements were included because these can easily be performed with a 
below knee plaster cast in situ.  
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Once all measurements were recorded for each movement, a below knee 3-
layer fiberglass polymer cast (3M Scotch-cast) was applied over wool and 
stockinet, supervised by a plaster technician. Popliteal vein velocity 
measurements at baseline and during movement were then repeated for each 
of the four movements with the cast in situ. Although ankle movements of 
dorsiflexion and ankle plantar flexion were not possible with cast in situ, 
participants could still perform isometric contraction of muscle groups. Group 
means were calculated for baseline and each movement pre and post cast 
application to allow comparison between groups.  
 
Statistical analysis 
A sample size calculation performed by Professor R Newcombe, Medical 
Statistics at Cardiff University. It was determined that 20 participants were 
required to detect a statistically significant change in pre and post cast peak 
systolic velocity at 80% power. Statistical analysis was performed using the 
group mean baseline and peak systolic velocity pre and post cast application 
using the paired t-test at the 5% alpha level. Two-sided p values of less than 
0.05 were considered statistically significant. All statistical analysis was 
performed using SPSS for Windows (SPSS, Chicago, Illinois). 
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4.2 The effect of active toe movement (AToM) on calf pump 
function and asymptomatic deep vein thrombosis in patients 
treated with acute foot and ankle injury treated with cast – A 
Prospective Randomised Controlled Trial 
 
Patients 
In this prospective randomized controlled study, 100 adult patients with acute 
bony or soft tissue foot or ankle trauma treated with below knee cast at the 
University Hospital of Wales between February 2014 and February 2015 were 
recruited. The local Ethics committee and Research and Development 
department approved this study. The study was registered on UK Clinical 
Research Network Portfolio Database (UKCRN ID: 17648. 
http://public.ukcrn.org.uk). Funding for consumables to conduct this study was 
provided by AO UK. In accordance with NICE guidance and local hospital 
protocols, all patients were assessed for risk of venous thromboembolism. If 
patients had any permanent risk factors for VTE they were not eligible for the 
study and were provided with Low molecular weigh heparin (Enoxaparin) 
thromboprophylaxis 40mg subcutaneous injection once daily and were not 
eligible for study participation. Patients currently taking Warfarin or Heparin for 
any other reason were also excluded.  
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Exclusion criteria 
Risk factors for VTE (exclusion criteria) were: Age >60 years, current 
hormone therapy (Oral contraceptive pill, Hormone replacement therapy, 
Tamoxifen), personal or first degree relative VTE history, any recent hospital 
admission or major surgery (within 3 months), pregnancy or immediate 
postpartum (6 weeks), any serious medical co-morbidity (including congestive 
cardiac failure, chronic obstructive pulmonary disease, chronic kidney 
disease, inflammatory bowel disease), extensive varicosities, active cancer, 
obesity (BMI over 30 kg/m2), known thrombophilia, achilles tendon rupture, 
equinus cast. All patients assessed as ‘low risk’ based on this risk 
assessment were potentially eligible for the study and were referred to the 
Chief Investigator (BH) for review in the next available fracture clinic. On 
review in clinic, VTE risk assessment was repeated to confirm patients were 
‘low risk’ and eligible for the study. Patients who were anticipated to be 
treated in a backslab or cast for less than 1 week were not recruited. Patients 
with injuries requiring surgery were also not recruited because these patients 
are provided with Low Molecular Weight Heparin. Patients presenting more 
than 72 hours after initial injury were excluded. 
 
Study design and intervention 
The Chief Investigator (BH) recruited all patients. After consenting for 
participation in this study, patients were allocated to either the intervention 
(AToM) or control group according to a pre-defined computerized 
randomization sequence with variable block sizes. Patients were not informed 
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of their randomization allocation group and all assessments of calf pump 
function and ultrasound for deep vein thrombosis were performed by medical 
physicists who were blinded to the randomization allocation. Participants who 
were allocated to the intervention group were provided with an active toe 
movement protocol to follow, with a compliance diary to complete. Patients 
allocated to the intervention group were instructed to perform maximal active 
toe flexion and extension movements as often as possible, with prescriptive 
advice to perform these movements at a minimum of 60 movements every 6 
hours. All patients were shown how to do this and observed doing the 
movements to confirm they understood. Patients were managed in fracture 
clinic depending on their injury until discharge. 
 
Outcome measures 
When the patient no longer required their below knee cast or boot 
immobilization as part of their treatment they attended the Medical Physics 
department for assessment of calf pump function and bilateral above and 
below knee venous Duplex scanning to screen for asymptomatic deep vein 
thrombosis. Historically, venography was used to screen for DVT’s, however 
current clinical practice is to use Duplex ultrasonography. This has previously 
been used in other similar studies (Selby et al., 2015). Any patient who was 
discharged from clinic prior to having Duplex scanning was sent an 
appointment letter to attend for Duplex scanning. Senior Medical Physicists 
who work within the National Health Service and perform these scan on 
patients routinely performed all scans. If a deep vein thrombosis was present 
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on Ultrasound scanning, the anatomical location and laterality in relation to 
the injured limb was recorded. The patient exited the study at this stage. 
Patients with positive Doppler scans for DVT were provided with treatment if 
the DVT was located in the above knee veins (Popliteal or more proximal). 
Patients with DVT in the below knee veins had a repeat Duplex scan a week 
later to assess for resolution or propagation of the DVT.  
 
In patients who did not sustain deep vein thrombosis, calf pump function was 
assessed using Doppler ultrasonography according to a standardized 
protocol. With the patient seated with hips and knees at 90 degrees flexion, 
baseline popliteal velocity was measured in the popliteal vein after cast 
removal, using Doppler ultrasound at rest. Each patient then performed 3 
consecutive active toe dorsiflexion exercises starting with the toe in neutral 
position, with a rest of 30 seconds between to allow for venous refilling. Peak 
popliteal velocity was recorded during active toe movement and the mean 
was calculated. Peak velocity was then recorded during active toe plantar 
flexion. This method has previously been used to assess calf pump function in 
healthy volunteers with and without lower limb cast applied (B. A. Hickey et 
al., 2014). 
 
Statistical analysis and early stopping 
A power calculation was based on the prediction that asymptomatic DVT 
would occur in 21.9% of patients with an anticipated intervention effect size of 
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63% reduction (Roderick et al., 2005). To allow for 5% withdrawal rate after 
randomization it was planned to randomize 150 patients to each group to 
achieve 80% power. To ensure randomization worked, baseline 
characteristics were analysed using t tests for continuous variables and chi 
square tests for proportions. Shapiro Wilk test was used to test for normality 
of calf pump function data and analysis of non-parametric results was 
performed with Mann Whitney U test. A generalization of the Mann Whitney U 
statistic was also performed to determine the effect size of AToM on calf 
pump function (Newcombe, 2006). All statistical analysis was performed using 
SPSS for Windows (SPSS, Chicago, Illinois). Analysis of DVT outcomes 
between groups was performed using Chi square test.  
 
After 100 patients had been recruited, analysis of the calf pump function 
between groups was performed to determine whether the intervention had 
any significant effect on baseline or peak popliteal velocities. The outcome of 
this was that although the intervention appeared to influence popliteal 
velocities, there was no statistically significant difference when compared to 
the control group. In view that AToM did not significantly influence calf pump 
function in patients, it was decided by the Chief Investigator (BH) with 
agreement of the steering committee to request a formal interim analysis of 
the effect of the intervention on asymptomatic deep vein thrombosis. At this 
stage in the study, the overall event rate was 33.3% (n=13) in intervention and 
20.5% (n=8) in control. Interim analysis found the confidence interval of the 
proportions ranged from 6.9% asymptomatic DVT reduction in the intervention 
to 31% increased incidence of asymptomatic DVT in the intervention group 
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(Newcombe, 1998). In view that the anticipated effect size was a 63% 
asymptomatic DVT reduction in the AToM intervention group, it appeared that 
the intervention was less effective than expected and the steering committee 
decided to stop recruitment (Briel, Bassler, Wang, Guyatt, & Montori, 2012). 
 
 
4.3 The association between mobility and subsequent 
development of Deep Vein Thrombosis in patients with lower 
limb trauma and cast treatment 
 
 
In this prospective study, 100 patients between the ages of 18 and 60 years of 
age, with acute lower limb trauma and below knee cast immobilisation were 
recruited from the Emergency Department at the University Hospital of Wales. 
This study had ethical approval and was approved by the research and ethics 
committee for Wales. All patients signed a consent form prior to participation. 
The study was funded by AO UK. All patients were assessed for risk of 
venous thromboembolism according to NICE and local guidelines provided 
with LMWH where indicated. Patients were excluded if they met any of the 
following criteria: Age >60 years, current hormone therapy (Oral contraceptive 
pill, Hormone replacement therapy, Tamoxifen), personal or first degree 
relative VTE history, any recent hospital admission or major surgery (within 3 
months), pregnancy or immediate postpartum (6 weeks), any serious medical 
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co-morbidity (including congestive cardiac failure, chronic obstructive 
pulmonary disease, chronic kidney disease, inflammatory bowel disease), 
extensive varicosities, active cancer, obesity (BMI over 30 kg/m2), known 
thrombophilia, achilles tendon rupture, equinus cast. All patients assessed as 
‘low risk’ based on this risk assessment were potentially eligible for the study 
and were referred to the Chief Investigator (BH) for review. Patients who were 
anticipated to be treated in a backslab or cast for less than 1 week were not 
recruited. Patients with injuries requiring surgery were also not recruited 
because these patients are provided with Low Molecular Weight Heparin. 
Patients presenting more than 72 hours after initial injury were excluded. 
 
All enrolled patients had a tri-axial accelerometer (Movband 2, Dynamic 
Health Strategies) applied to the cast by one author (BH) at time of cast 
application. Accelerometers were placed into a watertight bag and applied to 
a standardised position on the anterolateral aspect of their casted leg 
(approximately 10cm distal to the level of the tibial tubercle, lateral to the tibial 
crest). Accelerometers were fixed into the backslab cast between the wool 
and the crepe layers so that it was not possible to remove this without 
disrupting the backslab. Participants were advised to leave the accelerometer 
in the cast and only remove it if it caused irritation. 
 
On review in fracture clinic 1 week later, the accelerometer was removed and 
the first 5 days of mobility data was extracted (120 consecutive hours) from 
the accelerometer using USB interface with MOVband Dashboard Version 
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2.3. Mean daily ‘steps’, ‘moves’ and ‘miles’ were calculated for each 
participant. Any accelerometers that were removed in the interim were 
determined ‘non wear’ and excluded from analysis. The first 5 continuous 
days of accelerometer data were analysed because it was felt this would 
represent the period of least mobility. Sharma et al found that this was the 
case in women following child birth (Sharma, Atkin, Mackillop, & Paterson-
Brown, 2012). 120 hrs of consecutive accelerometer data collection was used 
in order to standardize data collection and reduce errors. It has previously 
been recommended that accelerometers should be worn for greater than 
12h/day to ensure accurate estimates of daily physical activity, with shorter 
wear times resulting in increased error of measurement (Herrmann, Barreira, 
Kang, & Ainsworth, 2014). Although it is possible to compare physical activity 
between groups, selecting a single random day of activity, the mean of the 
number of days recorded was used in this study (Wolff-Hughes, McClain, 
Dodd, Berrigan, & Troiano, 2016). Patients were managed according to 
fracture clinic protocols for their injury until cast removal, at which point the 
patient had bilateral lower limb venous ultrasound to screen for deep vein 
thrombosis. Unpaired t-test was used to determine statistical significant 
difference in average moves and average steps per day for DVT and no DVT 
groups. 
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Accelerometer details 
The MOVband 2 (Dynamic Health Strategies) is a triaxial accelerometer, 
which is 2 inches by 7/8 inches, weighing 0.4oz. This works using a 
proprietary algorithm to calculate moves, steps and miles. It can detect any 
type of movement as long as it is on a body part. The accelerometer 
generates activity when it experiences gravity <1 ms-2, with an Epoch length 
of 30 seconds. It will only record activity when the accelerometer moves in at 
least 2 of 6 degrees of freedom, meaning it does not record car travel 
because this is one continuous axis. Under test conditions, it has been found 
to have significant association with orbital shaker frequencies of 1.3, 1.9 and 
2.5 Hz for 5 minutes (Spearman rho 0.98) (Mendoza, Hickey, Young, & 
Freedson, 2015). Under free living conditions in young healthy adults, it has 
also been found to have strong positive correlations with the Actigraph GT1M 
research grade accelerometer (r=0.974 +/-0.06) (Williamson, Rebold, Carnes, 
Glickman, & Barkley, 2014) and the Actigraph GT1M research grade 
accelerometer in children (r=0.77, p<0.001) (Fennell, Kobak, Glickman, & 
Barkley, 2016). The majority of studies into physical activity use the Actigraph 
brand (Montoye, Moore, Bowles, Korycinski, & Pfeiffer, 2016). During outdoor 
walking at self selected speeds, the MOVband has been shown to have error 
rates of <15% when compared with observed steps (Taylor et al., 2014). This 
was acceptable for the purpose of this study. 
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4.4 Can we use biomarkers of coagulation to predict which 
patients with foot and ankle injury will develop deep vein 
thrombosis? 
 
As part of the Active Toe Movement study (AToM), adult patients presenting 
to the Emergency Department at University Hospital of Wales with lower limb 
trauma requiring treatment with a below knee non-weight bearing cast for at 
least 1 week were assessed for eligibility (B. A. Hickey, Cleves, et al., 2016a). 
All patients were risk assessed for venous thromboembolism according to 
hospital protocol and considered ‘low risk’. All patients were recruited within 
72 hours of injury, none were provided with chemical thromboprophylaxis. At 
time of enrolment to the study, 3.5ml of venous blood was taken using 
standard Vaccutainer technique into a 3.2% sodium citrate coagulation tube. 
This was centrifuged at 1500 rpm for 15 minutes and the supernatant plasma 
was frozen at -70 degrees centigrade within 1 hour of blood being withdrawn. 
Participants were managed in the fracture clinic with lower limb cast 
immobilization according to their injury. On discharge from clinic, patients 
underwent bilateral lower limb ultrasound scan to assess for above and below 
DVT. All assessments were performed by medical physicists who perform 
these venous ultrasound studies as part of their role in the National Health 
Service, all with a minimum of 5 years experience. After the last patient was 
discharged from clinic, blood samples were thawed and analysed. Plasma 
was tested for quantitative levels of Human Coagulation Factor III/Tissue 
factor, Interleukin 6 (IL-6), VCAM-1 and D-dimer. We used the Quanikine 
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ELISA Immunoassay kits (R&D Systems) for each test according to the 
manufacturers instruction. All kits were stored between 2 and 8 degrees 
centrgrade and used before their expiry dates. All tests were performed with 
the assistance of 2 experienced laboratory technicians, who were blinded to 
the DVT status of the patient. 
 
Tissue Factor testing protocol: 
Human Coagulation Factor III/Tissue Factor ELISA Immunoassay 
(Quantikine, R&D Systems, Catalog Number DCF 300) was used for this test. 
All samples underwent a 2 fold dilution with 150 microlitres of calibrator 
diluent RD5-20. 500mL wash buffer was created by addition of 20mL wash 
buffer concentrate to distilled water. Color reagents A and B were mixed in 
equal volumes. Human coagulation factor III standards were prepared by 
pipetting 100 microlitres of 5000 pg/mL standard into an Eppendorf tube, with 
900 microlitres of calibrator diluent RD5-20 added to the same tube (Tube A) 
and 500 microlitres was added to an additional 6 tubes (B,C,D,E,F,G). 500 
microlitres of the mixture from Tube A was added to Tube B, then 500 
microlitres was added from Tube B to Tube C. This process was repeated to 
create 7 standards: 500pg/mL, 250pg/mL, 125pg/mL, 62.5pg/mL, 31.3pg,mL, 
15.6pg/mL and 7.8pg/mL. A standard with 0 pg/mL was also created from 
calibrator diluent alone.  
After the samples, standards and reagents were prepared, 100 microlitres of 
RD1-89 Assay Diluent was added to each well of the microplate. 100 
microlitres of each sample was added to individual wells. 100 microlitres of 
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each standard was also added to separate wells. The 96 well microplate has 
a pre-coated surface of monoclonal antibody which binds to Tissue Factor on 
contact. The microplate was then incubated at room temperature on a 
horizontal microplate shaker set at 500 rpm. After incubation, wells were 
aspirated and washed using wash buffer for a total of four washes. The plate 
was inverted and blotted dry. Subsequently, 200 microlitres of Human 
Coagulation III conjugate was added to each well, wells were covered and 
incubated for a further 2 hours on the horizontal microplate shaker. After 2 
hours the wells were aspirated and washed. 200 microlitres of substrate 
solution was added to each well prior to a final incubation in dark for 30 
minutes on the benchtop. After 30 minutes incubation, 50 microlitres of stop 
solution was added to each well. The optical density of each well was then 
read using a microplate reader.  
 
Interleukin 6 testing protocol: 
Quantikine ELISA Human IL-6 Immunoassay kit (R&D Systems) was used to 
quantify Interleukin 6. Samples were analysed according to Catalog Number 
D6050). Wash buffer was made using the same method used for Tissue 
Factor. Substrate solution colour reagents A and B were mixed in equal 
volumes and protected from light. Human IL-6 Standard was reconstituted 
with Calibrator Diluent RD6F to produce a stock solution of 300pg/mL. 
Standards of concentrations 100pg/mL, 50 pg/mL, 25 pg/mL, 12.5 pg/mL, 
6.25 pg/mL and 3.13 pg/mL were created according to manufacturer 
instructions using similar methods for Tissue factor. 100 microlitres of assay 
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diluent RD1W was added to each well, followed by 100 microlitres of each 
sample (undiluted) to individual wells. 100 microlitres of each standard was 
also added to separate wells. The microplate was subsequently incubated at 
room temperature for 2 hours, after which wells were aspirated, washed four 
times with wash buffer and blotted dry. 200 microlitres of Human IL-6 
conjugate was then added to each well and these were incubated for a further 
2 hours at room temperature. Following this, wells were aspirated, washed 
and blotted dry as previously described. A final incubation at 20 minutes in the 
absence of light was performed after addition of 200 microlitres of substrate 
solution to each well. Finally, 50 microlitres of stop solution was added to 
each well and the microplate was read using an optical microplate reader. 
 
VCAM-1 testing protocol: 
Human VCAM-1/CD106 Immunoassay was performed according to R&D 
Systems Quantikine ELISA Catalog Number DVC00. Calibrator diluent in a 
1:5 dilution was prepared first by addition of 20mL Calibrator diluent RD5P 
concentrate to 80ml distilled water. Samples were subsequently diluted 20-
fold by addition of 380 microlitres of calibrator diluent RD5P to 20 microlitres 
of sample. Wash buffer was prepared as previously described for IL-6 
method. Human VCAM-1 standard was reconstituted to create a standard of 
400ng/mL, which was subsequently diluted with Calibrator diluent to create 
standards with VCAM-1 concentrations of 200ng/mL, 100ng/mL, 50ng/mL, 
25ng/mL, 12.5ng/mL and 6.25ng/mL. The calibrator diluent was used as the 
0ng/mL zero standard. 100 microlitres of Human VCAM-1 conjugate was 
0846014   105 
added to each well, followed by 100 microlitres of each diluted sample. 100 
microlitres of each standard were added to separate wells. Wells were then 
incubated for 1.5 hours at room temperature before being aspirated, washed 
four times and blotted dry. 100 microlitres of substrate solution was then 
added to each well and this was incubated at room temperature in darkness 
for 20 minutes. Finally, 50 microlitres of stop solution was added to each well 
and microplates were read using the microplate reader to measure optical 
densities. 
 
Optical density results 
Using the optical density results for each test, a standard curve was created 
using optical density (y axis) against the. Sample results were then calculated 
using this curve. Tissue Factor/Coagulation Factor III results were multiplied 
by 2 to account for the initial 2-fold dilution. Interleukin 6 results were tested 
undiluted, therefore did not require correction. To account for the initial 20-fold 
dilution, VCAM-1 results were multiplied by a factor of 20. 
 
D-dimer measurement protocol 
The HemosIL D-dimer HS was used (product code 0020007700). This is an 
automated latex enhanced immunoassay for the quantitative determination of 
D-dimer in human citrated plasma. The D-dimer HS latex reagent is a 
suspension of polystyrene latex particles of uniform size coated with a 
fragment of a monoclonal antibody highly specific for the D-dimer domain 
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included in fibrin soluble derivatives. When a plasma containing D-dimer is 
mixed with the latex reagent and the reaction buffer, the coated latex particles 
agglutinate. The degree of agglutination is directly proportional to the 
concentration of D-dimer in the sample and is determined by measuring the 
decrease of the transmitted light caused by the aggregates (turbidimetric 
immunoassay). All samples were tested in batch using a fully automated, 
bench-top, random access analyser (ACL TOP 700) after calibration and 
internal quality control using IL specific quality control plasmas at low and high 
control levels.  
 
Statistical analysis 
Test for normality were performed using Kolmogorov Smirnov test. Unpaired 
t-tests were used to test for statistical significance between Group 1 (DVT) 
and Group 2 (No DVT) where data was parametric. Mann Whitney U test was 
used for non-parametric data. 
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5 Results 
 
5.1 Effect of below knee cast application on calf pump 
function in healthy volunteers 
 
20 healthy staff were recruited. None of the hospital staff approached to 
participate had reason for exclusion (no previous medical history of peripheral 
vascular disease, diabetes, varicose veins, venous thromboembolism or 
previous foot and ankle surgery). Average participant age was 31 years 
(range 21 to 58). 11 were female. 
 
Baseline popliteal velocity 
160 measurements of resting baseline popliteal flow were taken. The baseline 
was calculated as a mean due to the physiological Baseline Variability that is 
shown in the Doppler image in Figure 5.1.  
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Fig. 5.1 Doppler ultrasound image showing baseline variability and peak 
systolic velocity during toe movement 
 
 
 
Prior to cast application, mean resting baseline popliteal vein velocity was 
9.16 cm/s (4.0-24.6 cm/s). After a below knee polymer cast was applied, the 
baseline velocity was 9.94 cm/s (9.5 – 26.4). The difference in baseline 
popliteal velocity pre and post cast application was not statistically significant 
(p=0.29). 
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Effect of active ankle or toe movement on popliteal velocities 
All movements tested resulted in a statistically significant increase in peak 
systolic velocity as compared to baseline measurement (p=0.0001) without a 
cast. Active toe dorsi-flexion increased the velocity in the popliteal vein from 
the baseline to 53.6 cm/s pre cast mean peak (12.8-152.8). Active toe plantar-
flexion resulted in an increase in velocity from baseline a pre cast mean peak 
of 49.7 cm/s (15.5-127.7). Ankle dorsiflexion increased velocity from baseline 
to 115.4 cm/s peak (31.5-189) pre cast. Ankle plantarflexion increased 
velocity from baseline to 86.6 cm/s mean peak (39.9-158.9) pre cast (Table 
5.1).  
 
Table 5.1 The effect of muscle contraction on Popliteal vein flow in the non-
casted leg 
Exercise Mean Resting 
baseline venous 
velocity 
(cm/s) 
Mean peak systolic 
velocity achieved with 
movement 
(cm/s) 
p value 
Seated toe dorsi 
flexion 
10.42     (4.2-32.1) 53.6     (12.8-152.8) 0.0001* 
Seated toe plantar 
flexion 
10.42     (4.2-32.1) 49.7     (15.5-127.7) 0.0001* 
Seated ankle dorsi 
flexion 
10.42     (4.2-32.1) 115.4     (31.5-189) 0.0001* 
Seated ankle plantar 
flexion 
10.42     (4.2-32.1) 86.6   (39.9-158.9) 0.0001* 
 
* statistically significant result 
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After a below knee cast was applied, active toe dorsi-flexion increased the 
velocity in the popliteal vein from the baseline to a mean 59.1 cm/s post cast 
mean peak (10.5-184.1) (pre-post cast peak mean difference p=0.572) (Table 
5.2). Active toe plantar-flexion resulted in an increase in velocity from baseline 
to a post cast mean peak of 57.3 cm/s (20.9-108.3) (pre-post cast peak mean 
difference p=0.299). Ankle plantar-flexion increased velocity from baseline to 
112.9 cm/s mean peak (34.1-265.5) post cast (pre-post mean difference 
p=0.23). Ankle dorsi-flexion increased velocity from baseline to 88.2 cm/s 
mean peak (23.2-234.2) post cast (pre-post mean difference p=0.045). 
Although the post cast peak velocity was reduced compared to pre cast peak 
for ankle dorsi-flexion, the post cast mean peak velocity still increased more 
than 10 times from baseline levels. 
 
Table 5.2 Comparison of Mean Peak Popliteal vein flow without and then with 
a below-knee cast 
 
Exercise Pre cast mean peak 
systolic velocity 
(cm/s) 
Post cast mean peak 
systolic velocity  
(cm/s) 
p value 
Seated toe dorsi 
flexion 
53.6     (12.8-152.8) 59.1     (10.5-184.1) 0.572 
Seated toe plantar 
flexion 
49.7     (15.5-127.7) 57.3     (20.9-108.3) 0.299 
Seated ankle 
dorsi flexion 
115.4   (31.5-189) 88.2     (23.2-234.2) 0.045* 
Seated ankle 
plantar flexion 
86.6     (39.9-158.9) 112.9   (34.1-265.5) 0.23 
 
* statistically significant result 
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5.2.1 The effect of active toe movement (AToM) on calf pump 
function and asymptomatic deep vein thrombosis in patients 
treated with acute foot and ankle injury treated with cast – A 
Prospective Randomised Controlled Trial 
 
 
During the recruitment, 342 patients between the ages of 18 and 60 years had 
injuries treated with below knee casts, 242 were excluded prior to 
randomization. 100 patients entered the study and were randomized to 
intervention (AToM) or control groups. 78 patients completed the study (Fig. 
5.2). There were no significant differences between the groups (Table 5.3).  
91% of injuries were bony (n=71), which included 57 ankle fractures (72%). 
Other bony injuries included 5th metatarsal fracture (n=3), anterior process of 
calcaneus fracture (n=1), cuboid fractures (n=2), avulsions of dorsal 
talonavicular ligament (n=4), lateral process of talus fracture (n=2), navicular 
fracture (n=2). 7 patients sustained soft tissue injuries, which included 6 grade 
3 ankle sprains and one Lisfranc ligament injury.  
22 (56%) of the patients randomized to the AToM group returned a fully 
completed toe movement activity diary with number of active toe movements 
recorded for each day during cast or boot treatment. 13 (59%) of these 
patients recorded that they achieved the minimum number of active toe 
movements (240) per day (range 16-600). 4 (31%) of these patients sustained 
asymptomatic DVT. There were no reported adverse events. 
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Fig. 5.2 Flow diagram of study participants 
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Table 5.3 Characteristics of Patients Randomised 
 
 
 
Calf pump function data was not normally distributed, and was analysed using 
Mann-Whitney test (Newcombe, 2006). The U/nm statistic of 0.572 (95% CI 
0.420 – 0.710) for both active toe dorsiflexion and active toe plantar flexion 
indicated that patients in the intervention group generally had greater peak 
velocities during these movements, however the effects were small (Table 
5.4). The mean baseline popliteal vein diameter was 7.9mm in both groups. 
Although baseline popliteal velocity, peak velocity during active toe 
dorsiflexion and peak velocity during active toe plantar flexion were greater in 
the AToM group patients, none of these differences were statistically 
significant (Table 5.5). 
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Table 5.4 Calf pump function results 
 
Calf pump function parameter AToM Control p-value 
Baseline popliteal vein diameter 
(mm) 
7.9 (1.736) 7.95 (SD 2.084) 0.933 
Baseline popliteal vein velocity  
(cm/s) 
7.33 (3.663) 6.8 (2.193) 0.579 
Peak popliteal velocity during active 
toe dorsi flexion (cm/s) 
44.04 (30.172) 34.20 (18.878) 0.361 
Peak popliteal velocity during active 
toe plantar flexion (cm/s) 
39.04 (23.699) 31.70 (16.398) 0.348 
 
Table 5.5 – Mann Whitney U statistic analysis of calf pump function 
parameters (U/mn) 
 
 
U/mn 95% confidence limits 
lower upper 
Baseline popliteal vein diameter - injured/cast leg 0.495 0.349 0.642 
Baseline popliteal vein velocity - injured/cast leg 0.533 0.384 0.676 
Peak velocity during active toe dorsi flexion 
(average) - injured/cast leg 
0.572 
0.420 0.710 
Peak velocity during active toe plantar flexion 
(average) - injured/casted 
0.572 
0.420 0.710 
 
 
5.2.2 Incidence and anatomical location of VTE in patients with foot and 
ankle trauma and casts 
 
Asymptomatic DVT 
21 (27%) patients were found to have deep vein thrombosis on ultrasound 
examination (Table 5.6). All of these occurred in the lower limb that had been 
injured and treated in cast. The DVT rate was 13/39 (33.3%) in intervention 
group, 8/39 (20.5%) in control group. These differences were not statistically 
significant (p=0.202). 3 DVT’s were above knee and were treated for oral 
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anticoagulants for 3 months. In all patients except 2, the peroneal vein was 
thrombosed. In 12 patients the DVT was an isolated peroneal DVT. 4 patients 
had combined peroneal and posterior tibial vein DVT, 1 patient had isolated 
posterior tibial vein DVT, 2 had popliteal vein DVT which appeared to arise 
from the peroneal vein, 1 patient had isolated popliteal vein DVT. The mean 
age of patients who sustained DVT was 36 years (range 21 to 53) with a 
mean BMI of 25kgm2 (range 19.7 to 30.4). 13 were male (65%). There was no 
statistically significant difference between age or BMI between patients who 
sustained DVT and those who did not.  
 
Table 5.6 Details of Deep Vein Thrombosis events 
 
 AToM (N=39) Control (N=39) 
Asymptomatic DVT in Popliteal vein or more 
proximal 
1 2 
Asymptomatic below knee DVT details:   
          Peroneal vein 8 5 
          Posterior tibial vein 1 0 
          Peroneal and posterior tibial veins 3 1 
Total n (%) 13 (33.3) 8 (20.5) 
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5.3 The association between mobility and subsequent 
development of Deep Vein Thrombosis in patients with lower 
limb trauma and cast treatment 
 
 
100 patients were recruited. 22 were lost to follow up. 10 patients were 
excluded because either accelerometers were lost (n=4) or failed to capture 
any data (n=6). 68 patients completed the study with full accelerometer data 
for 5 days (120 consecutive hours) and completed lower limb venous 
ultrasound scan to examine for DVT. The mean patient age was 38 years 
(range 18 to 60), 63% (n=43) were male. The majority of patients received 
below knee cast for ankle fracture (Table 5.7).  
 
Table 5.7 Characteristics of patients included 
 
Characteristics n=68 
Age, mean 38 
     Range 18-60 
Male sex, n (%) 43 (63%) 
Injuries, n  
     Ankle fracture –Weber A 12 
     Ankle fracture – Weber B 27 
     Ankle sprain 6 
     Anterior process of calcaneus fracture 1 
     Cuboid fracture 1 
     Dorsal talonavicular ligament avulsion 3 
     Fifth metatarsal fracture 3 
     Lateral process of talus fracture 2 
     Lisfranc injury 1 
     Medial malleolus fracture 9 
     Navicular fracture 2 
     Posterior malleolus fracture 1 
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For the 68 patients who completed the study, mean daily accelerometer 
recorded moves were 1043 (SD 1019), mean daily steps were 863 (SD 848) 
and mean miles recorded were 0.48 per day (SD 0.48). 9 patients (13%) 
recorded 0 moves, steps or miles for at least one day. Out of the 9 patients 
who recorded 0 for at least 1 day, 3 of these recorded 0 for 1 day. 3 of these 
patients recorded 0 for 3 or more consecutive days during the first 5 days 
treated in cast.  
 
26% (n=18) of the 68 patients were found to have asymptomatic DVT on 
bilateral lower limb venous ultrasound after a mean cast duration of 42 days 
(SD 14). One was above knee (Popliteal vein), the remaining 17 cases of DVT 
were below knee. None occurred in the patients who were immobile (3 
consecutive days of 0 recorded accelerometer moves or steps). Move and 
step data was normally distributed. There was no statistically significant 
difference in moves or steps between Group 1 (No DVT) and Group 2 (DVT) 
Table 5.8. 
 
Table 5.8 Accelerometer results for patients who did and did not sustain DVT 
 
  No DVT (Group 1) DVT (Group 2)   
Number of patients 50 18   
Males 32 11   
Age 38 (18-60) 36 (20-53)   
BMI 25 (19-32) 26 (20-32)   
Average Moves per day 1057 (SD 1095) 1005 (SD 793) p=0.8538 
Average Steps per day 877 (SD 909) 825 (SD 669) p=0.8251 
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5.4 Can we use biomarkers of coagulation to predict which 
patients with foot and ankle injury will develop deep vein 
thrombosis? 
 
100 patients were recruited as part of the AToM study. 22 were excluded 
because they did not attend for lower limb venous ultrasound to assess for 
DVT. 1 patient did not provide a blood sample. 77 patients were included. The 
majority were male (n=50). Patient demographics and injury types are 
displayed in Table 5.9. 27% (n=21) of the 77 patients were found to have 
asymptomatic DVT on bilateral lower limb venous ultrasound scanning, all of 
which occurred in the lower limb that had been injured and treated in cast. 2 
of the DVT’s were above knee (Popliteal vein or more proximal), the rest were 
below knee. 
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Table 5.9 Demographics and injury types 
  
No DVT 
(Group 1) 
DVT 
(Group 2) 
Number of patients 56 21 
Males 36 14 
Age 37 (18-60) 36 (20-53) 
BMI 25 (19-31) 25 (20-32) 
Injuries     
          Ankle fracture –Weber A 13 1 
          Ankle fracture - Weber A and 5th Metatarsal fracture 0 1 
          Ankle fracture - Weber A and undisplaced Talus fracture 1 0 
          Ankle fracture – Weber B 18 9 
          Ankle fracture - Weber B and Cuboid fracture 1 0 
          Ankle fracture - Weber B and 5th Metatarsal fracture 1 0 
          Ankle fracture - Weber C 1 0 
          Ankle sprain 4 2 
          Anterior process of calcaneus fracture 1 0 
          Cuboid fracture 2 0 
          Dorsal talonavicular ligament avulsion 2 1 
          Fifth metatarsal fracture 3 0 
          Lateral process of talus fracture 1 1 
          Lisfranc injury 0 1 
          Medial malleolus fracture 5 4 
          Navicular fracture 1 1 
          Posterior malleolus fracture 1 0 
          Talar neck and Dorsal Talonavicular ligament avulsion 1 0 
 
Tissue factor levels were normally distributed, therefore unpaired students t-
test was used to assess for statistically significant differences between Group 
1 (No DVT) and Group 2 (DVT) (Mean 23.92 pg/mL v 20.33 pg/mL, p=0.422). 
18 patients (23%) had TF levels >35pg/mL, 3 of these subsequently 
developed DVT. TF levels ranged from 0 to 68pg/mL. The other blood results 
were not normally distributed, therefore Mann Whitney U tests were used. 
There was no significant difference in Interleukin 6 levels between Group 1 
(median 3.91 pg/mL) and Group 2 (median 4.59 pg/mL), p=0.764), range 0 to 
84.68 pg/mL). Median values for VCAM-1 were also similar between groups 
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(552.98 v 496.84 ng/mL, p=0.111). VCAM-1 levels ranged from 412.63 to 
823.15 ng/mL. Although there was a trend for median D-Dimer to be higher in 
those who subsequently sustained DVT, this was also not significant 
(p=0.490). D-Dimer levels ranged from 31 to 1184 ng/mL. Results are 
displayed in Table 5.10. Subsequently, the three Receiver Operator Curves 
demonstrated that based on this sample of subjects, tissue factor, interleukin 
6 and VCAM1 are poor predictors of development of DVT (area under curve 
<0.5 in all cases, Fig. 5.3, 5.4, 5.5). 
 
Table 5.10 Blood results 
 No DVT (Group 1) DVT (Group 2)  
Tissue Factor (pg/ml) 23.92 (SD 17.52) 20.33 (SD 16.83) p=0.422 
Interleukin 6 (pg/ml) 3.91 (SD 13.07) 4.59 (SD 7.03) u=561.5, z=0.29, p=0.764 
VCAM 1 (ng/ml) 552.98 (SD 92.59) 496.84 (SD 114.02) u=448.5, z=1.58, p=0.111 
D-Dimer (ng/ml) 203.5 (SD 225.27) 236.0 (SD 262.95) u=527.5, z=-0.68, p=0.490 
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Fig. 5.3 ROC curve using IL-6 as a predictor of DVT - Area under the curve = 
0.446 
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Fig. 5.4 ROC curve using VCAM-1 as a predictor of DVT - Area under the 
curve = 0.397 
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Fig. 5.5 ROC curve using Tissue Factor as a predictor of DVT - Area under 
the curve = 0.478 
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6 Discussion 
 
6.1 Effect of below knee cast application on calf pump 
function in healthy volunteers 
 
This is the first study into the effects of a below knee cast on calf muscle 
pump function. Surprisingly, even with a below knee cast in situ, toe and ankle 
dorsi-flexion and plantar-flexion movements significantly increase peak 
systolic velocity measured at the popliteal vein to between 57.3 cm/s and 
112.9 cm/s, which is between six to ten times mean baseline levels. These 
findings are similar to those reported by Izumi et al (2010) who found that 
ankle movements in the un-casted limb resulted in popliteal velocities of 
75cm/s (40-152) (Izumi, Ikeuchi, Mitani, Taniguchi, & Tani, 2010). 
Comparing pre cast and post cast peak velocities, the cast did not significantly 
reduce velocities created by active toe movements or ankle plantar flexion. 
Although peak velocity resulting from ankle dorsi-flexion was reduced by the 
presence of a below knee cast compared to peak velocity prior to cast 
application (p=0.045), active ankle movement with cast in situ still resulted in 
a statistically significant increase in peak velocity from 10.3cm/s at baseline to 
88.2 cm/s during movement (p=0.0001). This was approximately 75% of the 
maximum achievable without the cast. 
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Although it is clear that systems which influence venous haemodynamics do 
reduce rates of venous thromboembolism, the minimum threshold for these 
systems is unknown (Andrews, Sommerville, Austin, Wilson, & Browse, 
1993). It is also unknown which haemodynamic parameter is most important 
in the prevention of DVT (Ricci et al., 1997). Furthermore, there is no clinical 
evidence that mechanical thromboprophylactic methods such as intermittent 
pneumatic compression devices, which produce higher venous velocities in 
the lower limb result in lower rates of deep vein thrombosis (R. J. Morris & 
Woodcock, 2004). However, active toe or ankle movements can influence calf 
pump function to a similar extent to other methods, such as intermittent 
pneumatic compression devices of the foot or calf. It is therefore possible that 
active toe movements in patients with lower limb cast immobilization could 
reduce rates of deep vein thrombosis. 
 
In one of the first experimental studies using the AV foot pump at different 
pressures, cycle rates and duration of compression settings, it was found that 
there was a statistically significant increase in maximum popliteal and femoral 
vein velocities when the pressure was increased from 50mmHg to 200mmHg. 
In the popliteal vein, peak velocity at 50mmHg foot compression pressure was 
31.4cm/s in men and 27.6 in women. At 200mmHg it was 53.5cm/s in men 
and 47.9cm/s in women. Differences between men and women were not 
statistically significant (Andrews et al., 1993). A similar study by Johnson et al, 
examined the effect of the AV foot pump on popliteal venous velocities in 14 
healthy volunteers of mean age 40 years. Foot pumps were set at 200mmHg 
compression with a 20 second cycle. Baseline popliteal velocities of 10.3cm/s 
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(9.4-10.8) increased to 36.8cm/s during foot compression (B. F. Johnson, 
Manzo, Bergelin, & Strandness, 1997). In this study, the baseline popliteal 
velocity was similar (mean 9.94 cm/s). The lowest mean popliteal velocity 
result in this study, with below knee cast in situ, was during active toe plantar-
flexion (57.3cm/s). This is higher than all popliteal velocities recorded in the 
studies of AV foot pumps, even at the highest foot pump setting of 200mmHg. 
One of the potential problems with foot pump compression devices is that the 
volume of blood in the plantar venous plexus of the foot is only 30ml, 
therefore high pressures are necessary to empty these veins (R. J. Morris & 
Woodcock, 2004). This can reduce patient compliance (Warwick et al., 1998). 
 
In view that calf is a greater reservoir of venous blood than the foot, 
compression devices, which compress the calf or combine calf and foot 
compression, have been developed. Many studies have shown that calf or 
combined compression devices enhance venous haemodynamics to a greater 
extent than foot compression devices alone (Delis et al., 2000). Ricci et al 
compared the effect of 4 different foot compression devices at different 
settings against an intermittent calf compression device in 27 healthy 
volunteers (Ricci et al., 1997). Each participant had popliteal vein baseline 
(referred to as resting systolic velocity) and peak velocities (referred to as 
maximum venous velocity) measured during foot or calf compression using 
each device. All scans were done with the patient in reverse Trendelenburg 
position. Mean baseline velocity at the popliteal vein was 12.5cm/s (+/- 3.7 
cm/s), which statistically significantly increased with all devices to a mean 
peak velocity of between 35.2 (+/- 16.3) and 55.3 +/- 19.5 depending on the 
0846014   127 
device. The intermittent calf compression device (encompassing the entire 
calf, with inflation time of 12 seconds, pressure of 40mmHg, with one cycle 
per minute) and the Kinetic Conceptions foot pump device, which had the 
highest compression setting (inflation time 2 seconds, pressure 160mmHg, 3 
cycles per minute) resulted in the greatest enhancement of peak velocities. A 
study using similar methodology, compared the effects of high pressure rapid 
inflation combined foot and calf pump devices (160mmHg compression with 2 
second inflation time) against standard pressure calf compression devices 
(50mmHg pressure, 12 second inflation time). The high pressure devices 
significantly increased popliteal velocities compared to standard pressures, 
from baseline mean of 11.3 cm/s by a mean of 37.3 cm/s (+/- 4.1) (M. D. 
Malone, Cisek, Comerota, Holland, & Eid, 1999). Again, the peak velocities 
with compression devices were still less than velocities achieved with simple 
active toe movements.  
The greatest increase in popliteal velocities using intermittent pneumatic 
compression was shown by Delis et al, in a study of 45 volunteers (20 healthy 
and 25 with intermittent claudication) using combined calf and foot 
compression with pressures of 180mmHg with 3 second inflation time. At 
these high settings, popliteal venous velocities reached 130cm/s. There was 
no statistically significant difference in increases found when measured at 
popliteal vein compared with measurements at the femoral vein. Increases in 
velocities found in claudicants were comparable to results in healthy 
volunteers (Delis et al., 2000). This increase in popliteal venous velocity is 
greater than all measurements achieved in this study. However, at such high 
pressures, the safety of using a device, especially under a below knee cast in 
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which it is not possible to monitor skin integrity is of concern. It is also unlikely 
that patients with injuries treated with casts would be able to tolerate such 
pressures due to discomfort. 
 
Alternative methods for enhancing venous return from the lower limb include 
neuromuscular stimulators of the peroneal nerve (transcutaneous electrical 
nerve stimulation) and electrical muscular stimulation of the calf muscle 
directly. One of the first studies to examine the effect of muscular stimulation 
was by Kaplan et al (2002). A neuromuscular stimulator was positioned over 
the gastrocnemius medial and lateral heads, followed by electrodes being 
placed on the sole of the foot. 49 healthy volunteers participated. Popliteal 
velocities were measured using Doppler ultrasound and compared with the 
unstimulated leg as a control, however the position of the leg during 
measurements was not stated. In this study, it was found that gastrocnemius 
stimulation resulted in a statistically significant increase in popliteal velocity of 
10.2 cm/s when compared to the control leg. Foot stimulation resulted in an 
increase velocity of 8.66 cm/s compared to the control leg, which was also 
statistically significant (Kaplan et al., 2002). A conclusion of this study was 
that the significance of findings in reduction of DVT require prospective study, 
however this has not been examined. Although no participants found the 
device uncomfortable, this degree of venous flow enhancement is small 
compared to findings of the present study. A more recent study examined the 
effects of Veinoplus calf muscle electrical stimulator in 24 healthy volunteers 
at different frequencies (Griffin et al., 2010). Baseline velocity at the popliteal 
vein was 10cm/s, which is similar to findings in this study (10.3cm/s). The 
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highest peak systolic velocities in this study were achieved with stimulation 
frequencies of between 2 and 8 per minute, which resulted in peak systolic 
velocities of 96-105 cm/s, which is greater than the peak velocities achieved 
by the majority of calf or foot compression devices.  
 
The only study of neuromuscular stimulation in patients with casts is by 
Warwick et al (2013) using the GEKO device. This is a peroneal nerve 
stimulator, which functions to stimulate muscles of the anterior and lateral 
compartment of the leg to contract. Interestingly, it is marketed as a calf pump 
stimulator but does not function by stimulating muscles of the deep or 
superficial compartment of the leg, which are traditionally considered as the 
calf pump. In a proof of concept study of 10 healthy volunteers, the GEKO 
was found to increase venous flow in the femoral vein by between 18 and 
131% baseline depending on the position of the leg. The GEKO statistically 
significantly increased popliteal vein velocities with the cast in situ in the 
supine position and standing positions (both non-weight bearing and weight 
bearing). When the leg was elevated, baseline popliteal velocities increased 
therefore the addition of the GEKO stimulation did not significantly increase 
popliteal velocity i.e. veins of calf were less filled than in other positions. 
Depending on the position of the leg, the GEKO increased peak venous 
velocity in the popliteal vein from baseline of between 10.0cm/s and 19.5cm/s 
to between 22.3cm/s and 29.3cm/s during activation. This increase is less 
than all studies of intermittent pneumatic compression and also less than 
possible with simple toe movement.  
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Two studies have compared different methods of lower limb venous 
haemodynamic enhancement (Izumi et al., 2010) (Broderick et al., 2010). The 
former compared the effects of a TENS machine positioned over the fibula 
head in 10 healthy volunteers, to stimulate the common peroneal nerve 
against electromuscular stimulation (EMS) and intermittent calf compression 
set at a pressure of 40mmHg (Flowtron AC 500). The effects of manual calf 
squeeze and active ankle dorsiflexion movement were also studied. Popliteal 
venous velocities were examined with Doppler ultrasound with the patient in 
the prone position. The mean peak velocities achieved, in order of decreasing 
were: TENS 102cm/s, EMS 97 cm/s, Calf squeeze 90 cm/s, Active ankle dorsi 
flexion 75cm/s, Intermittent pneumatic calf compression 65cm/s. In 
comparison to findings in this study, patients in the present study achieved a 
mean peak velocity of 112.9 cm/s even with a below knee cast in situ, which 
is greater than all results in this study. I similar study by Broderick et al 
studied compared the effects of Intermittent pneumatic foot compression and 
neuromuscular stimulation (Duostim tibial nerve stimulator) against weight 
bearing for 20 seconds and standing toe flexion exercises. Popliteal venous 
velocity, diameter and time of flow were measured at the popliteal vein and 
used to calculate an ejected volume in 10 healthy volunteers. The most 
significant finding of this study was that both weight bearing and weight 
bearing toe curl exercises resulted in the greatest ejected volumes (33ml and 
31ml respectively, with no statistically significant difference between results). 
In the supine position, simulated weight bearing did not result in significantly 
increased ejected volumes compared with toe curl exercises (17 v 15ml). 
However, standing weight bearing did result in greater ejected volumes (33ml) 
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when compared non-weight bearing toe curl exercises in the supine position 
(17ml). In the context of a patient with a below knee cast, this study may 
indicate that weight bearing would result in a greater ejected volume from the 
lower limb than non-weight bearing toe exercises (Broderick et al., 2010). 
 
Some of the differences between findings in this study and findings of others 
could be influenced by differences in the leg position during testing in different 
studies. The position of the lower limb affects the efficiency of the calf pump. 
An example of this is the study of the AV impulse foot pump by Fleming et al 
(2000). In their study, femoral venous velocities were measured in 10 healthy 
volunteers at settings of 200mmHg compression at a rate of 3 compressions 
per minute, with the lower limb in different positions. With the lower limb in the 
horizontal position, foot compression increased velocity by 27.2%. In the 25 
degree Trendelenberg position it increased by only 15.4% (not statistically 
significant difference). When the lower limb was positioned in the 25 degree 
reverse Trendelenberg position, femoral venous velocities increased 
significantly by 102.8% from baseline. Therefore, it appears that the foot down 
position may pre fill the lower limb veins to enable the foot and calf pump to 
work more effectively (Fleming, Fitzgerald, Devitt, Rice, & Murray, 2000). 
 
There are several limitations of this study. Firstly, measurements were 
performed on healthy participants and excluded participants with peripheral 
vascular disease, diabetes, varicose veins, deep venous thrombosis or 
previous foot and ankle surgery. Secondly, participants were asked to perform 
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movements to their best efforts. This is likely to have resulted in a best-case 
result, which may not represent clinical practice. However, the increases 
between baseline and peak popliteal velocity reached extreme statistical 
significance (p=<0.0001) in all cases and therefore it is possible that these 
movements would also result in significant increases in patients who may 
have impaired calf pump function due to co-morbidity. The focus of this study 
was the effect of active ankle or toe movements on calf pump function, 
measured as peak velocity at the popliteal vein. Some authors have studied 
additional haemodynamic measures of calf pump function, including return 
time (the time for the peak velocity to return to baseline) (Ricci et al., 1997). 
These may be important parameters, however there is no evidence that 
alterations of these additional measures reduces venous thromboembolism. 
There are other methods for measurement of calf pump function, including 
muscle strength testing and measurement of residual and ejected volumes 
using plethysmography. In this study, calf pump function was measured using 
Doppler, based on baseline and peak velocities, because this has been used 
extensively in previous studies of intermittent pneumatic compression devices 
as discussed. 
 
The findings of this study may have clinical relevance for several reasons. 
Until now an assumption has been made, that lower limb cast immobilisation 
resulted in loss of the calf pump and that this venous stasis could not be 
influenced. However, the results of this study show that despite having 
reduced movement of the foot and ankle active movements stimulate calf 
pump function. It is good practice to encourage patients to maintain knee and 
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toe movements when they are in a cast. These results demonstrate how 
important these movements are in maintaining physiological Popliteal vein 
flow and that this may be significant in reducing their risk of VTE. In much the 
same as airline passengers are now taking control of managing their flight 
risk, patients should be advised to perform these movements to reduce 
venous stasis. The recommended movements are ones that can occur 
naturally in patients with below knee casts as they mobilise around during the 
course of their day and they do not need to be dramatic in order to achieve 
good flow. Further study is necessary to determine the effect of active toe 
movement on calf pump function in patients. If this is effective, it could 
influence the incidence of deep vein thrombosis. 
 
6.2.1 The effect of active toe movement (AToM) on calf pump 
function and asymptomatic deep vein thrombosis in patients 
treated with acute foot and ankle injury treated with cast – A 
Prospective Randomised Controlled Trial 
 
 
This is the first study to examine the effects of active toe movement on DVT in 
patients with lower limb trauma treated with cast. Although it has previously 
shown that active toe movement (AToM) can influence calf pump function in 
healthy volunteers with below knee casts applied, it does not appear that this 
influences the incidence of DVT (B. A. Hickey et al., 2014). The concept that 
lower limb muscular contraction can influence thrombosis is not new. In a 
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prospective randomized study performed almost 20 years ago, 38 patients 
who underwent total hip replacement were randomized to a standardized foot 
and ankle movement protocol and venous plethysmography was performed 4 
days postoperatively (McNally, Cooke, & Mollan, 1997). Venous outflow was 
increased by 22% in the intervention group and it was recommended that 
regular foot and ankle exercises should be part of a prophylactic regimen 
against venous thrombosis (McNally et al., 1997). Although these exercises 
may have influenced calf pump function, there was no further study conducted 
to investigate the effects on deep vein thrombosis. Similarly, Kaplan et al 
(2002) found that electrical stimulation of the foot or calf muscles significantly 
increased popliteal and femoral vein velocities, but failed to investigate the 
effects on DVT (Kaplan et al., 2002). More recently, Fuchs et al (2005) 
conducted a prospective randomized controlled trial of 227 trauma patients 
with bony or ligamentous trauma to the spine, pelvis including acetabulum, 
femur, tibia or ankle (Fuchs, Heyse, Rudofsky, Gosheger, & Chylarecki, 
2005). All patients received unfractionated heparin, however the intervention 
group also received mechanical thromboprophylaxis with an ankle continuous 
passive motion machine (Arthroflow) for 30-minute sessions, three times per 
day (30 movements per minute, range of motion 20 degree dorsiflexion to 40 
degrees plantar flexion). Asymptomatic DVT diagnosed on ultrasound or 
venogram was significantly reduced in the Arthroflow group, from 25% to 
3.6% (p=0.001). Whitelaw et al (2001) compared the haemodynamic effects 
of 6 different mechanical thromboprophylactic devices on calf pump function 
and found that there was no statistically significant difference in increases in 
peak velocity between the most effective device (AirCast VenaFlow) and 
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active or passive dorsiflexion (Whitelaw et al., 2001). An early prospective 
randomized controlled trial of 290 patients who underwent total hip 
replacement, confirmed that not only did AV foot pumps influence popliteal 
venous velocities, but also reduced asymptomatic DVT to rates comparable to 
levels achieved with low molecular weight heparin (Warwick et al., 1998). 
Since then, intermittent pneumatic compression has been found to reduce 
symptomatic DVT (from 16.7% in control group, to 7.3% in IPC) and 
pulmonary embolism (from 2.8% to 1.2%) at meta-analysis level of 70 studies 
including over 16000 medial and surgical patients (Ho & Tan, 2013). It is also 
effective in reducing VTE in patients with hip fracture, patients undergoing 
total knee replacement and following stroke, all of which are considered high 
risk VTE groups (Handoll et al., 2000) (Kakkos et al., 2012) (Dennis et al., 
2013).  
Considering that active toe movement influences venous haemodynamics in 
healthy volunteers to a similar extent to intermittent pneumatic compression 
foot pump devices, it was anticipated that this may also reduce asymptomatic 
DVT in patients with casts (B. A. Hickey et al., 2014) (Whitelaw et al., 2001). 
One of the main reasons why AToM failed to reduce DVT rates may relate to 
the relative infrequent performance of exercises by patients. In the AToM 
study, participants in intervention group performed 60 sets of movements 4 
times per day, which equates to 240 sets in a 24 hour period. In comparison 
to patients using A-V foot pumps in the study by Warwick et al (1998) used 
them for a median of 15 hours in a 24 hour period at a 20 second cycle, 
equating to approximately 2700 compressions (Warwick et al., 1998). This is 
more than 10 times the number of compressions participants in the AToM 
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study would have performed. To achieve this with AToM, assuming patients 
sleep for approximately 8 hours and would be awake for 16 hours per day, 
participants would need to perform almost 170 sets of AToM per hour to 
achieve a similar amount of compression. Considering that many patients in 
this study were unable to achieve even the minimum suggested number of 
active toe movements (240 in 24 hours) and that none of them reported 
performing more than 600 active toe movement exercises in a 24 hour period 
it is unlikely that a patient would be able activate their calf pump as frequently 
as an AV foot pump. Therefore, although the effect of active toe movement on 
popliteal velocities is similar to the effect of AV foot compression devices, 
there is a great difference in the number of calf pump activations performed 
(Whitelaw et al., 2001). 
 
In view that the patient demographics in each study group were similar, it 
appears that the randomization sequence was effective. This is important, 
because unknown confounding factors are likely to have also been similar 
between groups (Bederman et al., 2010). This study was also free of 
thromboprophylaxis industry bias, being sponsored by AO UK. Follow up was 
almost 80%, which is higher than many previous randomized controlled 
studies of thromboprophylaxis in a similar patient group (Jørgensen et al., 
2002) (Spannagel & Kujath, 1993) (Lapidus et al., 2007). It has previously 
been acknowledged that co-ordination of studies to reduce the risk of VTE is 
challenging due the fact that patients with lower limb casts present and are 
treated in several areas within the hospital e.g. Emergency department, 
fracture clinic (Nokes & Keenan, 2009). Although the intervention was 
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relatively simple, this means the findings of the study have good external 
validity. It has previously been suggested that prospective randomized 
controlled trials are at risk of lacking external validity due to highly intensive or 
regimented intervention protocols (Castillo, Scharfstein, & MacKenzie, 2012). 
Although only 33% of patient in the intervention group reported achieving the 
minimum recommended number of active toe movements, this is an 
effectiveness study which assesses how the treatment works in the real world 
(Bederman et al., 2010). Although multiple practitioners performed 
assessment for DVT, all had a minimum of 5 years experience in the NHS 
performing these scan as part of their clinical practice. None of the ultrasound 
scans for DVT were likely to be false positives in view that all were still 
positive on repeat scanning after a week interval. All assessors of DVT were 
blinded to the patient randomization group. 
There are several limitations of this study. Firstly, only 100 (26%) patients 
were recruited after screening 342 for eligibility, due to the current NICE 
guidelines that recommend chemical thromboprophylaxis for patients with 
lower limb trauma treated with cast with additional risk factors. This meant 
that none of the patients who underwent surgery could be included (n= 105), 
with an additional 72 patients being prescribed LMWH for other reasons. 
Patients over the age of 60 years of age (n=97) during the study period 
because this is also considered to increase VTE risk in patients with lower 
limb trauma treated with cast (National Clinical Guideline Centre – Acute and 
Chronic Conditions (UK), 2010).  
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6.2.2 Incidence and anatomical location of VTE in patients 
with foot and ankle trauma and casts 
 
In this study, it was found that 27% of patients with lower limb trauma and 
cast immobilization, who are considered to be low risk for deep vein 
thrombosis go on to develop an asymptomatic DVT. This is an important 
finding, because it cannot be predicted which of these asymptomatic DVT's 
will become symptomatic (Nokes & Keenan, 2009). Comparing the findings of 
this study with the control group DVT incidence in previous studies into the 
effect of LMWH in patients treated with casts reveals that patients considered 
as ‘low risk’ sustain a similar number of DVT’s. For example, Spannagel et al 
found a 16.5% DVT rate in 127 patients, Jorgensen found an incidence of 
17% of 106 patients and Lassen found an incidence of 18% of 191 patients 
(Spannagel & Kujath, 1993) (Jørgensen et al., 2002) (Lassen et al., 2002). 
These studies included patients with both bony and soft tissue injuries, which 
is similar to the injury demographic in the present study. Studies limited to 
patients with ankle fractures reveal asymptomatic DVT rates of 23% in those 
treated non-operatively, and 28% in those treated operatively (Sultan et al., 
2014) (Lapidus et al., 2007). Patients with Achilles tendon injuries have 
consistently been found to have the highest incidence of asymptomatic DVT, 
which occur in between 33% and 42% of patients (Nilsson-Helander, Thurin, 
Karlsson, & Eriksson, 2009)(Lapidus and Rosfors 2007) (Domeij-Arverud et 
al., 2013).  
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Some studies have reported lower rates of asymptomatic DVT. The lowest 
rate was by Kock et al, in which only 4.3% of 163 patients with fracture of 
sprains developed this complication (Kock et al., 1995). Patil et al found that 
only 5% of 100 patients with isolated stable ankle fractures treated non-
operatively developed asymptomatic DVT on Ultrasound scanning within 7 
weeks of injury. It was concluded that this DVT incidence was low and 
therefore routine thromboprophylaxis was not recommended (Patil, Gandhi, 
Curzon, & Hui, 2007). There are several differences between this study and 
that by Patil, including that the majority of patients in their study were weight 
bearing (81%), and DVT scans were performed earlier following injury. The 
low incidence in the study by Patil may also be related to a higher false 
negative rate. Gehling et al also reported very low rates of asymptomatic DVT 
in 111 patients with lateral ligament injuries treated with cast immobilization 
for at least 1 week. Despite additional risk factors for DVT in 72% of these 
patients only 1 patient sustained an asymptomatic DVT when screened with 
venography. The median age of patients in this study was 26 years, and it has 
previously been suggested that this may be one of the reasons why the DVT 
rate was low (Nokes & Keenan, 2009). However, the mean age of patients 
who sustained DVT in this study was only 36 years (range 21 to 53), with 40% 
(n=8) of patients being aged 30 or younger.  
 
Considering all of the aforementioned literature, it appears that asymptomatic 
DVT occurs in 15% of patients with lower limb trauma treated with cast 
immobilization (145/985). Symptomatic deep vein thrombosis is less common. 
Considering all prospective randomized controlled trials of low molecular 
0846014   140 
weight heparin to date in this patient population, symptomatic DVT occurred in 
2.5% of patients (10/390) in the control group of studies which reported 
symptomatic DVT as an outcome measure (Lassen et al., 2002) (Lapidus et 
al., 2007) (Jørgensen et al., 2002). In non-randomized observational studies, 
the incidence of symptomatic venous thromboembolism has consistently been 
shown to be lower than this. In a large study of 2759 patients with lower limb 
injuries treated non-surgically, across 37 teaching hospitals and 413 non 
teaching hospitals over a 7 month period, it was found that 1% of patients 
sustained a symptomatic DVT (Riou et al., 2007). Although this study focused 
on adult patients not undergoing surgery, it included patients with both high 
and low VTE risk and also a variety of injuries ranging from minor injuries 
such as ankle sprains (34%) to severe injuries such as complete Achilles 
tendon rupture or ankle fracture (22%). Furthermore, LMWH 
thromboprophylaxis was provided to 61% of patients in this study, the 
decision being left to the treating clinician rather than any pre defined risk 
assessment score. Also, only 54% of patients in this study were treated with 
rigid cast immobilization i.e. resin or plaster cast, with the remaining patients 
treated with orthoses, taping and bandages. The important finding on 
multivariate analysis was that severe injury (complete Achilles tendon rupture 
or fracture), rigid cast immobilization, non-weight bearing and patients over 
age 50 years had higher risk of VTE (Riou et al., 2007). Therefore, the 
incidence of symptomatic VTE in a patient treated with a rigid cast as in this 
study is likely to be higher than 1%. In a single centre retrospective study, 
clinical records were reviewed for 381 consecutive patients treated with lower 
limb casts for any traumatic injury over a 1-year period. None received 
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thromboprophylaxis (Thomas & Van Kampen, 2011). The only exclusions 
were patients who had cancer or previous VTE. Patients who would normally 
be considered high risk for VTE, such as patients who underwent surgery or 
had Achilles tendon ruptures were included. The important finding from this 
study was that the overall symptomatic VTE rate was 1.84% (n=7). 4 patients 
(1%) sustained non-fatal pulmonary embolism. Considering the 4 patients in 
this study who sustained PE, 3 of them would have been provided with LMWH 
if they had been risk assessed as per NICE guidelines (one Achilles rupture, 
two underwent surgery). In view of this, it was concluded that 
thromboprophylaxis should be considered in those considered at high VTE 
risk. One patient however, was a 40 year old man with a non-operatively 
treated ankle fracture treated in non-weight bearing cast. Apart from smoking, 
he had no apparent risk factors and therefore it is unlikely this could have 
been prevented (0.2%) (Thomas & Van Kampen, 2011). For patients with 
ankle fracture who undergo surgical fixation, the incidence of symptomatic 
DVT and non-fatal PE is even higher (2.66 and 0.32% respectively) (Pelet, 
Roger, Belzile, & Bouchard, 2012). 
 
In a prospective study with greater numbers (n=1200) found a symptomatic 
VTE incidence of 0.6% within 3 month of injury in patients with non-
operatively treated fractures of the tibia, ankle, patella and foot (some 
operated). The only exclusions were patients with major trauma, active cancer 
or previous VTE. Of the 7 patients who sustained symptomatic VTE, 2 were 
proximal DVT’s, 3 were distal, 2 patients sustained non-fatal PE. In contrast to 
the conclusion in Thomas and Van Kampen’s study (2010), it was felt that 
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routine thromboprophylaxis was not warranted or cost effective (Selby et al., 
2014). It is important to recognize that a cost analysis was not performed in 
either of these studies. 
 
Achilles tendon rupture is associated with a particularly high incidence of 
symptomatic VTE. For this reason, NICE guidelines recommend that these 
patients are provided with chemical thromboprophylaxis. The first report of the 
association between Achilles tendon rupture and VTE was over 40 years ago, 
in a series of 6 patients who sustained symptomatic venous thromboembolic 
events associated with being treated with cast immobilization (Micheli, 1975). 
3 of these patients had cast immobilization for Achilles tendon rupture. 2 of 
these patients developed Pulmonary Emboli. Subsequently, Persson & 
Wredmark (1979) found a symptomatic VTE of 15% in their series of 20 
patients who had non-operatively treated Achilles tendon ruptures (Persson & 
Wredmark, 1979). The focus of their paper was on ankle range of motion and 
calf strength and it appears the significance of the high incidence of 
symptomatic VTE was not appreciated, in view that this was not even 
mentioned in the discussion. More recently, Healy et al (2010a) reported the 
incidence of symptomatic VTE in a series of 205 patients with Achilles tendon 
total of partial ruptures. 78% of these patients were treated non-operatively. 
6% (n=13) of patients sustained a symptomatic VTE (3 pulmonary emboli, 4 
proximal DVT, 6 distal DVT), of which only one had received chemical 
thromboprophylaxis (Healy et al., 2010). Domeij-Averaud et al (2013) found 
that the asymptomatic DVT incidence was over 60% in a series of 24 patients 
with Achilles tendon rupture treated operatively (Domeij-Arverud et al., 2013).  
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Although the incidence of asymptomatic DVT in patients with lower limb 
trauma treated with cast immobilization is very high (approximately 1 in 4 
patients), the incidence of symptomatic VTE appears to range from 0.6% to 
15% depending on the injury (Selby et al., 2014) (Persson & Wredmark, 
1979). In practice, the significance of this depends on what is perceived as an 
acceptable level of risk, which will differ between individuals depending on 
perspective. This perspective may differ between a stakeholder paying for 
thromboprophylaxis and a patient. It is important that patients with lower limb 
trauma and cast immobilization are provided with accurate information on 
which they can make decisions on taking thromboprophylaxis. Unless patients 
believe it is important, their compliance is likely to be low, which will impact on 
the efficacy of any proposed prophylactic method.  
 
Another important finding of this study, is that all DVT’s occurred in the veins 
of the lower limb that had been injured and treated in cast. This simple 
observation is not reported in previous studies into the incidence of DVT in 
patients treated with casts. As originally suggested by Virchow, thrombosis 
results from a triad of stasis, endothelial dysfunction and hypercoagulability 
(Virchow, 1856). In view that all DVT’s occurred in the limb which had been 
injured and casted, it is more likely that the former two components of this 
triad are more important. The energy transfer to the limb resulting in bony or 
soft tissue trauma is likely to result in endothelial damage. Venous stasis may 
result from pain, swelling occluding veins or the cast itself. A previous study 
by Solis and Saxby examined the incidence of below knee DVT in patients 
who underwent elective foot and ankle surgery. In their series of 201 
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consecutive patients, 3.5% of patients were found to have asymptomatic calf 
DVT on duplex follow up at between 6 and 18 days postoperatively. 86% of 
DVT’s occurred in the operated leg (Solis & Saxby, 2002). 33% of patients in 
this study had postoperative immobilization of the foot and ankle, which did 
not have a statistically significant association with DVT on logistic regression. 
This suggests that endothelial dysfunction may play a more important role in 
the pathogenesis of deep vein thrombosis than stasis. This requires further 
investigation. 
There are several limitations of this study. Due to the variety of injuries 
included, the duration of cast treatment was variable. As a result it was not 
possible to perform all Doppler scans at a specific time interval following 
injury. For logistical reasons it was not always possible for patients to wait to 
have bilateral lower limb Doppler ultrasound scans on day of cast removal. In 
these cases, patients had their scans arranged for their next fracture clinic or 
Physiotherapy appointment at the Hospital in order to minimize 
inconvenience. Some asymptomatic DVT’s may have resolved during this 
time, and therefore the finding of a 25% DVT rate may under-estimate the true 
incidence. The loss to follow up was 19%, which may have also resulted in an 
underestimate of asymptomatic DVT incidence. None of these patients lost to 
follow up sustained symptomatic VTE events. Historically, venography was 
the gold standard for diagnosis of DVT in leg after Orthopaedic surgery, now 
Doppler accuracy has increased it has become the gold standard. (Domeij-
Arverud et al., 2013). It is unlikely that any of the DVT’s in this study were 
false positives because all DVT’s were present on repeat scanning at 1 week 
after diagnosis.  
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6.3 The association between mobility and subsequent 
development of Deep Vein Thrombosis in patients with lower 
limb trauma and cast treatment 
 
 
Patients with lower trauma and cast treatment are often assumed to be 
immobile. Although some patients with lower limb trauma and cast treatment 
may find mobilization challenging, due to pain, anxiety or difficulty non-weight 
bearing, mobility of these patients has never previously been objectively 
studied (Harvey & Runner, 2011). In this study, using objective measurement 
of mobility, less than 5% of patients with lower limb trauma treated with non-
weight bearing below knee cast are immobile during the first 5 days of cast 
treatment (no steps or moves for 3 consecutive days). The remaining 95% 
were not immobile. Only 9 patients (13%) recorded 0 moves, steps or miles 
for at least one day.  
 
In theory, reduced mobility can lead to venous stasis in the lower limbs, 
however the association between mobility level and thrombogenesis is poorly 
documented (Emed et al., 2010). In a study by Gibbs et al (1957) sixty years 
ago, it was found during post mortem that the incidence of lower limb venous 
thrombosis was greater in patients who had been confined to bed for longer 
than 3 days (Gibbs, 1957). In practice, it is difficult to determine the 
association between mobility and DVT because the definition of immobility 
differs substantially between studies. In a review of the literature by Hull et al 
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(2013) it was found that definitions of immobility vary widely between studies 
of immobility, from walking within hospital room or to the bathroom for 3 or 
more days, to total bed rest (with bathroom privileges) for 4 days or more 
within 2 months of VTE event (Hull, 2013). They concluded that definitions 
need refining (Hull, 2013). Although a systematic review of cohort and case 
control studies in medical patients concluded that immobilization i.e. bed rest 
is associated with increased risk of VTE, the assumption that reduction in 
mobility is an independent risk factor for VTE may not be true because it is 
difficult to exclude an influence on VTE by the underlying conditions causing 
the reduction in mobility (Pottier et al., 2009). In contrast, Warlow et al (1976) 
found that in patients with acute stroke, the incidence of DVT was unaltered 
by early mobilization i.e. bed rest less than 4 days compared with those who 
were in bed for longer durations (Warlow, Ogston, & Douglas, 1976).  
 
In this study, 26% (n=18) of the 68 patients were found to have asymptomatic 
DVT on bilateral lower limb venous ultrasound after a mean cast duration of 
42 days (SD 14). One was above knee (Popliteal vein). However, there was 
no statistically significant difference in moves or steps between Group 1 (No 
DVT) and Group 2 (DVT). No DVT’s occurred in the 3 patients who were 
recorded as being immobile. 
 
Although there was no association between mobility and DVT, it appears that 
a mean step count of 863 found in this study is not normal. For example, 
students have been shown to walk an average of 10,000 steps per day when 
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measured using ActiGraph wGT3X-BT for 7 consecutive days (Clemente, 
Nikolaidis, Martins, & Mendes, 2016). Sisson et al (2010) reported similar 
findings in their study of healthy volunteers using the Actigraph AM-7164, 
recording on average 9876 +/- 107 steps per day (uncensored). Even when 
steps taken at an intensity of <500 counts per minute (indicating inactivity 
intensity) were excluded, volunteers still recorded 6540 +/- 106 steps per day 
(Sisson et al., 2010). Le Masurier et al (2003) found that healthy participants 
walking at speeds of between 54 and 107 metres per minute walked between 
461 and 660 steps in only 5 minutes of walking (Le Masurier & Tudor-Locke, 
2003). In the largest study of physical activity (the National Health and 
Nutrition Examination Survey (NHANES), 14446 adults of mean age 48 years 
had steps measured using the actigraph AM-7164 accelerometer worn at the 
hip for continuous monitoring for 7 days, for a minimum of 10hrs per day. 
13.3% of patients recorded a ‘basal' physical activity category (<2500 
steps/day), 22.7% met the limited category (2500-4999 steps per day), 27% 
were ‘low active’ (5000-7499), 19.3% were somewhat active (7500-9999), 
9.6% were active (10,000-12,499) and 8.1% were ‘highly active’ (>12,500 
steps per day). Based on this, all patients would be considered in the ‘basal’ 
physical category (Sisson et al., 2010).  
 
Some studies have objectively measured mobility in Orthopaedic patients. 
Lutzkner et al (2016) reported in their study that patients awaiting total knee 
replacement walk an average of 5371 steps per day (SD 2820) (C. Lützner, 
Beyer, Kirschner, & Lützner, 2016). Similarly, in a study of patient mobility 
before and after TKR, it was found that patients ambulate less at 2 months 
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following surgery as compared to pre-operatively. However this was not a 
statistically significant reduction (4,993 gait cycles per day preoperatively 
compared to 4730 cycles postoperative) (Brandes, Ringling, Winter, Hillmann, 
& Rosenbaum, 2010). Even after transtibial amputation, Desveaux et al 
reported that patients walk an average of 3809 +/- 2189 steps per day 
(Desveaux et al., 2016). These patients appear more mobile than those in the 
present study, which found that mean daily accelerometer recorded moves 
were 1043 (SD 1019), mean daily steps were 863 (SD 848) and mean miles 
recorded were 0.48 (SD 0.48). Pre injury mobility levels were not available for 
comparison. There is however some evidence that lower limb casts may 
reduce mobility. Recently, Ceroni et al measured activity in 50 children who 
were had a long leg non-weight bearing cast, using the Actigraph 7164 
uniaxial accelerometer and found a 62.4% reduction in mobility compared to 
controls (Ceroni, Martin, Lamah, et al., 2012b). Maggio et al (2016) measured 
activity-related energy expenditure in a series of 34 adolescents with lower 
limb casts using the same device and found a 16% reduction when compared 
with healthy controls, indicating they were less active (Maggio, Martin, & 
Ceroni, 2016). The only study of Orthopaedic patients which reports lower 
mobility than found in the present study is by Davenport et al (2015), who 
found that patients who underwent hip fracture surgery, postoperative mobility 
was only 36 steps per day (+/- 80.4). These patients were all admitted from 
their own home or low level care facility pre-fracture, so it could be anticipated 
that those from higher level care institutes such as nursing homes may 
mobilise even less (Davenport et al., 2015). Immobility to this extent may 
contribute to development of venous thrombosis. 
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Accelerometers and pedometers can both be used to detect ‘steps’ and have 
previously been shown to produce similar results when compared to actual 
video recorded steps taken under controlled treadmill conditions, between 
walking speeds of 1.1 – 1.8 m/s. However, at slow walking speeds of 0.9 m/s, 
accelerometers are significantly more sensitive and accurate. Participants in 
this study were between ages 20 an 55 years, which is comparable to our 
study group. Considering that many patients in our study would walk less then 
0.9 m/s, use of an accelerometer was more appropriate (Le Masurier & Tudor-
Locke, 2003). In a study of gait in 14 amputees walking with prostheses, 
Houdijk et al (2008) found that the DynaPort accelerometer was highly 
accurate in measurement of step count when compared with video recording 
(Pearson correlation co-efficient of 0.99, p<0.001). However, the DynaPort 
MiniMod accelerometer and accompanying GaitMonitor software are much 
more expensive than MOVband accelerometer, approximately $3,000 
.(Houdijk, Appelman, Van Velzen, Van der Woude, & Van Bennekom, 2008). 
The majority of studies into physical activity use the Actigraph brand, however 
we were limited by costs constraints (Montoye et al., 2016). Under free living 
conditions, consumer level activity monitors, worn for 48 consecutive hours, 
including the Fitbit One, Fitbit Zip, Jawbone UP, Misfit Shine, Nike Fuelband, 
Striv Smart Pedometer and Withings Pulse were all shown to have strong 
correlation (r > 0.9) for measuring step count in comparison with research 
grade devices such as the ActiGraph GT3X+ and the BodyMedia SenseWear) 
(Ferguson, Rowlands, Olds, & Maher, 2015). More recently, the MOVband 
has been shown to have strong positive correlation with the Actigraph GT1M 
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research grade accelerometer in both adults and children (Williamson et al., 
2014) (Fennell et al., 2016). 
 
At present there is no current consensus on the best method for 
measurement of physical activity using accelerometer data (Sabia et al., 
2014). However, one important aspect of data collection is minimum wear 
time. In an analysis of 1000 days of accelerometer data from 1000 
participants in the National Health and Nutrition Examination Study data set 
(NHANES), shorter wear times were found to be associated with increased 
errors of physical activity measurement (Herrmann et al., 2014). 
Subsequently, it was recommended that accelerometers should be worn for 
greater than 12h/day to ensure accurate estimates of daily physical activity 
(Herrmann et al., 2014). Rich et al calculated reliability coefficients in 7704 
participants who wore the Actigraph GT1M accelerometer and determined 
that devices should be worn for at least 10 hours per day for at least 2 days in 
order to reliably estimate physical activity (Rich, Geraci, et al., 2013b). 
Therefore, most studies using accelerometers to measure physical activity 
use a minimum of 4 days for a minimum of 10hrs per day (Skender et al., 
2016). In the present study, patients wore the accelerometers for 24hr/day for 
5 consecutive days, which should provide a valid measure of physical activity.  
For those who completed this study and attended for DVT ultrasound scans 
(n=78), only 4 (5%) accelerometers were lost and 6 accelerometers (8%) 
failed to capture any data (13% total failure). This rate of return is high in 
comparison to previous studies and is due to positioning the accelerometer 
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within the cast. For example, Sharma et al (2012) attempted to study the first 
7 days of mobility in women following child birth and found that only 36% of 
200 recruited patients returned the pedometer by post (Sharma et al., 2012). 
Similarly, in a series of 10034 participants asked to wear an accelerometer at 
hip level for 7 consecutive days, only 66.5% achieved the minimum wear time 
of at least 10 hrs per day for 2 or more days (Rich, Cortina-Borja, et al., 
2013a). Previous authors have also found difficulty with compliance when 
mobility-tracking devices have been applied to other regions of the body. For 
example, Ceroni et al (2012) measured post-operative mobility in 50 children 
following surgery and non-weight bearing long leg cast, during which all 
participants were asked to wear an Actigraph 7164 uniaxial accelerometer at 
the iliac crest of the right hip with an elastic belt for 10 days. 28% (n = 14) of 
patients were excluded because they failed to wear the accelerometer for at 
least 5 days or the instrument malfunctioned (Ceroni, Martin, Lamah, et al., 
2012b). Maggio et al measured physical activity in 50 adolescents with lower 
limb casts for fracture using ActiGraph 7164 attached to the iliac crest, but 
had to exclude 32% (n=16) due to wear time of less than 5 days or instrument 
malfunctions (Maggio et al., 2016). Harrison et al (2011) reported a similar 
experience in 48 pregnant women using the Actigraph GT1 M accelerometer 
where 38% either failed to wear the accelerometer or had incomplete data 
(Harrison, Thompson, Teede, & Lombard, 2011). Harding et al (2014) 
reported a lower total failure rate using the Actigraph GT1M accelerometer in 
57 patients who underwent hip or knee arthroplasty. Patients were asked to 
wear the accelerometer for 10hrs per day for 4 days and only 12% of patients 
were excluded because they either failed to wear the accelerometer for long 
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enough (n=5) or there was a technical problem with the monitor (n=2) 
(Harding, Holland, Delany, & Hinman, 2014). Hager et al (2015) achieved 
similar rates of failure (16%) in 457 adolescent girls asked to wear an Actical 
accelerometer at the ankle for 7 consecutive days (Hager et al., 2015). 
 
As discussed, it was considered important to apply the accelerometer to the 
cast this in order to increase compliance with wearing the accelerometer in 
free-living conditions. In order to standardize the accelerometer position in the 
cast, all accelerometers were fitted by one author (BH), as it has previously 
been suggested that even subtle differences in positioning of devices can 
influence results (Rispens et al., 2014). However, many recent studies have 
suggested that site of accelerometer attachment may not be so influential on 
results. Examples include the activPAL3c triaxial accelerometer, which can be 
worn on either thigh, either upper or lower without significantly affecting step 
count measurements (Stanton, Guertler, Duncan, & Vandelanotte, 2016). The 
ActiGraph GT3X accelerometer, for which Dieu et al found no significant 
difference in activity counts for x,y or z axes when devices were worn 
simultaneously on dominant and non-dominant wrists for 24 hrs (Dieu et al., 
2016). Similarly, Stepwatch accelerometer (Cyma, Seattle, Washington) step 
counts worn simultaneously at each ankle had excellent agreement, with 
disagreement of <1 step per minute at walking speeds of between 1 and 
3mph (Foster et al., 2005). Reliability of the Actigraph GT3X+ monitor has 
also been found to have average Intraclass Correlations of >0.86 when 
results were compared between measurements at wrist, hip and ankle (just 
above lateral malleolus) in 40 healthy volunteers (Ozemek, Kirschner, 
0846014   153 
Wilkerson, Byun, & Kaminsky, 2014). The differences between these newer 
studies and older studies such as previously discussed by Taraldsen et al 
(2011) may be due to the differences in accelerometer technology (Taraldsen 
et al., 2011). For example the ActivPAL used by Taraldsen et al was a 
uniaxial accelerometer, whereas modern accelerometers, including the 
ActivPAL 3c and MOVband use triaxial accelerometry, which may be less 
affected by device positioning. 
 
The main strength of this study is that objective measures were used to 
prospectively assess patient mobility in a consecutive series of patients with 
acute lower limb trauma treated with below knee cast. It was felt that this was 
more appropriate in view that the overall correlation between questionnaire-
assessed and accelerometer-assessed physical activity was low in a large 
cohort study (Spearman’s r = 0.3) (Sabia et al., 2014). To standardize data 
collection one author applied all accelerometers and a minimum wear time of 
a consecutive 120 hours was used, which enables valid conclusions to be 
made from the data. Accelerometer failures and losses were less than 13%, 
which is better than achieved in the majority of other studies in to physical 
activity using accelerometers. Particular attention has been given to reporting 
of the methods, providing specific details of the accelerometer used, 
according to recent guidance from Montoye et al (2016) (Montoye et al., 
2016). Although this was a proof of principle study, it is likely that it was 
powered to detect significant differences in physical activity between groups. 
Assuming a 20% difference in steps per day between DVT and no DVT 
groups, with baseline activity levels of 1000 steps per day (SD 500), 28 
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participants would have needed to be recruited for power 0.8 at the 0.05% 
level of significance (Davenport et al., 2015). Our loss to follow up was higher 
than anticipated, mainly because 22% of recruited participants failed to attend 
for their lower limb ultrasound to assess for deep vein thrombosis. 
 
Conclusion 
 
Using objective measurement, this study reveals that the majority of patients 
(95%) with acute lower limb trauma treated with non-weight bearing below 
knee cast are not immobile during the first 5 days after cast application. 
Immobility was not associated with subsequent development of DVT. 
Although it is likely that patients with lower limb trauma treated with casts are 
less mobile than their pre injury states, physical activity levels do not appear 
to provide discriminatory value in predicting which patients will develop deep 
vein thrombosis. In view of this, patient mobility should not be used to stratify 
these patients into risk of DVT. 
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6.4 Can we use biomarkers of coagulation to predict which 
patients with foot and ankle injury will develop deep vein 
thrombosis? 
 
 
None of the plasma biomarker levels tested in this study (Tissue Factor, 
Interleukin 6, VCAM-1 and D-Dimer) were able to predict development of 
subsequent DVT. Although they are involved in venous thrombosis, they have 
no useful role risk stratification of patients with acute foot and ankle injury.  
 
Tissue factor, also known as Thromboplastin or Coagulation factor III is a 
transmembrane glycoprotein (Mackman, 2006) found in the vascular 
adventitia (Girard & Nicholson, 2001). Vessel wall tissue factor is the principal 
initiator of thrombosis (Day et al., 2005) (Khorana et al., 2008) (Kretz, 
Vaezzadeh, & Gross, 2010), acting as the co-factor for factor VII. The 
combination of these results in activated VIIa, which activates factors X and IX 
(Chouhan et al., 1999). It is also found in the blood, stored in alpha granules 
of platelets and becomes expressed on the surface after platelet activation 
(Müller et al., 2003). The majority of blood-borne tissue factor is derived from 
monocytes and is functionally ‘inactive’ until ‘decrypted’ to act as a catalytic 
co-factor for factor VIIa (Bogdanov & Versteeg, 2015). In a rabbit model, 
Himber et al demonstrated that inhibition of tissue factor inhibited venous 
thrombosis propagation (Himber et al., 2003). However, despite these 
findings, there are limited numbers of studies which have investigated the 
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association between TF and subsequent development of VTE.  
 
Khorana et al used a custom made ELISA test to measure plasma tissue 
factor antigen in 11 patients with Pancreatic cancer and found a significant 
association between TF antigen levels and subsequent development of 
symptomatic VTE (p=0.036) (Khorana et al., 2008). TF antigen levels in the 
two patients who subsequently developed VTE were 377 pg/mL and 504 
pg/mL. For comparison, the highest TF level in the present study was 68 
pg/mL. This patient did not develop DVT. In a study of patients with lower limb 
trauma treated with cast, Walenga et al (2014) measured tissue factor antigen 
at time of injury, between day 10 to 14 post injury and on cast removal. 
Interestingly, at time of injury, levels were not elevated above normal 
(<35pg/mL). Also, there were no significant differences in TF levels between 
fracture, Achilles and soft tissue injury groups (Walenga et al., 2014). In the 
present study, 18 patients (23%) had TF levels >35pg/mL, 3 of these 
subsequently developed DVT. In the present study, tissue factors were 
23.92pg/ml in patients who did not develop DVT, compared with 20.33pg/ml in 
those who did (p=0.422). In contrast to the findings of this study, Walenga et 
al (2014) found that those who developed VTE had significantly higher tissue 
factor levels (median 49.05 pg/mL vs 14.86 pg/mL, p = 0.003). This difference 
was present at baseline, between 10 to 14 days post injury and at time of cast 
removal (Walenga et al., 2014). In contrast, Johnson et al (2009) measured 
several types of tissue factor in a series of 19 patients who underwent total 
knee replacement. Interestingly, plasma tissue factor levels did not increase 
significantly. However, the peripheral blood mononuclear cell functional tissue 
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factor procoagulant activity did increase on day 1 and 2 post surgery (G. J. 
Johnson et al., 2009).  
 
DVT is associated with an inflammatory response (Mosevoll et al., 2015) (Hou 
et al., 2012), however, it unclear whether this is a cause or a consequence of 
thrombosis. Cheng et al found that IL-6 levels significantly increased on day 1 
after total knee replacement when compared to pre-operative levels, 
suggesting that tissue injury activates inflammation (Cheng, Giebaly, 
Campbell, Rumley, & Lowe, 2014). In view that IL-6 creates a prothrombotic 
state by increasing the expression of tissue factor (Kerr, Stirling, & Ludlam, 
2001), it is logical to consider that tissue injury may result in venous 
thrombosis. In a study of 717 patients with first acute symptomatic DVT, all 
had IL-6 blood test on USS confirmation of DVT. IL-6 was measured using 
ELISA (R&D systems). Higher IL-6 levels were found to be significantly 
associated with extent of DVT and clinical symptoms at diagnosis 
(Rabinovich, Cohen, Cushman, Kahn, BioSOX Investigators, 2015). 
 
In this study, median IL-6 levels were 3.91 pg/mL in those who did not 
subsequently develop DVT and were 4.59 pg/mL in those who did develop 
DVT (p=0.764) (range 0 to 84.68 pg/mL). Similarly, Mosevall et al (2015) used 
the R&D systems Luminex assay to measure inflammatory markers in plasma 
of patients suspected of having lower limb DVT. They found no significant 
difference between IL-6 levels in those with (1.240 pg/ml), compared to those 
without (2.020 pg/ml) on subsequent venous USS. Furthermore, IL-6 levels in 
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the 21 patients found to have DVT on USS, were not significantly higher than 
20 normal control patients without DVT (1.240 pg/ml vs 3.470 pg/ml. 
p=0.1967) (Mosevoll et al., 2015). In a series of 40 patients with 
phlebographically proven lower limb DVT, Roumen-Klappe et al measured IL-
6 on day of presentation and compared levels to a group of 33 controls. They 
also measured IL-6 on the subsequent 5 days following DVT. Interestingly, 
they found that IL-6 levels were significantly higher in the group with DVT 
(15pg/mL, range <3 to 70 pg/mL) as compared with the control group (<3 
pg/mL, range <3 to 11 pg/mL), but subsequently decreased during the 
following 5 days, to 5.5 pg/mL by day 5 (p <0.01). This indicates that that the 
raised IL-6 levels were the result of thrombosis rather than the cause 
(Roumen-Klappe et al., 2002). At 32 months after DVT, patients continue to 
have increased levels of IL-6 compared to controls, suggesting a persistent 
chronic sub-clinical response (Bittar et al., 2015). In view of that there were no 
significant differences in IL-6 between those who did and did not develop DVT 
This may represent that none had DVT at the time of measurement. It 
appears that IL-6 levels are raised in response to DVT rather than being the 
cause. 
 
VCAM-1 levels are increased at sites of endothelial inflammation and are 
involved in leukocyte adhesion and migration across vascular endothelium 
(Yang et al., 2013) (Bouman et al., 2014). In a study of 135 patients 
suspected of having DVT, Bozic et al (2002) used R&D Systems quantitative 
ELISA to measure plasma VCAM-1. The 39% percent of patients who were 
subsequently found to have DVT on lower limb doppler ultrasound, had 
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significantly higher VCAM-1 levels (392 micrograms/litre vs 417 (p=0.03). 
However, VCAM-1 was not as accurate as D-dimer in diagnosis using ROC 
analysis (0.6 vs > 0.8 depending on D-dimer method used) (Božič, Blinc, & 
Stegnar, 2002). In a similar recent study of 89 patients suspected of having 
DVT, Mosevoll et al (2015) measured VCAM-1 using R&D systems Luminex 
assay. VCAM-1 levels were significantly higher in the 21 patients who were 
subsequently found to have DVT on lower limb ultrasound (850.161 ng/ml, 
range 104.311 to 1571.607 vs 635.436, range 290.605 to 2793.862, 
p=0.0009). Furthermore, in comparison to 20 control patients, VCAM-1 levels 
were also significantly higher in patients with DVT (Mosevoll et al., 2015). In 
the present study, median VCAM-1 levels were 552.98 ng/mL in those who 
did not develop DVT, as compared with 496.84 ng/mL in those who did 
(p=0.111). VCAM-1 levels ranged from 412.63 to 823.15 ng/mL. In view that 
the same number of patients sustained DVT in this study as reported in the 
study by Mosevoll et al, it is likely to be adequately powered to detect 
statistically significant differences in VCAM-1 between groups who did and did 
not subsequently sustain DVT (Mosevoll et al., 2015). In a recent mouse 
model, thrombin was recently shown to induce the expression of VCAM-1, 
suggesting that VCAM-1 is increased prior to thrombus formation (Bertin, 
Lemarié, Robins, & Blostein, 2015). However, levels of VCAM-1 may be 
increased before levels of D-Dimer rise. The difference with this study is that 
VCAM-1 was measured within 3 days of injury, as opposed to at time of 
diagnosis of DVT. This may have been too early, before a prothrombotic state 
had occurred. 
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Fibrin clots form to cause haemostasis, and are subsequently broken down by 
the action of plasmin into d-dimer products (Hou et al., 2012). Many studies 
have shown that patients who undergo lower limb venous ultrasound and 
subsequently found to have deep vein thrombosis (DVT), also have 
significantly higher d-dimer levels than those with normal imaging (Božič et 
al., 2002). However, the challenge of using d-dimer to diagnose DVT is that it 
can be elevated in many situations, including following surgery, trauma, 
pregnancy, liver disease and increasing age (Hou et al., 2012) (Sudo et al., 
2009). It is therefore useful for excluding VTE but is not specific enough to 
diagnose it (Coleman & Wakefield, 2012). In combination with pre test clinical 
probability scores such as the Wells score, the diagnostic accuracy of this test 
is improved, to the extent that patients with low clinical suspicion and low d-
dimer can exclude DVT and negate the requirement for further imaging of the 
lower limb venous system (Perrier, 2006). Recently, a d-dimer result of 
<500ng/ml was shown to have a negative predictive value of 99.48% 
irrespective of clinical suspicion of DVT (Michiels et al., 2015). In patients who 
have undergone surgery, cut off levels for excluding DVT are higher. Abraham 
et al (1999) found that a d-dimer cut off level of <2808ng/mL on day 1 post 
total hip or knee arthroplasty was associated with a significantly lower 
incidence of subsequent asymptomatic DVT (USS proven) on postoperative 
day 7 (8% vs 21.4%) (Abraham et al., 1999). Yoo et al measured d-dimer on 
day 3 following total hip replacement or surface replacement in 221 patients 
and found a significant correlation with the finding of DVT on 
ultrasound/venogram at day 7 postoperative. A cut off value of 2640 ng/mL 
had a negative predictive value of 98.8% (Yoo, Cho, Ghanem, Ramteke, & 
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Kim, 2009). Sudo et al (2009) suggested a cut off level of 17700 ng/mL after 
hip or knee arthroplasty (Sudo et al., 2009).  
 
In view that raised D-dimer may indicate a thrombotic state, some authors 
have attempted to use this to predict who will subsequently develop clinical 
signs of DVT. For example, in a study of 99 patients who underwent THR or 
TKR, d-dimer was measured pre and postoperatively at intervals. Patients 
also had DVT ultrasound scan at day 4 and 10 postoperatively. 15% were 
found to have a DVT. D-dimer levels were significantly higher postoperatively 
as compared to pre-operative levels. Those who were subsequently found to 
have DVT had statistically significantly higher d-dimer levels than those who 
did not, at days 4, 7, 10 and 14 postoperatively. Interestingly, there was no 
significant difference in d-dimer levels on day 1 postoperative between those 
who subsequently developed DVT and those that did not (Sudo et al., 2009). 
An et al measured d-dimer in 177 patients who underwent THR or TKR and 
found that d-dimer levels peaked 2 weeks postoperatively. None of these 
patients developed a symptomatic DVT (An et al., 2016). Similarly, Yoshioka 
et al (2010) found that d-dimer measurements within the first 3 days following 
spinal surgery were not predictive of findings of DVT on screening USS 
between days 7-10 postoperative. Interestingly, there was a statistically 
significant difference in d-dimer levels between those who did and did not 
have DVT, when measured on day 7 postoperative due to a rise in d-dimer in 
those with DVT. These studies suggests that there is a delay in prothrombotic 
state and subsequent rise in d-dimer following surgery (Yoshioka et al., 2010). 
In this study of patients with lower limb cast treatment for soft tissue injury or 
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fracture, blood samples were taken at baseline (time of randomisation), 
between day 10 and 14 after injury and again at time of cast removal. 18.6% 
of 188 patients who did not receive thromboprophylaxis developed VTE, 
which is similar to findings of this study. Similarly, all DVT's occurred in the 
injured leg. Interestingly, thrombin-antithrombin complex (TAT), which 
represents thrombin generation, was normal at time of injury and not 
significantly different at baseline between patients who went on to develop 
VTE compared with those who did not. However, when compared at between 
day 10-14 post injury, it was significantly higher in the group who were 
subsequently found to have DVT (Walenga et al., 2014). In the present study, 
D-Dimer levels were only 203.5 ng/mL in those who did not develop DVT and 
236 ng/mL in those who did (p=0.490). Levels ranged from 31 to 1184 ng/mL. 
Considering the aforementioned literature, it is possible that blood samples in 
this study were taken prior to the prothrombotic state occurring. Although it is 
not possible to draw direct comparisons between absolute D-dimer levels in 
this study and those found by others due to differences in methods used to 
quantify D-dimer, it is evident that levels in the present study are relatively low 
(Crowther et al., 2004).  
 
Limitations 
In this study, quantitative levels of Tissue factor, IL-6, VCAM-1 and D-dimer 
were measured. For some of these tests, such as for Tissue factor it would 
have been useful to measure activity, because levels and activity may be 
independent. Also, Tissue factor pathway inhibitor (TFPI) was not considered, 
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so it is possible that the thrombogenic effect of exposed subendothelial tissue 
factor secondary to injury may have been prevented by TFPI (Maroney & 
Mast, 2015). Finally, blood samples were only taken at time of recruitment i.e. 
within 3 days of injury. It may have provided additional understanding if further 
samples had been taken at intervals, which may have enabled trends in levels 
of biomarkers to be assessed. 
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7 Conclusion 
 
LMWH reduces the incidence of both asymptomatic and symptomatic VTE 
events. However, there is a risk of major bleeding (0.11%) which needs to be 
carefully considered against the benefit of prevention of symptomatic VTE 
events. Considering that the number needed to prevent symptomatic VTE 
was found to be 82, 11 symptomatic VTE events would be prevented for 
every major bleed. The clinical and financial implications of this require further 
prospective study. It is also vital to identify which patients in casts are most 
likely to develop VTE, to enable thromboprophylaxis to be prescribed 
accurately to those at highest risk. Multi centre studies are necessary to 
achieve definitive answers. Current guidelines will make such studies difficult, 
due to recommendation for thromboprophylaxis in many patients with casts 
and perceived additional VTE risk factors.  
 
Regular active toe movement by patients treated with lower limb cast for 
acute foot and ankle trauma did not significantly influence calf pump function 
or reduce the incidence of asymptomatic deep vein thrombosis. All cases of 
deep vein thrombosis occurred in the limb, which had been injured and 
treated in cast. The majority (90%) of venous thrombosis involved the 
peroneal veins. Advice to patients to perform regular active toe movement 
alone appears insufficient to reduce the risk of development of asymptomatic 
deep vein thrombosis. 
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27% of patients with lower limb trauma treated with below knee cast 
immobilization will sustain an asymptomatic deep vein thrombosis, even in the 
absence of any other apparent risk factors. 15% of these DVT’s involve the 
veins at the level of the popliteal vein or more proximal and required treatment 
with anticoagulation. All cases of deep vein thrombosis occurred in the limb 
that had been injured and treated in cast. The effect of asymptomatic deep 
vein thrombosis in patients with lower limb trauma and cast treatment requires 
further study to determine the long-term outcomes on venous function. 
 
The majority of patients (95%) with acute lower limb trauma treated with non-
weight bearing below knee cast are not immobile during the first 5 days after 
cast application. Immobility was not associated with subsequent development 
of DVT. Although it is likely that patients with lower limb trauma treated with 
casts are less mobile than their pre injury states, physical activity levels do not 
appear to provide discriminatory value in predicting which patients will 
develop deep vein thrombosis. In view of this, mobility of these patients 
should not be used to stratify these patients into risk of DVT. 
 
In this study of patients with acute foot and ankle trauma, there was no 
association between levels of plasma Tissue factor, IL-6, VCAM-1 or D-dimer 
and subsequent development of DVT. These appear to have no predictive 
role when measured within the first 3 days of injury. Further study is required 
to determine which biomarkers of thrombosis can be used and when these 
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should be measured in order to identify patients that will subsequently 
develop DVT. 
 
In conclusion, weak evidence exists for the effectiveness of chemical 
thromboprophylaxis in prevention of deep vein thrombosis in patients with foot 
and ankle trauma treated with below knee cast. There is no evidence that 
mechanical thromboprophylaxis is effective. DVT appears to solely occur in 
the lower limb that has been injured and treated in cast, but the development 
cannot be predicted using level of mobility or markers of tissue injury. 
 
 
8 Further work 
 
Future work should aim to prospectively validate VTE risk assessment tools, 
to enable risk stratification of patients and provide prophylaxis to those at 
greatest risk. Long term outcome of cast related asymptomatic and 
symptomatic DVT requires further evaluation, to determine their association 
with post thrombotic syndrome and clinical relevance of these outcomes. 
Mechanical prophylactic strategies should focus on the prevention of stasis in 
the leg that has been injured and treated with cast, the effect of 
neuromuscular calf pump function stimulators on DVT occurrence requires 
study.  
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